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SUMMARY
The experiments described in this thesis illustrate three approaches to the investigation 
of leukaemias and lymphomas for evidence of a viral aetiology. These approaches are 
(1) to target specific disease entities for investigation on the basis of epidemiological 
and clinical features suggestive of a viral aetiology, (2 ) to investigate the molecular 
association between a known virus and leukaemia and lymphoma tissue and (3) to 
search for novel viruses related to a known leukaemogenic virus.
Some of the clinical and epidemiological features of Hodgkin’s disease (HD) are 
suggestive of an infectious or transmissable aetiology. As part of an investigation into 
the pathogenesis of HD 35 samples from HD patients were characterized by the 
molecular analysis of the T-cell receptor (TCR) and immunoglobulin (Ig) genes. Ig 
gene rearrangements were detected in 9/35 HD samples. No TCR gene rearrangements 
were detected. Seven of the cases in which IgH gene rearrangements were detected 
contained high numbers of Reed-Sterberg cells and their mononuclear variants. The 
data are consistent with the hypothesis that HRS cells are derived from lymphocytes at 
varying stages of differentiation.
Forty seven HD samples were analysed for the presence of human herpesvirus 6 - 
(HHV-6-) specific DNA sequences. HHV-6-specific DNA sequences were not detected 
in any of the 35 HD samples. The results do not support a direct role for HHV-6  in the 
aetiology of HD. HHV-6  DNA sequences were detected in 2/53 samples obtained from 
patients with non-Hodgkin’s lymphoma (NHL). The positive cases were a patient with 
angioimmunoblastic lymphadenopathy (AIL), which had progressed to T-zone 
lymphoma, and a patient with a B-cell NHL occurring in the context of Sjogren’s 
syndrome. Viral DNA sequences were detected in tumour and in non-tumour tissue 
from both patients. HHV-6  has been previously isolated from a patient with AIL 
(Salahuddin et a l  1986) and HHV-6-specific DNA sequences have been detected in a 
B-cell lymphoma occurring in a patient with SjSgren’s syndrome (Josephs etal. 1988a). 
The data obtained in this study do not support a direct role for HHV-6 in the aetiology 
of either condition, however the possibility that the virus could be indirectly involved 
in disease pathogenesis remains. In particular the association between HHV-6  and 
lymphomas occurring in the context of Sjogren’s syndrome appears worthy of further 
investigation.
xiv
The presence of antibodies that cross-react with proteins encoded by the gag-gene of 
human T-lymphotropic virus type I (HTLV-I) in sera from persons who do not appear 
to be HTLV-I-infected may indicate infection with an HTLV-I-related retrovirus. A 
novel approach to investigating this possibility was devised. Overlapping octapeptides 
spanning the length of the pl9 gag protein of HTLV-I were synthesized and used in an 
enzyme-linked immunoassay to identify the regions of p i9 that bound antibodies in 
cross-reactive sera. Cross-reactive serum samples obtained from persons who appeared 
to be HTLV-I negative were shown to react with epitopes near the C-terminus of pl9. 
HTLV-I positive serum samples also reacted with octapeptides near the C-terminus of 
p i9. The data obtained from the analysis of 9 cross-reactive sera obtained from 
residents of Papua New Guinea provide some support for the hypothesis that these 
persons may be infected with a retrovirus related to HTLV-I. The data also provide 
information that could be used for further testing of this hypothesis.
xv
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CHAPTER ONE
GENERAL INTRODUCTION:
THE INVOLVEMENT OF VIRUSES IN THE AETIOLOGY OF 
HUMAN LEUKAEMIAS AND LYMPHOMAS.
l
1. INTRODUCTION.
Members of two families of viruses, the Retroviridae and the Herpesviridae, are known 
to be involved in the aetiology of leukaemias and lymphomas in animals. Leukaemias 
known to have a viral aetiology provide useful models for developing approaches to the 
investigation of viral involvement in other haematopoietic neoplasms. Sections 1.1-1.2 
provide a brief review of the associations between retroviruses and herpesviruses and 
lymphoid malignancies. The leukaemias and lymphomas of humans that are considered 
to have a viral aetiology are discussed in more detail.
In sections 1.3-1.5 three general approaches to the investigation of leukaemias and 
lymphomas for evidence of a viral aetiology are described. These may be summarized 
as follows: L3, the targeting of specific disease entities on the basis of clinical and/or 
epidemiological evidence suggestive of an infectious or viral aetiology; L4, the analysis 
of leukaemias and lymphomas for evidence of a molecular or serological association 
with a specific virus; L5, the use of molecular or serological techniques to search for 
unidentified viruses that are related to known leukaemogenic viruses. These approaches 
have provided the justification for the experiments described in this thesis.
1.1. RETROVIRUSES.
The family Retroviradae includes a group of related viruses which possess an RNA 
genome and an RNA dependant DNA polymerase. Members of the family have a 
number of common morphological and biochemical characteristics (Teich 1984). 
Morphologically the viruses are spherical enveloped particles of 80-120nm in diameter, 
which may have visible surface projections on electron microscopy (Figure 1.1).
The replication of retroviruses has been reviewed by Varmus and Swanstrom (1984). 
Infection of an host cell occurs following interaction between the viral envelope 
glycoprotein and a specific receptor on the cell surface. Following entry of the core 
particle, the viral RNA genome is released into the cytoplasm and transcribed into DNA 
by the viral reverse transcriptase. A number of molecules of this enzyme are contained 
within the virion. The DNA copy of the viral genome is integrated into the host cell 
genome, the integrated viral DNA is known as a provirus. The mechanism of 
integration has been recently reviewed by Brown (1990); no specific target sequences
2
Figure 1.1. Electron micrograph of retrovirus virions
(HTLV-I. x 150 000)
are required, though some regions of the host cell genome appear to be less accessible 
than others. Once integrated, the provirus is stably maintained in the cell and replicates 
when cell division occurs. Infection is thus transmitted to the daughter cells with 
cellular DNA. During viral replication proviral DNA is transcribed into messenger 
RNA (mRNA) encoding viral proteins and into genomic RNA, the latter being 
incorporated into new virions. Virions are assembled as they are released from the host 
cell by budding through the plasma membrane. In the majority of retroviral infections, 
virion release is not associated with a cytopathic effect.
The family Retroviridae has been subdivided into three subfamilies on the basis of 
differences in biological behaviour and pathological effects (Teich 1984): (1) The 
Oncovirinae, which includes the oncogenic viruses and closely related non-oncogenic 
viruses, (2) Lentivirinae, which are viruses inducing non-oncogenic diseases with a 
long latent period, (3) Spumavirinae, viruses which produce a characteristic ,,foamy,, 
cytopathic effect in vitro, and induce persistent infections without known clinical 
consequences. More recently, the availability of nucleotide sequence data for many 
retroviruses has led to attempts to classify this family on the basis of sequence 
similarity and genomic organization. Doolittle et al. (1990) have identified four major 
subgroups of retroviruses using this approach: (a) the slow viruses, or lentiviruses, (b) a 
group including the human T-cell leukaemia viruses (HTLV) and bovine leukaemia 
virus (BLV), (c) a group of exogenous and endogenous viruses and intracistemal 
particles showing diverse morphology and (d) a mixed group of various leukaemia 
viruses, several endogenous viruses and the spumaviruses.
1.1.1. Leukaemogenic retroviruses.
Exogenous retroviruses from the subfamily Oncovirinae have been identified as 
aetiological agents of haematopoietic malignancies in a number of animal species, 
including chickens, mice, cats, cattle, apes and humans. Some of these viruses have also 
been shown to cause other neoplastic and non-neoplastic diseases. The development of 
disease usually occurs after a prolonged latent period and is associated with persistent 
virus infection of the host. The disease associations of a number of leukaemogenic 
retroviruses are shown in Table I.I. Retroviruses that cause immunosuppression in their 
hosts, such as the human immunodeficiency viruses (HIV) and the feline 
immunodeficiency virus (FIV) may be indirectly involved in leukaemogenesis, as 
discussed further in section 1.4.2.
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1.1.2. Human T-cell leukaemia viruses (HTLV).
Human T-cell leukaemia virus type I (HTLV-I).
HTLV-I was the first oncogenic human retrovirus to be isolated (Poiesz et al. 1980) 
following the development of techniques allowing the long term culture of T- 
lymphocytes. HTLV-I was subsequently shown to be aetiologically associated with an 
aggressive T-cell maligancy, adult T-cell leukaemia/lymphoma (ATL) first described 
by Uchiyama et al. (1977) in southern Japan. The virus has also been aetiologically 
linked with a progressive demyelinating neurological disorder known as tropical spastic 
paraparesis (TSP) in the Cambean, and as HTLV-1 associated myelopathy (HAM) in 
Japan (Gessain etal. 1985; Osame etal. 1986).
Associations between HTLV-I and other diseases are less well established. An 
increased incidence of HTLV-I antibodies in B-CLL relative to control sera was 
reported by Blattner et al. (1983a). More recently, a serological association between 
HTLV-I infection and polymyositis in Jamaica has been identified (Morgan et al. 
1989).
Human T-cell leukaemia virus type H (HTLV-H).
A second human retrovirus, designated HTLV-II, was first isolated from a patient with 
a T-cell variant of hairy cell leukaemia (HCL) (Kalyanaraman et al. 1982). An 
additional isolate has been reported from a patient with the more common B-cell form 
of HCL (Rosenblatt etal. 1986) though in this patient the virus was shown to be present 
in T-cells and not in the leukaemic B-cells (Rosenblatt et al. 1988). Serological and 
molecular studies have failed to show a consistent association between HTLV-II and 
HCL (Rosenblatt et al. 1987; Lion et al. 1988). Further HTLV-H isolates have been 
made from persons with immunodeficiency (Hahn et al. 1984; Chorba et al. 1985). 
However an association between HTLV-II infection and disease has not yet been 
demonstrated.
4
A number of studies have identified intravenous drug abusers as a population at 
increased risk of HTLV-H infection (Tedder et a l  1984; Ehrlich et a l 1989; Lee et a l  
1989; Kwok et a l  1990a; Zella et al. 1990). Lairmore et a l  (1990) have reported the 
isolation of HTLV-II from a member of the Guaymi Indian population of Panama. 
HTLV-H infection was detected in additional, seropositive, members of this population 
by using the polymerase chain reaction (PCR) to analyse peripheral blood mononuclear 
cells (PBMCs) (Heneine et a l  1990). These authors suggest that HTLV-H may be 
endemic in this population.
Cell tropism.
Both HTLV-I and HTLV-H are tropic for, and transform, CD4 positive T-lymphocytes 
in vitro (Yamamoto et a l  1982a; Chen et a l  1983). HTLV-I has been detected and 
shown to replicate in B-lymphocytes and in a variety of non-lymphoid cells and cell 
lines in vitro (Yamamoto et al. 1982b; Clapham et al. 1983; Longo et al. 1984; 
Hiramatsu et a l  1986; Akagi e ta l  1988). However it is not known whether these cell 
types are susceptible to infection in vivo.
The mechanism by which HTLV-I and HTLV-H are thought to transform T-cells in 
vitro is discussed further in section 1.1.5.
1.13. Adult T-cell leukaemia/lymphoma (ATL).
The clinical features of ATL have been reviewed by Uchiyama (1988) and Yamaguchi et 
a l  (1990). The median age of onset of disease has been estimated at 55-56 years, with 
an age range of 16-63 years. Typically the disease has an acute onset, more than 50% of 
cases show symptoms of lymphadenopathy, hypercalcaemia and hepatomegaly. Up to 
50% of affected patients also have splenomegaly and skin lesions. Opportunistic 
infections frequently develop, reflecting an underlying immunodeficiency. Patients with 
acute forms of ATL show a poor response to treatment and have mean survival times of 
4.4-7.5 months (Uchiyama 1988). Less acute "preleukaemic" and "smouldering" forms 
of the disease have been described (Kinoshita et a l  1985; Yamaguchi et a l  1985).
5
Molecular analysis of leukaemic cells from ATL patients has shown monoclonal or, 
rarely, oligoclonal integration of the complete provirus (Wong-Staal et al. 1983; 
Yoshida et al. 1984; Claik et al. 1988). Occasionally partially deleted proviruses have 
been detected (Wong-Staal et al. 1983; Clark etal. 1988).
The cell surface phenotype of the neoplastic cells in ATL is in most cases CD1-, CD2+, 
CD3+, CD4+, CD8-, HLA-DR+/-, CD25+, identifying the neoplastic cells as mature 
peripheral T-cells of the T-helper subtype (Uchiyama et al. 1988). In vitro studies 
have, however, failed to detect helper activity by the neoplastic cells (Uchiyama et al. 
1983). Clonal chromosomal abnormalities have been detected in the leukaemic cells of 
ATL patients (Ueshima etal. 1981; Miyamoto et al. 1984). No consistent abnormalities 
were reported in these studies, though a high incidence of trisomy 7 was detected by 
Ueshima et al. (1981), while Miyamoto etal. (1984) reported frequent rearrangements 
of chromosomes 6 ,1 and 3.
1.1.4. Epidemiology of HTLV-I infection and of ATL.
The epidemiology of HTLV-I infection has been recently reviewed by Blattner (1989). 
The seroprevalence of HTLV-I in endemic areas of Japan and the Caribbean varies 
from 5-10%. HTLV-I infection also appears to be endemic in parts of Africa (Saxinger 
et al. 1984; Biggar et al. 1984; Delaporte et al. 1989; Goubau et al. 1990). Familial 
clustering of seropositive persons is observed, reflecting the requirement for intimate 
contact for virus transmission. Transmission of HTLV-I occurs through the transfer of 
virus-infected cells by three major routes: the transfer of cellular blood components 
from infected donors by blood transfusion (Okochi et al. 1984) or intravenous drug 
abuse (Tedder etal. 1984; Lee et al. 1989; Kwok et al. 1990a), transmission of virus- 
infected cells from HTLV-I positive mothers to children in breast milk (Nakano et al. 
1986) and transmission during sexual intercourse (Nakano etal. 1984).
ATL shows pronounced geographical clustering in south Japan and the Carribean 
(Hinuma etal. 1981; 1982; Yoshida et al. 1982; 1984; Blattner et al. 1983b), areas 
where HTLV-I infection is endemic. The epidemiology of HTLV-I associated disease 
in Africa is poorly described, though TSP and ATL-like disorders have been reported 
in HTLV-I-infected Africans (Williams et al. 1984; Delaporte etal. 1989; de-The et al. 
1989a)
6
HTLV-I infected persons have a low risk of developing ATL; the annual incidence rate 
for Japanese virus carriers older than 40 years has been estimated at 0.6-1.7% (Tajima 
et al. 1990). Studies of populations that have migrated from endemic areas indicate that 
a long latent period may elapse between infection by the vims and the development of 
disease (Greaves et al. 1984). Murphy et al. (1989) have suggested that HTLV-I 
infection in childhood is an important risk factor for the development of ATL. In this 
study the cumulative risk of developing ATL for seropositive children under 20 years 
old was estimated at 4.0% for males and 4.2% for females.
The low incidence of ATL in HTLV-I infected persons indicates that HTLV-I is a 
relatively inefficient leukaemogenic vims and that additional factors are likely to be 
involved in disease development. The monoclonal origin of the vims infected tumour 
cells also suggests that multiple events are required for oncogenesis. However the high 
level of correlation between the epidemiology of ATL and the seroepidemiology of 
HTLV-I indicates that the major risk factor for ATL development is HTLV-I infection. 
Other risk factors have not yet been convincingly identified, though the age at which 
infection is acquired may be important
1.1.5. HTLV-I in T-cell transformation and leukaemogenesis.
HTLV-I and the related retroviruses, HTLV-II and BLV have a genome organization 
which differs from that of other non-defective, leukaemogenic retroviruses. The viral 
genomes possess an additional protein coding region at the 3’ end of the env gene 
which extends into the viral long terminal repeat (LTR) (Seiki et al. 1983; Shimotohno 
et al. 1984; Sagata et al. 1985). The tax protein of HTLV-I and HTLV-II, which is 
encoded by this region, has been shown to activate transcription from the viral LTR in 
trans (Yoshida and Seiki 1987; Green and Chen 1990). Expression of the tax protein is 
also associated with trans-activation of a number of cellular genes, including the genes 
for the interleukin 2 receptor a-chain , (IL -2R a), in terleukin  2 (IL-2), 
granulocyte/macrophage colony stimulating factor (GM-CSF), c-fos and c-sis (Greene 
et al. 1986; Inoue etal. 1986; Fujii et a l  1988; Green and Chen 1990).
The involvement of tax in leukaemogenesis by HTLV-I in vivo via the trans-activation 
of cellular genes has been proposed by many groups (e.g. Wong-Staal and Gallo 1985; 
Arima et al. 1987; Yoshida and Seiki 1987; Tanaka et al. 1990). A similar mechanism 
has been proposed for the immortalization of T-lymphocytes by HTLV-I and HTLV-II
7
in vitro. T-cells transformed in vitro by HTLV-I express large amounts of mRNA for 
both structural and non-structural proteins (de Rossi et al. 1985). Events in addition to 
virus infection appear to be required for transformation in vitro, as an initial poly- or 
oligoclonal proliferation of infected cells is followed by outgrowth of a dominant clone 
which may eventually become independent of IL2 (de Rossi et al. 1985).
The infrequent development of ATL in HTLV-I infected persons and the long latent 
period between infection and the onset of leukaemia indicate that the pathogenesis of 
ATL is also likely to require multiple events. Expression of the viral genome in fresh 
leukaemic cells from ATL patients is limited, suggesting that HTLV-I infection may be 
important in the early stages of cell transformation. In early studies, the expression of 
mRNA coding for viral proteins was not detected by Northern blotting, though rare 
exceptions were reported (Franchini et al. 1984; Umadome et al. 1988). More recent 
studies using reverse transcription followed by amplification of DNA sequences with 
the PCR have detected low levels of tax RNA in PBMCs and lymph node tissue from 
ATL patients (Kinoshita etal. 1989; Greenberg et al. 1990). However neither of the 
latter reports demonstrated that viral mRNA expression was occurring in the leukaemic, 
rather than the normal, virus-infected lymphocytes.
Experimental evidence identifies tax as a candidate transforming gene (Hinrichs et al. 
1987; Grassmann et al. 1989; Tanaka et al. 1990). It is possible that low level 
expression of tax is sufficient to maintain the transformed phenotype, though it should 
be noted that tax expression was not detectable in all ATL cases in the studies of 
Kinoshita et al. (1989) and Greenberg et al. (1990). Alternatively tax, or some other 
viral function, may be involved in an early step in leukaemogenesis, and virus gene 
expression may not be required for maintenance of the neoplastic state. A model in 
which HTLV-I is involved in the early stages of leukaemogenesis in vivo has been 
described by Yoshida and Seiki (1987). In this model HTLV-I infected T-cells are 
induced to proliferate due to ttmy-activation of cellular genes by tax. The virus induced 
polyclonal proliferation creates a large pool of rapidly dividing cells which are then 
susceptible to additional transforming events.
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1.2 HERPESVIRUSES.
The characteristics of Herpesviruses have been reviewed by Roizman (1982). The 
Herpesviridae are a family of DNA viruses with a large, linear, double stranded 
genome. Morphologically the virions are enveloped particles of 120-150nm in diameter 
with surface projections that are visible with an electron microscope (Figure 1.2). The 
viral nucleic acid is contained in the nucleocapsid, which is an icosahedron made up of 
162 capsomeres.
The replication of herpesviruses has been reviewed (Kieff and Liebowitz 1990; 
Roizman and Sears 1990; Stinski 1990). The virus gains access to the cell following 
interaction with a specific cell surface receptor. After entering the cell nucleus, the 
herpesvirus DNA molecules are thought to circularize or to form concatemers. 
Transcription and replication of viral DNA takes place in the nucleus, followed by the 
assembly of capsids. Immature nucleocapsids appear to bud through the inner lamella 
of the nuclear membrane. Enveloped viral particles are released from the cell surface. 
Productive herpesvirus replication results in lysis of the host cell.
Herpesviruses are also able to establish latent infections in some infected cell types 
(Roizman 1982). During latent infection limited regions of the virus genome are 
expressed. Viral DNA is maintained in various forms in latently infected cells. EBV 
genomes are maintained as covalently closed circular episomes, integration into the 
cellular genome has also been detected (Lindahl et a l  1976; Matsuo et al. 1984). The 
genomes of other herpesviruses may be maintained as circular, concatemeric or linear 
forms in latently infected cells (Rziha etal. 1986; Mellerick and Fraser 1987).
Herpesviruses have been divided into three subfamilies, the Alphaherpesvirinae, 
Betaherpesvirinae and Gammaherpesvirinae. Viruses were originally assigned to these 
subfamilies on the basis of their biological properties (Roizman 1982).
The alphaheipesviruses have a variable host range in vivo and in vitro and have a short 
reproductive cycle. These viruses are highly cytopathic in vitro and frequently establish 
latent infections in ganglia. The betaherpesviruses show a restricted host range in vivo 
and in vitro and have a relatively long reproductive cycle. The cytopathic effect in vitro 
is associated with the enlargement of infected cells. The site(s) of latency for most 
betaherpesviruses are unknown. The gammaherpesviruses show a narrow host range in 
vivo and replicate and establish non-lytic persistent infections in lymphoblastoid cells
9
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Figure 1.2. Negatively stained electron micrograph  ^
of herpesvirus virions (HHV-6. x 75 000).
in vitro. The duration of the reproductive cycle is variable. Latent infections are 
frequently established in lymphoid tissue in vivo.
Grouping of herpesviruses according to the structure of their genomes, in cases for 
which information is available, does not give consistent agreement with the above 
classification system (Roizman 1982). Molecular analysis of herpesvirus genomes has 
resulted in the reclassification of some viruses on the basis of their nucleotide sequence 
homology with other herpesviruses and similar genome structure. Thus Marek’s disease 
virus (MDV), originally considered a gammaherpesvirus, has been shown to be more 
closely related to the alphaherpesviruses following the analysis of nucleotide 
composition, genome organization and gene sequences (Cebrian et al. 1982; 
Buckmaster etal. 1988; Honess et a l  1989).
1.2.1 Herpesvirus associated lymphoid malignancies.
The associations between herpesviruses and lymphoproliferative diseases are 
summarized in Table LD. Two herpesviruses have been associated with the induction of 
lymphoid malignancies in their natural hosts: Marek’s Disease virus (MDV) in 
chickens and Epstein-Barr virus (EBV) in man. Both these viruses infect and 
immortalize lymphoid cells in vitro (Powell etal. 1974; Henle et al. 1967; Pope et al. 
1968). A number of herpesviruses cause lymphoproliferative diseases when 
experimentally innoculated into animals other than their natural hosts (Table LD).
Other herpesviruses that have not been directly associated with lymphoproliferative 
malignancies, have in some cases been shown to have oncogenic properties in vitro. 
The oncogenic properties of human herpesviruses have been reviewed by Sugden 
(1986). Genomic fragments of the human alphaherpesviruses, herpes simplex virus 
type 1 and type 2, have been shown to have transforming potential in vitro. A fragment 
of human cytomegalovirus (HCMV), a betaherpesvirus, has also been shown to induce 
transformation of cultured rodent cells. Galloway et al. (1986) report that the 
transforming region of HCMV may act as a transcriptional enhancer and suggest that 
the transforming region of herpes simplex virus type 2 may be a weak mutagen. The 
relevance of these findings to the pathogenic effects of these viruses in vivo is not 
certain.
10
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.
1.2.2 Epstein-Barr virus (EBV).
EBV was first isolated by Epstein et al. (1964) and has since been linked to the 
aetiology of a number of lymphoproliferative disorders. The association between EBV 
and a high grade B-cell lymphoma, Burkitt’s lymphoma (BL) in Africa is discussed 
further in sections 1.2.3-1.2.4.
The virus has been identified as the aetiological agent of infectious mononucleosis 
(IM), which occurs predominantly in young adults of between 15 and 25 years of age 
(Henle etal. 1968; Evans and Neiderman 1989). IM is characterized clinically by fever, 
pharyngitis and lymphadenopathy, these symptoms are associated with a rapid 
lymphoproliferative response, which is usually self-limiting (Purtillo etal. 1985; Evans 
and Niederman 1989). Persons with inherited immunodeficiency syndromes are 
susceptible to chronic and fatal forms of IM (Purtillo etal. 1985).
EBV has also been associated with the development of B-cell lymphoproliferative 
disorders and lymphomas in persons with primary or secondary immunodeficiency 
(Hanto etal. 1985). EBV-associated benign polyclonal B-cell hyperplasias, oligoclonal 
B-cell lymphomas and m onoclonal lymphomas have been described in 
immunosuppressed tissue-allograft recipients (Hanto et al. 1985). These disorders 
show a spectrum of histological appearances, large non-cleaved cell and immunoblastic 
lymphomas are frequently reported. EBV DNA has been detected in 28-50% of 
lymphomas occurring in HIV infected individuals (Suber et al. 1988; Emberg 1989; 
Hamilton-Dutoit etal. 1989). The virus-positive lymphomas are histologically diverse; 
immunoblastic lymphomas are seen in patients with more severe immune deficiency, 
while BL-like tumours appear to be associated with a less compromised immune system 
(Evans and de The 1989).
EBV has been been linked with the aetiology of an epithelial tumour, nasopharyngeal 
carcinoma (NPC). NPC is an aggressive squamous cell carcinoma that is common in 
south-east Asia (de-The etal. 1989b; Evans and de-The 1989). Patients with NPC have 
high levels of antibodies to a number of EBV antigens and EBV DNA has been 
detected in the majority of NPC biopsies (zur Hausen et al. 1970; de Schryver et al. 
1972; Desgranges etal. 1975; de The etal. 1978a). The epidemiology of NPC indicates 
that genetic and environmental factors are important in disease pathogenesis (de-The et 
al. 1989b). The interactions between these factors and EBV and the role played by the 
virus in the development of this tumour are not understood.
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Molecular associations between EBV and other B- and T-cell non Hodgkin’s 
lymphomas (NHLs) have been reported (Bomkamm et al. 1976; Jones et al. 1988; 
Chappuis and Muller-Hermelink 1989; Murphy et al. 1990; Richel et al. 1990; Rouah 
etal. 1990). The role of EBV in the pathogenesis of these lymphomas is unknown. The 
serological and molecular evidence linking EBV to the aetiology of Hodgkin’s disease 
(HD) is discussed in Chapter 4 of this thesis.
In vitro cell tropism.
EBV is tropic for resting human B-cells in vitro and transforms infected cells into 
permanent lymphoblastoid cell lines (LCL) (Henle etal. 1967; Pope et al. 1968). The 
viral genome is maintained in multiple episomal copies in immortalized cells and shows 
a restricted range of gene expression (Speck and Strominger 1989). Productive viral 
replication occurs in a small proportion of transformed cells and is associated with loss 
of the transformed phenotype and B-cell differentiation (Wendel-Hansen et al. 1987). 
The relationship between EBV-induced immortalization of B-cells in vitro and the 
pathogenesis of EBV-associated B-cell lymphomas in vivo is discussed further in 
section 1.2.5.
EBV is also tropic for, and replicates in, oropharyngeal epithelial cells in vivo (Sixbey 
1989). Infection of epithelial cells by EBV has not been succesfully reproduced in vitro,
1.23 Burkitt’s lymphoma (BL).
The epidemiology of BL has been reviewed by Evans and de-The (1989). BL occurs in 
two epidemiologically distinct forms, an endemic, or high incidence form and a 
sporadic, or low incidence form. The geographical distribution of endemic BL (eBL) 
shows a close correlation with the incidence of malaria caused by Plasmodium 
falciparum (P. falciparum). Sporadic BL (sBL) occurs at a low frequency in many 
geographical areas; the distribution of disease is unrelated to the prevalence of malaria.
The histopathological features of both forms of BL are similar (Berard 1985; Wright 
1985). The tumour is classified as a high grade lymphoma of small noncleaved cell type 
according to the "working formulation" (Rosenberg 1982). The malignant cells are
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monomorphic and express surface immunoglobulin (Ig). Some differences in the 
pattern of cell surface antigen expression by the tumour cells of sBL and eBL have been 
described; the malignant cells in eBL appear to have a less mature B-cell phenotype 
than those in sBL (Preud’homme et al. 1985).
Differences in the clinical features of sBL and eBL have also been reported. African 
cases of BL usually present with lymphomas occurring in the jaw and/or abdomen 
(Ziegler 1977). Jaw tumours are rarely seen in sBL, which frequently presents with 
abdominal masses and lymph node tumours (Levine et al. 1982). The peak age 
incidence of eBL is 6-8 years old, while the peak incidence of sBL is in older children 
of 10-12 years (Levine etal. 1982). However BL occurring in non-endemic areas is an 
heterogeneous disease and a significant proportion of cases cannot be distinguished 
clinically or morphologically from eBL (Levine et al. 1982).
The association between BL and EBV has been recently reviewed by Evans and de-The 
(1989) and Rowe and Gregory (1989). The results of seroepidemiological and 
molecular studies support a role for EBV in the aetiology of eBL. African patients with 
BL have significantly higher antibody titres to EBV than control populations (Henle et 
al. 1969) and elevated antibody titres to the EBV viral capsid antigen are associated 
with an increased risk of developing BL (de-The et al. 1978b). EBV DNA is detected 
in 98-99% of biopsies obtained from African patients with BL (Zur Hausen et al. 1970; 
Nonoyama etal. 1973). Viral DNA is present in the tumour cells as multiple episomal 
copies, occasionally integrated virus has been detected (Kaschka-Dierich et al. 1976; 
Lawrence etal. 1988). EBV genomes have also been detected in the tumour cells of 15- 
20% of sBL cases (Andersson et al 1976; Philip 1985). Raab-Traub and Flynn (1986) 
have shown that the EBV-infected tumour cells are clonal in origin, indicating that 
virus-infection has occurred prior to malignant transformation.
Chromosome translocations occurring in BL.
Both sBL and eBL are consistently associated with the presence of one of three 
chromosomal translocations (Croce 1986). Croce (1986) has reviewed the 
characteristics of the three types of chromosome translocation, each of which involves 
the c-myc locus on chromosome 8. In 75% of cases the translocation also involves the 
immunoglobulin heavy chain (IgH) locus on chromosome 14. The remaining 25% of 
tumours have either a t(8;22)(q24;ql 1) or a t(2;8)(pl l;q24) chromosomal translocation,
13
involving the immunoglobulin light chain (IgL) lambda or kappa loci respectively. The 
results obtained in a number of studies indicate that juxtaposition of the c-myc gene 
and the immunoglobulin loci results in constitutive and elevated expression of c-myc 
(e.g. Dalla Favera etal. 1983; Erikson etal. 1983).
The translocations occurring in BL have been shown to involve different sites on 
chromosomes 8 and 14 in the endemic and sporadic forms of the tumour (Erikson etal. 
1982; Dalla Favera et al. 1983; Neri et al. 1988). In most African cases of BL the 
translocation breakpoint on chromosome 14 occurs within, or 5* to the joining region of 
the IgH locus. The breakpoint on chromosome 8 usually occurs several kilobases (kb) 
upstream of the c-myc gene. In the sporadic form of BL the translocation appears to 
involve the heavy chain switch region on chromosome 14 and the first intron of the c- 
myc gene.
1.2.4 Epidemiology of EBV infection and BL.
The epidemiology of EBV infection has been reviewed by Evans and Niederman 
(1989). EBV infection is acquired at an earlier age in developing countries than in 
developed countries. Seroprevalence increases with age and 90-100% of adults over the 
age of 50 years are EBV-antibody-positive (Schmader et al. 1989). Epidemiological 
data suggest that transmission of EBV in adults occurs mainly through intimate oral 
contact with virus-excreting healthy carriers. Consistent with this, excretion of EBV in 
saliva has been detected in the majority of healthy virus-infected individuals (Yao etal.
1985).
Despite the ubiquitous distribution of EBV infection, the incidence of EBV associated 
tumours shows significant geographical variation. The risk of developing BL is 
strongly associated with P. falciparum infection. This may be due to reduced EBV- 
specific T-cell immunity (Moss et al. 1983), or related to P.falciparum-inductd 
proliferation of B-cells (Morrow 1985). In addition de-The (1977) has suggested that 
the acquisition of EBV infection at an early age may be important in the development 
ofBL.
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The risk of developing other EBV-associated diseases depends on a number of factors. 
The association between various types of immune deficiency and EBV-associated 
lymphoproliferative disease indicates the importance of immune status in determining 
the outcome of EBV infection. The age at which EBV infection is acquired is 
considered to be a significant factor in the development of IM (Evans and Niederman 
1989).
1.2.5. EBV, B-cell transformation and BL.
The mechanism by which EBV immortalizes B-cells in vitro is not fully understood. 
Knutson and Sugden (1989) have recently reviewed the evidence for the involvement of 
viral gene products in cell transformation. A number of viral proteins are expressed in 
LCL, the EBV nuclear antigens- (EBNA-) 1-6, the latent membrane protein (LMP) and 
the terminal protein. EBNA-2 has been shown to be required for the immortalization of 
B-lymphocytes, while LMP has been shown to have a transforming function when 
expressed in rodent cells. EBNA-1 appears to frans-activate a viral promoter and is 
required for maintenance of the viral episomes in dividing cells. Whether this protein is 
able to trans-activate any cellular genes or plays an additional role in B-cell 
immortalization is not known.
Expression of EBV gene products in BL tumour cells is more restricted than in LCL. 
EBNA-1 expression is readily detectable in fresh biopsy tissue and BL cell lines, but 
EBNA-2 and LMP do not appear to be expressed at detectable levels (Rowe et al. 
1987). In addition deletion of EBNA-2 has been reported in BL cell lines, indicating 
that EBNA-2 expression is not required to maintain the transformed state (Knutson and 
Sugden 1989).
Two alternative models for the role of EBV in BL have been proposed. Klein (1979;
1987) has suggested that EBV-induced immortalization of B-cells creates an expanded 
target cell population, which is able to proliferate at an increased rate in persons with 
malaria-related immune dysfunction. This proliferating population of cells is then more 
susceptible to a second transforming event, i.e. a chromosomal translocation involving
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c-myc. This model has some features in common with the model for HTLV-I 
involvement in ATL proposed by Yoshida and Seiki (1987) and discussed in section
1.1.5. In both models the virus plays a role in the early stages of leukaemogenesis by 
stimulating cell proliferation and therefore increasing the probability that additional 
transforming events will occur.
An alternative model has been proposed by Lenoir and Bomkamm (1987). These 
authors suggest that P. falciparum  infection induces chronic immunological 
stimulation of B-cells, thus increasing the probability that the c-myc translocation will 
occur. At least one additional event is needed for acquisition of the full neoplastic 
phenotype and this event may, in eBL, be EBV infection. In EBV-negative sBL, some 
other event is substituting for EBV infection.
1.2.6. HTLV-I and EBV as models for human leukaemia viruses.
The evidence described above for the involvement of HTLV-I and EBV in the aetiology 
of ATL and BL respectively may be summarized under four headings.
1. Virus-determined antigens and/or viral genomes are present in the 
tumour cells.
2. Antibodies to virus-determined antigens occur at higher frequency 
and/or titres in patients with these diseases than in appropriate controls.
3. Both viruses are capable of transforming normal human cells in vitro.
4. Both viruses, or closely related viruses, are capable of tumour 
induction in animals other than humans.
These four lines of evidence are similar to the criteria suggested by Henle (1971) for the 
assessment of viruses as aetiological agents of cancer in humans. However it is 
debatable whether or not these criteria should still be considered appropriate. In 
particular, failure to fulfil the third criterion could reflect lack of an appropriate system 
for in vitro culture of the target cells for viral infection. Failure to fulfil the fourth 
criterion could reflect inability of the virus or related viruses to establish infection in 
animals other than humans.
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An additional criterion that has been used by some authors to assess the potential role of 
viruses in human neoplasia is that the seroprevalence of the virus infection should 
parallel the geographic distribution of the neoplasm (e.g. Henderson 1989). HTLV-I 
clearly fulfills this criterion with regard to ATL, however, as discussed previously the 
geographic distribution of BL bears no relationship to the seroprevalence of EBV. A 
possible explanation for the latter finding, i.e. the importance of P. falciparum infection 
as a cofactor in disease pathogenesis, has been described above. Thus while a 
correlation between the distribution of virus infection and of disease may provide 
powerful support for an aetiological association, the absence of a correlation does not 
necessarily provide evidence against it.
The mechanisms by which EBV and HTLV-I are thought to contribute to 
leukaemogenesis involve direct effects on virus infected cells (section 1.4.2). However 
other possible mechanisms by which viruses could take part in the pathogenesis of 
leukaemias and lymphomas have been proposed, not all of which require virus infection 
of the tumour cells. The use of the above criteria may be inappropriate for the 
assessment of the pathogenic role of a virus that induces lymphoproliferative diseases 
by an indirect mechanism. A number of mechanisms of viral leukaemogenesis and 
some of the difficulties that may be encountered in determining the association between 
a virus and disease are discussed in section 1.3.
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1.3. APPROACHES TO THE INVESTIGATION OF VIRAL
INVOLVEMENT IN THE AETIOLOGY OF LEUKAEMIAS AND 
LYMPHOMAS: 
(A) THE TARGETING OF SPECIFIC DISEASES FOR 
INVESTIGATION.
The investigation of specific disease entities for evidence of a viral aetiology may be 
prompted by the identification of clinical or epidemiological features that are 
characteristic of an infectious disease. Similarities with a type of leukaemia or 
lymphoma known to have a viral cause may also identify a condition with an unknown 
aetiology as a potential target for investigation. The accurate classification of 
leukaemias and lymphomas into distinct entities is critical if this is to be a useful 
approach.
1.3.1. The classification of haematopoietic malignancies.
Leukaemia and lymphoma classification has become increasingly complex with the 
evolution of techniques permitting more detailed characterization of the malignant cells. 
Early classification systems were based mainly on the morphology of malignant tissues 
visualized under a light microscope (e.g. Bennet et al. 1976). The development of 
immunological techniques for the characterization of cell surface phenotypes has 
perm itted further subclassification  of many leukaem ias and lymphomas. 
Immunophenotyping has been particularly useful for the identification of distinct 
subtypes of lymphoid leukaemia (Foon et al. 1982; Schroff et al. 1982; Nadler et al. 
1984) and NHL (Picker et al. 1987; Salter et al. 1988). More recently molecular 
techniques for the determination of the B- or T-cell lineage of lymphoid neoplasms 
have been developed (Arnold et al. 1983; Toyanaga and Mak 1987). The application of 
the latter techniques for the classification and diagnosis of malignant lymphomas is 
discussed further in Chapter 3.
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The identification of distinct disease entities may reveal epidemiological features 
suggestive of a viral aetiology that were previously obscured by inappropriate 
classification. For example, the identification of ATL followed the development of 
techniques for the immunophenotyping of leukaemias (Uchiyama et al. 1977). This 
study describes the first identification of ATL as an aggressive form of T-cell leukaemia 
with characteristic clinical and pathological features. The identification of ATL as an 
entity distinct from other leukaemias permitted the epidemiological observations 
described by Uchiyama etal. (1977). The geographical clustering of patients with ATL 
was strongly suggestive of a viral aetiology. Following the isolation of HTLV-I by 
Poiesz etal. (1980) a serological association between HTLV-I infection and ATL was 
rapidly established (Hinuma etal. 1982; Robert-Guroff et al. 1982).
Two lymphoproliferative disorders which have epidemiological and/or clinical features 
suggestive of an infectious or viral aetiology are HD and angioimmunoblastic 
lymphadenopathy (AIL). These disorders are discussed further in the following sections 
and are the subjects of some of the investigations described in Chapters 3 and 4. The 
clinical similarities between ATL and other cutaneous T-cell lymphomas (CTCLs) has 
stimulated interest in the possibility that a retrovirus related to HTLV-I may be 
involved in the aetiology of CTCL. The relevant clinical features of these conditions are 
described in section 1.3.4. The evidence supporting a role for an HTLV-I-related 
retrovirus in the aetiology of CTCL is discussed further in Chapter 5.
1.3.2 Hodgkin’s Disease (HP).
Controversy over the nature of HD has persisted since the first description of the 
disease. This debate has been reviewed by Kaplan (1972). Some early investigators 
considered HD to be neoplastic in nature, though others suggested that the disease was a 
form of tuberculosis. Alternative proposals included an auto-immune origin for HD and 
a secondary inflammatory reaction to virus infection. Until relatively recently the 
neoplastic nature of HD was still being debated (Lukes and Butler 1966).
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Clinical features.
The clinical features of HD have been reviewed by Selby and McElwain (1987). The 
majority of patients present with lymphadenopathy, while approximately one third of 
patients have systemic signs ("B" symptoms) at presentation. Interest in a possible 
infectious origin for HD was stimulated by some of the systemic signs observed in 
patients, as the occurrence of persistent pyrexia, night sweats, pruritis and weight loss 
are features more commonly associated with infectious diseases.
Histopathological features.
The histological appearance of tissues affected by HD, in particular the reactive nature 
of the cellular infiltrate, led to early suggestions that the disease was caused by a virus 
(e.g. Order and Heilman 1972; DeVita 1973).
The histological features of HD have been reviewed by Lukes and Butler (1966), 
Williams (1985) and Lee (1989). Affected tissues show diverse morphological features, 
but are characterized by the presence of variable numbers of Reed-Stemberg (RS) cells. 
RS cells show some variation in appearance, but classically are large with either a 
bilobed nucleus or two nucleii, each of which has a large nucleolus (Figure 1.3). The 
detection of these cells is a prerequisite for a diagnosis of HD. RS cells and their 
mononuclear variants (collectively abbreviated as HRS cells) are usually relatively 
scarce and are intermixed with large numbers of inflammatory cells.
The numbers of HRS cells and the nature of the inflammatory infiltrate have been used 
to subclassify HD (Lukes et al. 1966; Lukes and Butler 1966). The Rye classification 
(Lukes et al. 1966) divides HD into four subtypes, lymphocytic predominance (LP), 
nodular sclerosis (NS), mixed cellularity (MC) and lymphocytic depleted (LD). LPHD 
is characterized by the presence of "L & H" type RS cells, or "popcorn" cells, large 
numbers of mature lymphoctyes and very few classical RS cells (Figure 1.3, panel A). 
LPHD is divided by some authors into nodular and diffuse forms, histiocytes may be 
the predominant cell type in the latter form (Lukes and Butler 1966; Williams 1985). 
The NS subtype of HD shows varying degrees of fibrosis, with connective tissue 
subdividing the cellular infiltrate into nodules (Figure 1.3, panel B). A variant form of 
RS cell, the lacunar cell, is frequently seen in NSHD. Diagnostic RS cells are usually 
scarce but may be numerous in some cases. NSHD has been divided into two types
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Figure 1.3. A, lymphocyte predominant HD. The lymph node 
contains a  polymorphic cellular infiltrate with many small 
lymphcytes and small numbers of large binucleate and 
mononuclear cells (RS cells and their variants. The two large 
cells with multilobated nucleii in the upper left quadrant are 
similar to the "popcorn" cell variants of RS cells.
B, nodular sclerosing HD. Bands of fibrous connective tissue 
divide the lymph node into nodules. Many "lacunar" cells are 
visible.
Figure 1.3. Lymphocyte predom inant (A) and 
nodular sclerosing (B) Hodgkin’s  d isease. 
(Haemotoxylin and eosin-stained sections).
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based on the predominant cell types in the nodules (Lee 1989). MCHD has a 
polymorphic cellular infiltrate which includes many cell types, HRS cells may be 
numerous (Figure 1.4, panel A). LDHD is characterized by small numbers of 
lymphocytes and a variable extent of disordered fibrosis (Figure 1.4, panel B). The 
number of classical RS cells may be large.
The four histopathological subtypes show differences in the sites of disease 
involvement, clinical stage at presentation, prognosis and age and sex distribution 
(Keller et al. 1968; Symmers 1978). NSHD is the commonest subtype in developed 
countries, making up 50-75% of cases; this subtype occurs mainly in adults less than 40 
years old (Lee 1989). Patients with NSHD who are between 15 and 24 years of age 
represent the only group of HD cases to show an excess in females (McKinney et al.
1989). MCHD accounts for 17-31% of HD cases and occurs more frequently in older 
adults (Symmers 1978; Lee 1989). LPHD and LDHD are less common, forming 10- 
17% and 4-14% of cases respectively (Symmers 1978; Lee 1989). LPHD and NSHD- 
type I have a better prognosis than MCHD and NSHD-type n, while the prognosis for 
patients with LDHD is poor (Linch and Vaughan-Hudson 1988). Grufferman and 
Delzell (1984) have suggested that different aetiological factors may be associated with 
the different subtypes of HD.
Epidemiology.
Subdivision of HD cases according to age of onset has also suggested the existence of 
distinct forms of the disease (MacMahon 1966; Grufferman and Delzell 1984). 
MacMahon (1966) identified three subgroups of HD associated with a clinical onset of 
disease at ages of 0-14 years, 15-34 years and over 50 years. The descriptive 
epidemiology of HD occurring in persons in these age-groups differed. MacMahon 
advanced the hypothesis that the aetiology of HD occurring in young and old adults is 
different and that the disease occurring in young adults has an infectious aetiology.
The age-related incidence of HD has been reviewed by MacMahon (1966), Gutensohn 
and Cole (1980) and Grufferman and Delzell (1984). Most studies performed in 
developed countries report a bimodal age-incidence curve with a peak in incidence 
between the ages of 15 and 40 years and a second peak at over 50 years. A recent study
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Figure 1.4. A, mixed cellularity HD. There is a  polymorphic 
cellular infiltrate with many small lymphocytes and occasional 
large mononuclear and multinuclear cells.
B, lymphocyte depleted HD. There is extensive fibrosis with a 
scanty polymorphic cellular infiltrate.
Figure 1.4. Mixed cellularity (A) and 
lymphocyte depleted (B) Hodgkin’s  d isease . 
(Haemotoxylin and eosin-stained sections)
in the U.K. did not detect the second, age-related incidence peak, but found that 
separate consideration of HD subtypes revealed different incidence peaks (McKinney et 
al. 1989). In this study, NSHD showed a peak incidence in young persons aged 14-35 
years, while the other subtypes showed an increase in incidence with increasing age.
High socioeconomic status and small family size have been associated with an 
increased risk of HD (Gutensohn and Cole 1981; Gutensohn 1982; Bernard et al. 1987). 
Gutensohn (1982) found that risk of HD was associated with higher social class in 
young adults, but not in older adults.
These epidemiological data are consistent with MacMahon’s proposals (1966) that HD 
in young adults is distinct from HD occurring in older persons and that the former may 
have an infectious aetiology. Increasing economic development has been associated 
with a shift in the peak age incidence of HD from childhood to young adults. This has 
been compared to changes in the epidemiology of poliomyelitis in developing and 
developed countries (Grufferman and Delzell 1984). The parallel with poliomyelitis led 
a number of groups to suggest that HD in young adults represents an unusual host 
response to a common infection, the risk of which is related to the age at infection 
(Gutensohn and Cole 1980; Grufferman and Delzell 1984).
Supportive evidence for the involvement of a transmissable agent in the aetiology of 
HD is provided by numerous reports in the literature documenting temporal or 
geographical clusters of HD (e.g. Grufferman et al. 1977; Grufferman and Delzell 
1984; Mangoud etal. 1985; Davis 1986). Most studies have focused on HD occurring 
in young adults, though Mangoud et al. (1985) reported clustering of older HD cases. 
Alexander et al. (1989) found evidence of spatial clustering of HD in young adults (0- 
34 years). Analysis of their data according to histopathological subtype indicated that 
clustering might, rather, be associated with NSHD, the predominant subtype in this 
age range.
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HD classification: The nature of the HRS cell.
The above discussion indicates that HD is an heterogeneous disorder. Classification of 
HD cases according to histopathological subtype or age of onset reveals variation in the 
clinical behaviour and epidemiology of the disease. Different aetiological factors may 
be associated with the different histological subtypes, or with HD occurring in different 
age groups. The evidence that HD may have a transmissable aetiology is strongest for 
cases occurring in young adults. The studies by McKinney et al. (1989) and Alexander 
etal. (1989) emphasize that it may be difficult to separate an association with age from 
an association with histological subtype. It is possible that both age and histological 
subtype are inadequate parameters for the classification of HD and do not accurately 
reflect the heterogeneity of the disease.
Detailed characterization of HD is therefore important, in order to establish criteria for 
improved classification systems for this disease. The present histopathological 
classification is based mainly on the variations seen in the non-neoplastic components 
of HD. Characterization of the HRS cells, the putative malignant cells, has been 
difficult due to the small numbers of these cells that are usually present in affected 
tissues. The use of immunological techniques to study the surface phenotype of HRS 
cells has been reviewed by Jones (1987), Lee (1987) and Drexler and Leber (1988). 
Despite extensive study, the cellular origin and lineage of HRS cells have not been 
conclusively identified. Many studies suggest that HRS cells are lymphocytic in origin 
(Falini etal. 1987; Casey et al. 1989; Drexler et al. 1989; Herbst et al. 1989), though 
this remains a controversial issue (Hsu and Hsu 1989; Hsu 1990; Naumovski et al.
1990). The results obtained in these studies are discussed in more detail in Chapter 3.
More recently, the availability of molecular techniques for the detection of clonal 
populations of B- or T-lymphocytes has permitted further evaluation of the possible 
lymphoid origin of HRS cells. Chapter 3 describes the application of these techniques 
for the characterization of HD material.
The experiments reported in Chapter 3 were performed in parallel with investigations 
into the involvement of viruses in the aetiology of HD. The evidence supporting a 
transmissable aetiology for HD in young persons, suggests that the aetiological agent(s) 
is likely to be ubiquitous and transmitted during close person-to-person contact. 
Members of the human herpesviruses show these features and have been proposed as 
candidate transmissable agents. Many studies have demonstrated serological
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associations between human herpesviruses and HD (Henle and Henle 1973; Hesse etal. 
1977; Evans and Gutensohn 1984; Ablashi et al. 1988; Biberfeld et al. 1988; Clark et 
al. 1990). This evidence in discussed in more detail in Chapter 4, which describes the 
results of experiments to determine the involvement of human herpesvirus type 6 
(HHV-6) in HD.
1.3.3. Angioimmunoblastic lvmphadenopathv (AIL).
AIL shares a number of clinical and morphological features with HD, and these two 
conditions may be difficult to differentiate (Lukes and Tindle 1975; Krajewski etal.
1988). Interest in the possibility that AIL has a viral aetiology has been stimulated by 
the clinical and pathological characteristics of the disease. AIL was originally described 
as a distinct clinicopathological entity by Frizzera et al. in 1974. A disorder showing 
similar features was described as immunoblastic lymphadenopathy by Lukes and 
Tindle (1975).
Clinical features.
The clinical features of AIL have been reviewed (Frizzera etal. 1974; 1975; Lukes and 
Tindle 1975; Azevedo and Yunis 1985; Steinberg et al. 1988). The clinical 
manifestations of AIL include systemic signs resembling those of HD: night sweats, 
pyrexia, weight loss, skin rashes, pruritis, generalized lymphadenopathy and 
hepatosplenomegaly. Patients with AIL usually also show immunological abnormalities 
not typical of HD patients, such as hypergammaglobulinaemia and Coombs* test- 
positive haemolytic anaemia.
The clinical course of AIL is variable (Lukes and Tindle 1975; Pangalis et al. 1983). In 
the majority of patients the disease is rapidly fatal, though up to a third of patients may 
show complete and prolonged remission of symptoms (Frizzera et al. 1975; Pangalis et 
al. 1983). Infectious complications are the most frequent cause of death (Frizzera etal. 
1975; Nathwani et al. 1978; Pangalis et al. 1983), reflecting the extent of the 
immunological abnormalities associated with AIL.
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Histopathological features.
Frizzera et al. (1974; 1975), Lukes and Tindle (1975) and Nathwani et al. (1978) have 
described the histopathology of AIL. The normal lymph node architecture is replaced to 
a variable extent by a pleomorphic cellular infiltrate, similar to that seen in HD (Figure 
1.5). The distinctive histological features of AIL include the presence of a promininent 
proliferation of immunoblasts, an arborizing network of "high endothelial venules" and 
the interstitial deposition of an amorphous acidophilic material. Immunoblasts 
resembling RS cells may be detected, but classical RS cells are not usually seen in AIL 
(Nathwani etal. 1978).
Pathogenesis.
Many alternative mechanisms for the pathogenesis of AIL have been proposed. When 
first described, AIL was considered to be non-neoplastic (Frizzera et al. 1974; Lukes 
and Tindle 1975). Frizzera et al. (1974) suggested that the clinical and pathological 
features of AIL were consistent with those of a graft-versus-host reaction. Lukes and 
Tindle (1975) proposed that AIL represented a benign hyperimmune disorder, in which 
there was an increased tendency to develop malignant lymphoma. Drug exposure 
resulting in hypersensitivity or autoimmunity has been suggested as a pathogenetic 
mechanism by some authors (Frizzera et al. 1975; Lukes and Tindle 1975).
The clinical features of AIL are consistent with those of an infectious disease and the 
histological features of AIL are predominantly those of a reactive process. Prominent 
proliferations of postcapillary venules and immunoblasts may also be seen in conditions 
such as IM and postvaccinial lymphadenitis (Frizzera et al. 1975). The involvement of 
both herpesviruses and retroviruses in AIL has been proposed (Azevedo and Yunis 
1985; Honda et al. 1985). Evidence relevant to the possible viral aetiology of AIL is 
discussed further in Chapter 4.
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Figure 1.5 A, AIL-like T-cell lymphoma. There is a 
polymorphic infiltrate of lymphocytes with irregular nucleii, 
eosinophils, plasma cells and a  number of blast cells. The 
lower right quadrant contains a  longitudinal section through a 
high endothelial venule.
B, AIL-like T-cell lymphoma. This section is from case  107, 
described in Chapter 3. The infiltrate is composed mainly of 
lymphocytes, many with irregular nucleii. There are a few 
blast cells with clear cytoplasm. High endothelial venules can 
be seen on the left.
Figure 1.5. Angioimmunoblastic lym phadenopathy­
like T-cell lymphoma.
(Haemotoxylin and eosin-stained sections)
Classification.
In early studies, the development of malignant lymphoma was reported in occasional 
cases of AIL (Lukes and Tindle 1975; Fisher et al. 1976; Yatanagas et al. 1977). Later 
reports suggested that a higher proportion of cases showed features of malignancy 
(Nathwani et al. 1978; Shimoyama et al. 1979; Watanabe et al. 1980). These findings 
led to suggestions that lymphomas with histological features of AIL represented a 
distinct disease entity (Shimoyama et al. 1979) or alternatively, that AIL was a 
malignant disease from the outset (Watanabe etal. 1980; 1986).
The results of immunophenotypic, karyotypic and genotypic investigations have 
suggested that neither of these interpretations is correct, but that AIL is an 
heterogeneous disorder. These studies are discussed further in Chapter 3.
The accurate characterization of AIL cases will therefore be important in any 
investigation into the possible role of viruses in the aetiology of AIL. Chapter 3 
describes the use of molecular analysis for the investigation of the clonality and lineage 
of 5 cases of AIL. These cases were also included in a study investigating the role of 
herpesviruses in lymphopioliferative diseases. The results of the latter investigations are 
discussed in Chapter 4.
1.3.4. Cutaneous T-cell lymphoma (CTCL).
The CTCLs include a range of lymphoproliferative disorders characterized by skin 
infiltration by mature T-lymphocytes. The clinical and morphological features of CTCL 
have been reviewed by Lutzner et al. (1975), Stansfeld (1985) and MacKie (1989). 
Mycosis fungoides (MF) presents clinically with skin eruptions appearing as plaques, 
ulcers or tumours. A proportion of cases progress to lymph node and visceral 
involvement. Sezary syndrome (SS) also frequently presents with skin lesions, but in 
addition involves lymph nodes, spleen and peripheral blood. SS may represent a 
leukaemic variant of MF.
A number of additional disorders have been described, in which the skin lesions are 
difficult to differentiate from those seen in MF. Some of these conditions, such as 
lymphomatoid papulosis and large plaque parapsoriasis, are considered to be 
premycotic lesions as a proportion evolve into MF (Slater 1987; MacKie 1989).
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The first two isolates of HTLV-I were obtained from patients reported to have MF 
(Poiesz etal. 1980) and SS (Poiesz etal. 1981). These findings stimulated considerable 
interest in the possibility that HTLV-I might be the aetiological agent of CTCL, 
however antibodies to HTLV-I were rarely detected in the sera of CTCL patients (Gallo 
et al. 1983). A later review of the clinicopathological features of the two original cases 
indicated that both were consistent with ATL (Blattner et al. 1983b).
Most cases of ATL can be readily distinguished clinically and morphologically from 
MF and SS (Stansfeld 1985; Suchi etal. 1987). However there is some clinical and 
pathological overlap between ATL and CTCL. The clinical features of ATL have been 
described briefly in section 1.1.3. Clinically CTCL is associated with a better prognosis 
and more indolent course than ATL. The median survival for patients with MF was 
estimated at 10-12 years by Epstein et al. (1972) and 5 years by Cohen et al. (1980). 
Neither MF nor SS are associated with hypercalcaemia.
It may however, be more difficult to distinguish between the less aggressive forms of 
HTLV-I associated malignancy, as described by Yamaguchi etal. (1985) and Kinoshita 
etal. (1985), and other forms of CTCL. The cases of "smouldering" and "preleukemic" 
ATL described by Yamaguchi et al. (1985) and Kinoshita et al. (1985) did not follow 
an aggressive course and many presented with skin lesions. In addition, an aggressive 
form of Sezaiy cell-like leukaemia has recently been described (Matutes etal. 1990). 
HTLV-I antibodies were detected in one of the cases described in this study and the 
authors suggest that some cases of SS may be variant forms of ATL. Blattner (1989) 
has reviewed the evidence suggesting that the clinical features of the malignancies 
associated with HTLV-I show overlap with T-cell chronic lymphocytic leukaemias and 
T-cell NHLs in addition to MF and SS (Figure 1.6). In agreement with this, HTLV-I 
infection has been reported in a small number of cases of typical MF and SS (Kaplanski 
etal. 1986; Detmar et al. 1991).
The histopathology of the skin lesions seen in ATL, MF and SS is similar. MF and SS 
are characterized by the presence of small T-lymphocytes with many nuclear 
indentations ("cerebriform" cells), larger abnormal cells are also usually seen and both 
cell types may accumulate in the epidermis (Stansfeld 1985; Suchi etal. 1987). Clusters
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Figure 1.6. T-cell malignancies associated with 
HTLV-I infection.
ATL
Chronic
^A TL2 T-CLL
Smoldering
^ A T L ^T-NHL
MF-Sezary
ATL, adult T-cell leukaemia; MF-Sezary, mycosis fungoides or 
Sezary syndrome; T-CLL, T-cell chronic lymphocytic 
leukaemia; T-NHL, T-cell non-Hodgkin’s  lymphoma. The 
shaded area indicates the proportion of cases which are either 
positive for HTLV-I antibodies, or in which integration of HTLV-I 
genom es may be detected. From Blattner (1989).
of these cells (Pautrier microabscesses) are usually present in MF and may be seen in 
the skin lesions of patients with SS. In ATL the malignant cells seen in skin lesions are 
also small or medium sized T-lymphocytes with convoluted nucleii; Pautrier 
microabscesses and epidermal infiltration may be observed (Suchi et a l 1987).
The cell surface phenotype of the malignant cells of SS and MF is similar to that of the 
malignant cells in ATL (Picker et a l  1987; Slater 1987). In contrast to ATL, the 
malignant cells in CTCL have been reported to be CD25- by some authors (e.g. Matutes 
et a l  1990). However other studies have reported CD25 expression in CTCL (Nasu et 
a l 1985; Ralfkiaer e ta l  1985; Slater 1987) and rare cases of ATL are CD25+ (Pandolfi 
et al. 1985; Yoshida et al. 1989).
The majority of patients with CTCL are not seropositive for HTLV-I (Gallo et a l  
1983). However, the clinical and pathological overlap between ATL and other CTCLs 
has stimulated interest in the possibility that retroviruses related to HTLV-I might be 
involved in the aetiology of the latter conditions. A number of ultrastuctural and 
serological studies have provided evidence supporting this notion (van der Loo et a l 
1979; Fullbrandt et a l  1983; Slater et a l 1985; Lange-Wantzin et a l 1986; Ranki and 
Krohn 1987; Saal et a l  1989; Srivastava et a l  1990). These studies are discussed 
further in Chapter 5 and an experimental approach to the detection of HTLV-I related 
retroviruses is described.
1.4. (B) INVESTIGATION OF THE DISEASE ASSOCIATIONS OF
A KNOWN VIRUS.
A complementary approach to the analysis of specific lymphoproliferative diseases for 
evidence of a viral aetiology is to investigate the disease-associations of a previously 
identified virus. Such investigations are likely to focus on viruses that are related to 
known leukaemogenic agents, viruses that show transforming potential in vitro, or 
viruses that have been isolated fiom patients with lymphoproliferative disease. The role 
of a known virus in the pathogenesis of lymphoid malignancy may be investigated by 
determining the molecular association between the viral genome and tumour tissues 
(section 1.4.1). and the serological association between virus infection and disease 
(section 1.4.2).
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Some features of the recently isolated virus, HHV-6 , have stimulated interest in the 
possible involvement of this virus in haemopoietic malignancies. HHV-6 was first 
isolated from patients with a variety of lymphoproliferative disorders (Salahuddin etal.
1986) and is lymphotropic in vitro (Lusso et al. 1988). More recently this virus has 
been shown to have tumorigenic potential in nude mice (Razzaque 1990). Chapter 4 of 
this thesis describes the results of experiments to investigate the role of HHV-6 in the 
pathogenesis of human lymphomas.
1.4.1 Molecular analysis of the association between a virus and 
lymphoproliferative disease.
The association between a candidate virus and lymphoproliferative disorders may be 
analysed using a number of approaches. The presence of viral nucleic acid or viral 
protein in tumour cells may be determined using molecular or immunological 
techniques. The mechanism of viral leukaemogenesis will determine whether a disease 
association is amenable to molecular analysis. Mechanisms by which viruses may 
contribute to lymphoproliferative disease are described in the following section.
1.4.2. Mechanisms of viral leukaemogenesis.
Viruses that are known to induce leukaemia and/or lymphoma appear to do so via a 
variety of different pathogenic mechanisms. The mechanism of involvement of a virus 
in the induction of disease will determine the molecular association between the virus 
and the tumour cells. The following sections describe the direct and indirect 
mechanisms that may be involved in viral leukaemogenesis.
Direct mechanisms of viral leukaemogenesis.
Direct mechanisms of viral leukaemogenesis may be defined as those in which the 
presence of all or a part of the virus in the neoplastic cell is required at some stage in the 
transformation process. A number of different types of direct mechanism have been 
shown, or proposed, to occur in virus-induced haematopoeitic neoplasms.
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a) Cis-acting
Cis-acting mechanisms have been shown to be important in retroviral leukaemogenesis 
(e.g. Hayward et al. 1981; Neil et al. 1984). This type of mechanism involves the 
activation of cellular oncogenes by viral transduction or by insertional mutagenesis 
(Figure 1.7).
Transduction of c-myc has been shown to be a frequent event in naturally occurring 
FeLV-induced thymic lymphosarcoma (Mullins et al. 1984; Neil et al. 1984). However 
oncogene transduction appears to be relatively rare in lymphoid tumours associated 
with experimental infections of FeLV and murine and avian retroviruses (Hayward et 
aL 1981; Neil and Onions 1985).
Activation of oncogenes by insertional mutagenesis may occur via a number of 
mechanisms (Figure 1.7) (Neil and Forrest 1987). Activation of c-myc expression by 
promoter insertion has been reported in a high percentage of ALV-induced lymphomas 
(Hayward etal. 1981). In T-cell lymphomas caused by MuLV, insertion of enhancer 
elements within the viral LTR into the proximity of c-myc are thought to result in 
increased gene expression (Corcoran etal. 1984; Li et al. 1984; Selton et al. 1984).
Additional c/s-acting mechanisms are theoretically possible. Insertion of viral DNA into 
the regulatory sequences of a cellular oncogene could result in abnormal levels of 
expression (Neil and Onions 1985). Disruption of the regulatory sequences of "tumour 
suppressor" genes, or of the genes themselves, by viral insertion could result in reduced 
levels of the gene product.
b) TVfl/is-acting.
Cell transformation by some retroviruses is not associated with cw-activation of cellular 
oncogenes. For HTLV-I the failure to identify common integration sites in tumour cells 
has led to the conclusion that cell transformation is induced by a frans-acting 
mechanism (Seiki etal. 1984; Wong-Staal and Gallo 1985). Similar findings have been 
reported for BLV (Gelmann et al. 1984; Gregoire et al. 1984). EBV also appears to 
transform cells by a tfms-acting mechanism.
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Trans-acting mechanisms of leukaemogenesis are likely to involve interactions between 
viral gene products and cellular genes that play a role in the control of cell proliferation 
and/or differentiation. The mechanisms by which HTLV-I and EBV are considered to 
transform their target cells in vitro and contribute to leukaemogenesis in vivo have been 
discussed in sections 1.1.5 and 1.2.5.
c) Receptor-mediated leukaemogenesis.
The possibility that leukaemias could be induced in retrovirus-infected cells via a 
receptor-mediated effect was proposed originally by McGrath et al. (1978). This group 
reported evidence that the interaction between a radiation leukaemia virus-induced 
lymphoma and its cognate retrovirus was mediated by the T-cell receptor (TCR) 
(O’Neill et al. 1987). Evidence that this mechanism is important in naturally occurring 
virus-induced leukaemias has not been reported.
Molecular analysis of tumours induced by direct mechanisms.
Molecular analysis of tumours induced by cw-acting effects on cellular genes will show 
the presence of viral DNA. However the viral genome may be highly defective, as 
activation of oncogene expression may require only limited regions of the virus, i.e. 
those containing promoter or enhancer sequences. Viral gene products may not be 
detectable, or may be expressed as fusion proteins with host gene products.
Molecular analysis of tumours induced by a virus operating through a trans-acting 
mechanism should reveal the presence of viral nucleic acid. Defective viral genomes 
may be detected if expression of the trans-acting function requires only limited viral 
sequences. Analysis of viral expression should permit the detection of the viral gene 
produces) responsible for trans-activation.
However, virus involvem ent may be im portant only in an early  stage of 
leukaemogenesis, and may not be required for later stages, or for the maintenance of the 
tumour phenotype. The hosts immune system may exert considerable selection pressure 
on virus-infected malignant cells, permitting preferential survival of cells in which virus 
gene expression has been reduced to a minimum. The limited expression of viral gene 
products in both BL and ATL may be examples of this effect. An alternative scenario 
may be envisaged, in which selection pressure due to the hosts immune response
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permits preferential survival of cells in which viral nucleic acid has been lost from 
tumour cells. This would represent a "hit and run" effect by the virus. Analysis of the 
malignant cells would not reveal the presence of viral nucleic acid in tumours induced 
by this type of mechanism. However the analysis of premalignant lesions may enable an 
association between virus infection and disease pathogenesis to be established.
Molecular analysis of the tumour cells in a lymphoproliferative disorder induced by a 
receptor-mediated mechanism should reveal the presence of both viral nucleic acid and 
viral proteins. Loss of viral gene expression would be associated with loss of the 
proliferative signal and therefore with the regression of disease.
Indirect mechanisms of viral leukaemogenesis.
Failure to detect evidence of virus infection of tumour cells does not preclude the 
possibility that the virus is involved in the pathogenesis of disease. Viruses may play a 
role in the pathogenesis of leukaemias or lymphomas in the absence of infection of the 
tumour cells. A variety of mechanisms by which viruses may contribute indirectly to 
leukaemogenesis have been proposed.
a) Virus induced immunosuppression.
Immunosuppression is associated with an increased incidence of lymphomas and 
leukaemias (Filipovich etal. 1990). Neil and Forrest (1987) have reviewed some of the 
models that could explain this phenomenom. A compromised immune system may be 
less able to eliminate transformed cells. Alternatively immunosuppression may permit 
infection by some other oncogenic virus or reactivation of a latent oncogenic virus. An 
immunosuppressive virus could contribute to leukaemogenesis by increasing the rate of 
recruitment of undifferentiated haematopoietic cells due to the destruction of mature 
lymphoid cells. The increased pool of proliferating cells would increase the probability 
that additional, tumorigenic, genetic events will occur.
A number of viruses induce immunosuppression in infected hosts. HIV infection is 
associated with an increased risk of developing lymphomas; between 7% and 12% of 
AIDS patients have been estimated to develop NHL during the course of disease 
(Cremer etal. 1990; Ziegler and McGrath 1990). The majority of these are high grade 
B-cell lymphomas which frequently occur in extra-nodal sites (Ziegler and McGrath
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1990). The pathogenesis of HIV-associated B-cell NHL appears to involve multiple 
mechansisms. Between 38% and 50% of lymphomas occurring in HIV-infected persons 
are associated with EBV (Suber etal. 1988; Boiocchi et al. 1990; Chappuis et al. 1990; 
Cremer et al. 1990).
b) Immune stimulation.
Many models of leukaemogenesis have, as a central tenet, the assumption that increased 
proliferation of immature lymphocytes increases the risk of transforming events 
occurring in the dividing (and differentiating) cells. Examples are the models proposed 
by Klein (1979) and Yoshida and Seiki (1987) for the pathogenesis of BL and ATL 
respectively. These authors suggest that lymphocyte proliferation is induced by virus 
infection of the target cells.
Chronic activation of the immune system due to other causes would also be expected to 
result in an increased risk of developing lymphoid malignancies. Virus infections could 
result in chronic stimulation of the immune system due to continued antigen 
presentation in persistently infected hosts, or as a result of virus induced release of 
growth factors. Virus infection may also result in changes in antigen expression by 
infected cells (Miyagawa et al. 1988; Baboonian et a l  1989). Such changes could 
create novel targets for the immune system and thus result in chronic immune 
stimulation.
Immune stimulation in response to acute encounters with infectious agents may also be 
important in predisposing proliferating lymphoid cells to tumorigenic events. 
Stimulation of the immune response in infancy and early childhood, as a result of initial 
encounters with exogenous antigens, has been proposed as an explanation for the age 
distribution of the common (B-cell precursor) form of acute lymphoblastic leukaemia 
(Greaves 1988).
(c) Interactions between viruses.
Infection by a virus may indirectly contribute to leukaemogenesis by activating other 
oncogenic viruses. This may involve direct effects on viral replication following 
infection of the same cell, or an indirect effect, through stimulating cell proliferation 
and activating replication of a latent virus present in the cell. Interactions between 
herpesviruses and retroviruses are discussed further in Chapter 4.
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Molecular analysis of tumours induced by indirect mechanisms.
Molecular analysis of tumour samples from patients with lymphoid malignancies that 
are induced by the indirect mechanisms described above will not, in most cases, reveal 
the presence of virus.
However for some of the possible indirect mechanisms described above, molecular 
analysis may provide circumstantial evidence for viral involvement in disease 
development. If chronic antigenic stimulation and/or lymphokine release by virus 
infected cells is important in pathogenesis, evidence of viral antigen expression in the 
tissues in which lymphomas develop may be detectable.
The detection and interpretation of evidence for the involvement of viral interactions in 
leukaemogenesis may be difficult. The results obtained in molecular analysis will 
depend on the mode of interaction between the viruses and on the mechanisms of 
leukaemogenesis.
1.4.3 Determining the significance of a molecular association.
a) Determination of the clonality of the tumour cells and virus infected cells.
Techniques for determining the clonal nature of lymphoproliferative disorders have 
been mentioned in section 1.3.2 and are discussed further in Chapter 3. Viruses capable 
of transforming cells by a single step mechanism would produce polyclonal tumours. 
Viruses containing transduced oncogenes may induce polyclonal malignancies when 
experimentally transmitted to susceptible hosts (Frykberg et al. 1983; Teich et al. 
1984). However many oncogene-containing viruses induce monoclonal tumours (e.g. 
Baumbach et al. 1986) suggesting that additional events may be required for 
transformation in vivo.
The majority of clinically overt lymphomas and leukaemias are monoclonal in nature. 
Determination of the clonality of virus-infected cells permits an assessment of the 
possible role of the virus in disease pathogenesis. If the virus is present in the tumour 
cells, evidence that the clonality with respect to virus infection differs from that of the
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tumour suggests that the virus is not playing a direct role in the development of the 
malignancy. In particular, failure to detect evidence that clonal proliferation of virus- 
infected cells has occurred indicates that virus infection has taken place after tumour 
development.
The clonal origin of retrovirus infected cells may be assessed by the molecular analysis 
of integration sites. Clonal expansion of a single retrovirus-infected cell produces a cell 
population with a common site of retroviral integration, which can be detected by 
molecular analysis. A technique for determining the clonal origin of EBV-infected cells 
has been described by Raab-Traub and Flynn (1986). Size variations in the fused 
terminal fragments of the virus are generated when replicating linear virus forms 
circular episomes following cell infection. The detection of a unique fused terminal 
fragment of EBV in a cell population indicates amplification of a single episome of 
EBV and by inference, clonal proliferation of a single EBV-infected cell (Figure 1.8).
However the demonstration that the clonality of the virus infected cells coincides with 
the clonality of the malignancy does not necessarily prove that the virus is involved in 
disease pathogenesis. The same result could be obtained if malignant transformation 
occurs in a cell which is already infected by virus. Henderson (1989) has suggested that 
EBV is purely a passenger virus in NPC and that the association between NPC and 
EBV is due to malignant transformation of epithelial cells that normally harbour EBV. 
This is, however, a contentious suggestion (see for example de-The et al. 1989b).
b) Determination of the consistency of an association between the presence of a 
virus and disease.
The detection of a consistent association between a particular lymphoid malignancy and 
the presence of a virus in the tumour cells would be significant evidence supporting a 
role for the virus in the pathogenesis of that malignancy. However such a finding may 
not be considered proof that the virus is playing a role in disease development, even if 
the virus infected cells are shown to be clonal.
As mentioned above, Henderson (1989) has suggested that EBV is a passenger virus in 
NPC, despite the detection of EBV DNA in nearly 90% of NPC biopsies (Zur Hausen 
1970; Nonoyama et a l 1973; Desgranges et al. 1975). If EBV is not involved in the 
pathogenesis of NPC, it is necessary to postulate virus infection of approximately 90%
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or greater of the epithelial cells that are the tumour cell precursors. Alternatively virus 
infection of this cell type must occur in approximately 90% or more of individuals that 
are susceptible to the development of NPC.
Conclusive proof that EBV is a passenger virus in NPC is likely to be difficult to 
establish. Seroepidemiological studies demonstrate a characteristic immune response to 
EBV antigens in NPC patients, suggesting that the host-virus interaction is disrupted in 
NPC (de-The etal. 1989b). However this could conceivably occur as a consequence of 
tumour development
Failure to detect a consistent association between the presence of a virus in tumour cells 
and a specific malignancy may be taken to indicate lack of viral involvement in the 
aetiology of that disease. However alternative interpretations should also be considered, 
as discussed below.
(i) Inappropriate disease classification.
The importance of disease classification in investigating the viral aetiology of 
lymphoproliferative disorders has been discussed in section L3. The detection of viral 
involvement in a consistent proportion of cases of a particular malignancy may indicate 
the existence of distinct entities within the disease classification.
(ii) Genetic events producing the same phenotypic changes.
For many of the direct and indirect mechanisms of viral leukaemogenesis described 
above, it is possible to envisage genetic or other non-virus related events that could 
produce the same effect. The resulting tumour could be phenotypically identical to 
virus-induced tumours, but molecular analysis would not reveal the presence of virus. A 
similar explanation was proposed by Shimoyama et al. (1986) to explain the occurrence 
of ATL in five persons, in the absence of molecular or serological evidence of HTLV-I 
infection. A second example is provided by the occurrence of EBV-positive and EB V- 
negative sBL.
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1.4.4. Seroepidemiological analysis of the association between a virus
and lymphoproliferative disease.
Evidence for the involvement of a virus in lympoproliferative disease may also be 
obtained as the result of seroepidemiological studies. Such analyses may provide the 
only way to establish the indirect involvement of a virus in disease pathogenesis. The 
relationship between the occurrence of disease and virus seroprevalence will depend on 
the efficiency with which the virus induces disease and on the involvement of non-virus 
associated factors in disease pathogenesis.
Non-virus associated factors that have been identified as influencing the development 
of virus-induced lymphoid malignancies include the dosage of infecting virus, the age 
at which virus infection is acquired and the immune status of the host The importance 
of the latter two parameters in the development of HTLV-I and EBV-associated 
lymphomas has already been discussed (sections 1.1.4 and 1.2.2-1.2.4).
The establishm ent of a correlation between disease development and viral 
seroprevalence will not be possible if virus infection is ubiquitous, as is the case for 
many of the human herpesviruses. Virus involvement in disease may, however, be 
reflected by abnormal or distinctive responses to viral antigens, as has been reported for 
patients with NPC or BL who show elevated antibody titres to specific EBV antigens 
(de-The et al. 1989b; Evans and de-The 1989).
The use of seroepidemiological studies to evaluate the role of viruses in the aetiology of 
leukaemias and lymphomas is not discussed further here, as this approach was not used 
in the experiments described in this thesis. Chapter 4 describes the results of 
experiments to determine the role of HHV-6 in lymphoproliferative diseases. Molecular 
analysis of biopsy material from patients with a variety of disorders was used to 
determine the presence of HHV-6  DNA sequences in tumour samples. These 
investigations were performed in parallel with a case-controlled study to determine the 
seroprevalence and titres of HHV-6 antibody in patients with various haematological 
malignancies (Clark eta l. 1990). The results obtained in the molecular studies 
described in Chapter 4 are discussed in the context of findings of Clark et al. (1990).
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1.5 (C) THE DETECTION OF VIRUSES RELATED TO KNOWN 
LEUKAEMOGENIC VIRUSES.
A third approach to the identification and isolation of novel leukaemogenic viruses of 
humans is to search for viruses related to known leukaemia viruses. Members of the 
Herpesviridae and Retroviridae are known to be leukaemogenic in man and other 
animals. Both molecular and serological approaches have been used in attempts to 
isolate novel, related viruses.
1.5.1 Molecular approaches.
A number of groups have used low-stringency hybridization of retroviral probes to 
search for related DNA sequences in the human genome (e.g. Bonner etal. 1982; Noda 
et al. 1982; Callahan etal. 1985). The puipose of most of these studies was to search 
for endogenous retroviral sequences, rather than to identify novel exogenous 
retroviruses. A similar approach has been employed to analyse lymphoma material for 
the presence of HTLV-related sequences (Manzari et al. 1987; R.F. Jarrett and S. 
Gledhill, unpublished data). The results obtained by Manzari etal. (1987) are discussed 
further in Chapter 5. Low-stringency hybridization suffers from the disadvantage that 
related sequences in cellular DNA will give background hybridization and will limit the 
sensitivity of the technique.
The development of the PCR has permitted a more specific approach based on the use 
of conserved regions of viral genomes for PCR primers to obtain the amplification of 
intervening divergent sequences. The use of the PCR allows the analysis of small 
amounts of sample DNA and permits the precise selection of sequences predicted to be 
conserved. Selection of appropriate primer sequences may utilize regions that have been 
identified as being highly conserved between viruses.
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Bangham etal. (1988) used primers derived frompol gene sequences, which are highly 
conserved between diverse retroviruses, to amplify HTLV-I sequences from DNA 
samples from patients with TSP. Amplification of a number of retrovirus related 
sequences was also obtained, these included two endogenous Moloney MuLV-related 
retroviruses. The results described in this report illustrate one of the limitations of this 
approach, as selection of highly conserved retroviral sequences is likely to increase the 
probability of amplifying endogenous retroviral DNA.
1.5.2. Serological approaches.
*
Serological approaches to the detection of novel leukaemogenic viruses have utilized a 
variety of assays to detect the presence of antibodies in patient sera that cross-react with 
viral antigens. A novel retrovirus has been detected using this approach; the patient 
from which HTLV-II was first isolated was initially identified using assays for HTLV-I 
antibody (Kalyanaraman etal. 1982). Many studies have analysed sera from patients 
with a variety of malignancies for evidence of antibodies that cross-react with retroviral 
antigens (e.g. Lange Wantzin et al. 1986; Maeda et al. 1986; Ranki and Krohn 1987; 
Kovarik et al. 1989; Srivastava et al. 1990). Enzyme-linked immunoassays (ELISAs) 
and Western blots (WB) using HTLV-I proteins have been used by a number of groups 
to search for evidence that either HTLV-I or a related retrovirus is present in patients 
with CTCL (Lange Wantzin etal. 1986; Ranki and Krohn 1987; Srivastava et al. 1990). 
The results obtained in these studies are discussed further in Chapter 5.
The results of such studies may be difficult to interpret as a variety of alternative 
explanations for the detection of antibodies to retroviral antigens in sera of non-infected 
persons have been proposed (Barbacid et al. 1980; Snyder and Fleissner 1980; Talal et 
al. 1990a). In addition, confirmation that the cross-reacting antibodies do indicate 
infection with a related virus requires the isolation or identification of the virus by other 
means, such as electron microscopy.
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1.5.3 A combined approach.
Some of the problems associated with the use of the PCR for the amplification of 
conserved viral sequences, and with the use of serological assays for the detection of 
cross-reacting antibodies could be circumvented by a combined approach. The 
identification of the precise regions of viral proteins that are reacting with antibodies in 
sera that show cross-reactivity in immunological assays will indicate the location of 
conserved regions in a related virus. The amino acid sequence of the putative conserved 
regions could then be used to derive redundant nucleotide sequences for use as PCR 
primers. Chapter 5 describes the results of experiments designed to identify the regions 
of HTLV-I core proteins that cross-react with HTLV-I-negative sera. The purpose of 
these experiments is to generate information that could be used to design PCR primers 
for the amplification of HTLV-I related retroviruses.
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CHAPTER TWO 
GENERAL MATERIALS AND METHODS.
41
Table ll.l. Sources of routinely used materials.
Materials Source
Apparatus for agarose gel electrophoresis BRL
Apparatus for polyacrylamide gel electrophoresis Biorad
Corex centrifuge tubes (30ml) Sarstedt
Falcon tubes (15ml, 50ml) A&J Beveridge Ltd.
Filter paper (Whatman, grade) Scotlab
Filter paper (Whatman, 3MM) Scotlab
Filtration units (Nalgene, 0.2um) A&J Beveridge Ltd.
Fliptop microcentrifuge tubes (1.5ml) Scotlab
Nylon membrane (Hybond-N) Amersham Int. pic.
Oakridge centrifuge tubes (30ml) Sarstedt
Petri dishes Scotlab
Pipette tips (Rainin) Scotlab
Pipette tips (Treff) Scotlab
Polaroid film (Type 57) Genetic Research 
Instrumentation Ltd.
Table 11.11. Stock solutions and buffers.
Acrylamlde stock solution (30%)
acrylamide 29%
N.N’-methylenebisacrylamide 1%
6% acrylamide solution for denaturing polyacrylamide gels
acrylamide stock solution (30%) 200mls/L
TBE 1 x
urea 7.6M
Alkaki buffer
sodium hydroxide 0.5M
sodium chloride 1.5M
adjusted to >pH12.0
Denhardt’s  solution (100 x)
Ficoll 2%
Bovine serum albumin (Fraction V) 2%
poiyvinylpyrollidone 2%
Elution buffer for removal of DNA fragments from DEAE membrane
sodium chloride 1M
TrispH9.0 50mM
EDTA 1mM
Extraction buffer for the purification of high molecular weight DNA
sodium chloride 144mM
Tris 10mM
EDTA 1mM
adjusted to pH8.0
10 x Loading buffer for nondenaturing gel electrophoresis
bromophenolblue 0.42%
xylene cyanol 0.42%
glycerol 50%
Neutralizing buffer
Tris base 0.5M
sodium chloride 3M
concentrated hydrochloric acid 3.3%
adjusted to pH8.0
Table 11.11. Stock solutions and buffers (continued).
Potassium acetate (3M/5M)
potassium acetate (5M) 
glacial acetic acid 
deionized water
ssc
sodium chloride 
sodium citrate
Southern hybridization buffer
Formamide
sodium dodecyl sulphate
Denhardts solution
Tris pH7.4
EDTA
SSC
TAE
Tris
sodium acetate 
sodium chloride 
EDTA
adjusted to pH8.0
TBE
Tris
boric acid 
EDTA
adjusted to pH8.0
TrispH8.0 
EDTA pH8.0
TNE
sodium chloride
Tris
EDTA
adjusted to pH8.0
60mls 
11 mis 
28.5mls
0.15M 
0.015M
50%
0.1%
5x
50mM
10mM
3x
40mM
20mM
20mM
2mM
90mM
90mM
2.25mM
10mM
1mM
0.1 M
10mM
1mM
Table ll.lll. Composition of bacterial media.
Luria-Bertanl (LB) medium
sodium chloride 
bactotryptone 
bacto-yeast extract 
adjusted to pH7.0
Minimal medium
potassium hydrogen phosphate (monobasic)
potassium hydrogen phosphate (dibasic)
ammonium sulphate
sodium citrate
magnesium sulphate
glucose
thiamine
SOB
bactotryptone 
yeast extract 
sodium chloride 
potassium chloride 
magnesium chloride 
magnesium sulphate 
adjusted to pH7.0
170mM
1%
0.5%
50mM
10mM
30mM
8.5mM
0.4mM
11mM
60um
2%
0.5%
10mM
2.5mM
10mM
10mM
2. GENERAL MATERIALS AND METHODS.
The following sections describe the materials and methods that have been used 
frequently in the experiments reported in this thesis. In addition, the majority of the 
experimental methods involving DNA manipulations are described in this chapter. The 
details of the materials and methods employed in additional experiments are given in 
the relevant chapters.
2.1. MATERIALS.
The sources of routinely used materials are detailed in Table II.I. The sources of 
additional materials are given elsewhere in the text.
2.1.1. Chemicals.
All chemicals were of Analar or molecular biology grade and were obtained from The 
Sigma Chemical Company or BDH except where stated. Deionized, filtered water 
(MilliQ water filtration system, Millipore) was used in all the buffers utilized for 
enzyme-catalysed reactions and also for the dissolution of DNA and proteins. 
Deionized water obtained from a MilliQ reverse osmosis system (Millipore) was used 
to make up all other buffers and for all other procedures.
2.1.2. Bacterial strains.
Eshchericia coli (E. coli) strains HB101 (genotype supE44 hsdS20[rg-mg-] recA13 
ara-14 proA2 lacYl galK2 rpsL20 xyl-5 mtl-1) and DH5a (genotype supE44 
lacli 169[d>801acZ M15] hsdR17 recAl endAl gyrA96 thi-1 relAl) were obtained from 
Gibco BRL. E. coli strains JM105 (genotype supE endA sbcB15 hsdR4 rpsL thi [lac- 
proAB] F*[traD36 proAB+ lacW lacZ M15]) and JM109 (genotype recAl supE44 
endAl hsdR17 gyrA96 relAl thi [lac-proAB] F’[traD36 proAB+ lacl^ lacZ M15]) 
were obtained from Pharmacia.
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2.2. PURIFICATION AND SEPARATION OF NUCLEIC ACIDS.
2.2.1. Preparation of high molecular weight DNA from eukaryotic 
cells.
High molecular weight DNA was prepared from PBMCs or biopsy material as follows. 
Tissue biopsies were disrupted in 5mls of extraction buffer (Table II.II) in a sterile 
polythene bag using a Stomacher 80 (Colworth). The resulting cell suspension was 
pelleted by centrifugation at 2500 revolutions per minute (ipm) for 5 minutes at room 
temperature and then washed twice in extraction buffer.
PBMCs were isolated from whole blood by centrifugation in Ficoll Paque. Peripheral 
blood samples were collected into an equal volume of RPM I1640 containing 20u/ml 
preservative free heparin. Five to twenty millilitres of the diluted sample was layered 
onto an equal volume of Ficoll Paque and centrifuged at 2500 rpm for 15 minutes at 
room temperature. Mononuclear cells were removed from the interphase and washed 
twice in extraction buffer.
The cell pellets from either source were resuspended in 5-25mls of extraction buffer. 
Sodium dodecyl sulphate (SDS) and proteinase K were added to final concentrations of 
0.5% and 50|ig/ml respectively and the mixture incubated at 50°C for 60 minutes or at 
40°C for 90 minutes. An equal volume of phenol was added to the lysate and the phases 
mixed slowly for 10 minutes. Phenol was equilibrated with 0.1M Tris pH8.0 prior to 
use. Following centrifugation at 2500 rpm for 10 minutes at room temperature the 
aqueous phase was removed to a sterile tube using a wide-tipped pasteur pipette. An 
equal volume of chloroform containing 4% isoamylalcohol was added, the phases 
mixed thoroughly and then separated as before. A wide-tipped pipette was used to 
transfer the aqueous phase into at least two times the volume of 100% ethanol. High 
molecular weight DNA was spooled onto a sealed pasteur pipette and transferred to a 
microcentrifuge tube. The DNA pellet was washed first in 70% ethanol then in 100% 
ethanol and the pellet dried for 2-3 hours. The DNA pellet was resuspended in TE 
(Table II.II) and incubated at 37°C for 5-16 hours until the DNA was completely 
dissolved.
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The concentration and purity of the DNA solution were determined by measuring the 
optical density of the solution at wavelengths of 260nm (O .D ^ q )  anc* 280nm 
(O J).2go)‘ The concentration of the DNA solution was estimated on the basis of the 
assumption that an O.D.250  of 1-0 corresponds to 50ug/ml of double stranded DNA 
(Maniatis et al. 1982). The purity of the solution was determined by calculating the 
O.D.26()/O*D-280 ra^°* ^  this value deviated significantly from the value expected for 
pure DNA solutions, i.e. 1.8 (Maniatis et al. 1982), the estimated DNA concentration 
was not considered to be reliable.
2.2.2. Preparation of plasmid DNA.
a) Small-scale procedure.
Small quantities of plasmid DNA were prepared for analysis using the alkaline lysis 
method described by Bimboim and Doly (1979).
A single bacterial colony was inoculated into 5mls of culture medium containing the 
appropriate antibiotic and incubated overnight at 37 °C with vigorous shaking. E. Coli 
strains HB101 and DH5a were cultured in Luria-Bertani (LB) medium (Table n.m), E. 
Coli strains JM105 and JM109 were cultured in minimal medium (Table n.III). A 
1.5ml aliquot of the culture was transferred into a microcentrifuge tube and centrifuged 
briefly. The supernatant was discarded and the pellet resuspended by vortexing in lOOfil 
of ice cold 25mM Tris, lOmM disodium ethylene diamine tetraacetate (EDTA), 50mM 
glucose, pH8.0 (solution 1), The tubes were left at room temperature for 5 minutes and 
then 200pl of a freshly prepared solution of 0.2M sodium hydroxide, 1% SDS (solution 
2) added. The tube contents were mixed gently and placed on ice for 5 minutes. One 
hundred and fifty microlitres of an ice cold solution of potassium acetate 3M/5M, pH 
4.8 (solution 3, Table H.II) were added, the mixture vortexed gently and then stored on 
ice for 5 minutes. Cell debris and bacterial DNA were pelleted by centrifuging briefly 
in a microcentrifuge and the supernatant was removed to a fresh tube. The solution of 
DNA was further purified by adding an equal volume of 50% phenol, 48% chloroform, 
2% isoamyl alcohol (PCI9), vortexing, centrifuging for 2 minutes and transferring the 
aqueous phase to a clean tube.
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The DNA was precipitated by the addition of 2 volumes of 100% ethanol. The mixture 
was incubated at room temperature for 2 minutes and the DNA pelleted by 
centrifugation in a microcentrifuge for 15 minutes at room temperature. The supernatant 
was decanted and the pellet washed by vortexing in lOOpl of 70% ethanol. After 
aspiration of the supernatant the pellet was allowed to dry then resuspended in 50jil of 
TE.
The identity of purified plasmid DNA was routinely checked by digestion of lOjil of 
DNA in TE with appropriate restriction endonucleases as described in section 2.3.2 and 
analysis of the fragments by agarose or polyacrylamide gel electrophoresis (sections 
2.2.3 and 2.2.5).
b) Large-scale procedure.
Large quantities of plasmid DNA were prepared using a similar procedure, modified as 
described in Maniatis et al. (1982). Bacteria containing the required plasmid were 
grown in 500mls of LB or minimal medium, as detailed above, with the appropriate 
antibiotic at 37°C for 16 to 20 hours.
The cells were harvested by centrifugation at 7000rpm for 10 minutes at 4°C and 
resuspended in TNE (Table HII). Cells were washed once in TNE and resuspended in 
8mls of solution 1. Lysozyme was added to a final concentration of 5mg/ml and the 
mixture incubated at room temperature for 5 minutes. The DNA was denatured by the 
addition of 16mls of freshly made solution 2. The mixture was vortexed and incubated 
on ice for 10 minutes. Plasmid DNA was reannealed by neutralizing the solution with 
12mls of solution 3. After gentle agitation the mixture was replaced on ice for a further 
10 minutes.
Cell debris was pelleted by centrifugation at 19000rpm for 30 minutes at 4°C in a JA20 
rotor (Beckman). The supernatant was transferred into 30ml glass corex tubes, mixed 
with 0.6 volumes of isopropyl alcohol and the DNA precipitated by incubation at room 
temperature for 15 minutes. The precipitate was collected by centrifugation at 
lOOOOrpm for 30 minutes at 4°C in a JA20 rotor, washed with 70% ethanol and dried 
for 10 minutes.
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The plasmid DNA was further purified by centrifugation to equilibrium in a caesium 
chloride/ethidium bromide gradient. The DNA pellet was suspended in 4-5mls of TE 
and lg of caesium chloride added per millilitre of DNA solution. Ethidium bromide was 
added to a final concentration of 740}i,g/ml and the solution transferred to Beckman 
’quick seal* centrifuge tubes. Any air space remaining in the tubes was filled with light 
paraffin oil and the tubes were then heat sealed. DNA was separated on a density 
gradient by centrifugation in a Vti 65.2 rotor (Beckman) at 49000rpm for 16 hours at 
20°C. Supercoiled plasmid DNA bands at higher density on the gradient than 
fragmented bacterial DNA due to a lower level of incorporation of ethidium bromide 
(Radloff etal. 1967), and thus may be visualized as the lower band on the gradient The 
lower band was removed in a volume of 2mls using a 23 gauge hypodermic needle and 
5ml syringe.
The solution was diluted three to four-fold with TE and the ethidium bromide removed 
by repeated extraction with water saturated 1-butanol. When no visible colour was 
detectable in the aqueous phase, 2 volumes of 100% ethanol were added and the 
plasmid DNA was precipitated at -20°C for 2 hours. The DNA was then pelleted by 
centrifugation at lOOOOrpm for 30 minutes at 4°C in a JA20 rotor. The pellet was 
washed with 70% ethanol, allowed to dry for 1 hour and resuspended in TE. Plasmids 
were routinely stored at 4°C.
Before use in nucleotide sequencing reactions, plasmid DNA was further purified by 
dialysis. Approximately lmg of plasmid DNA was diluted in 2.5mls of TE, clamped in 
prepared dialysis tubing of three quarters of an inch diameter (Gibco BRL) and dialysed 
against 2L of TE (3 x 8 hours) at 4°C. The DNA was precipitated from solution by the 
addition of sodium chloride to a final concentration of 0.4M followed by the addition of 
2 volumes of ethanol. The DNA was pelleted by centrifugation at lOOOOrpm for 30 
minutes at 4°C, washed in 70% ethanol and resuspended in TE.
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2.2.3. Agarose gel electrophoresis.
The following protocol was used for the separation of restriction enzyme digested high 
molecular weight DNA. Following restriction enzyme digestion, DNA fragments were 
size separated in agarose on horizontal slab gels. Agarose was made up at 0.6-0.8% 
weight/volume (w/v) in TBE buffer (Table n.II) and dissolved by heating. The solution 
was cooled to 55°C before pouring onto a horizontal perspex bed and was left to 
solidify with the well-forming comb in position. The gel was submerged in an 
electrophoresis tank, covered with TBE buffer and the well-forming comb removed.
Prior to electrophoresis, restriction endonuclease-digested DNA samples were heated to 
65°C for 5 minutes and a 1/10 volume of loading buffer (Table II.II) added. The 
samples were loaded into the wells and a constant potential difference of 1.3 V/cm 
applied across the gel for 20 hours. The gel was then immersed in a staining solution of 
TBE containing 0.5jig/ml of ethidium bromide for 30 minutes and destained in TBE for 
a further 30 minutes. The DNA was visualized on a transilluminator (Foto/Prep I, 
Fotodyne Inc.) at 300nm, in analytical mode and photographed on a Polaroid MP4 
Land camera with Polaroid Type 57 high speed film.
The sizes of restriction enzyme-digested DNA fragments were estimated by 
comparison with the migration distances of DNA fragments of known sizes. For this 
purpose, 0.5-1.0|ig of Hindlll digested bacteriophage (phage) lambda DNA (Gibco 
BRL) were electrophoresed alongside each batch of DNA samples.
2.2.4. Purification of DNA inserts from agarose gels.
DNA fragments larger than 0.5kb were purified on agarose gels following restriction 
endonuclease digestion. Agarose gels were prepared with a 0.8% solution of agarose in 
TAE buffer (Table II.II) essentially as described above but with the addition of 
0.5pg/ml ethidium bromide to the agarose solution immediately prior to pouring the 
gel. DNA samples were loaded into wells at 2-5}ig per 0.5cm well and electrophoresed 
at 4V/cm for 3-5 hours. The separation of DNA fragments was checked by 
visualization under ultraviolet light (366nm) using a hand-held transilluminator (Model 
UVGL-58, UVP Inc., Gallenkamp).
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DNA fragments were purified from agarose gels using one of two methods.
a)DEAE membrane.
Following separation of DNA fragments as described above, a scalpel incision was 
made in the gel immediately in front of the DNA fragment to be purified. A strip of 
NA45 DEAE membrane (Schleicher and Schuell, Anderman & Co.) was inserted into 
the incision such that further migration of the DNA fragment would be completely 
impeded by the membrane. The gel was replaced in the electrophoresis tank and a 
potential difference reapplied. When the DNA fragment had migrated onto the DEAE 
membrane this was removed from the gel and excess membrane trimmed away.
The DEAE membrane was then placed in sufficient elution buffer (Table 11.11) to just 
cover the membrane and incubated at 65 °C for 1 hour. Complete elution of DNA from 
the membrane was confirmed by examination under ultraviolet light. An equal volume 
of PCI9 was added and the mixture vortexed then centrifuged briefly in a 
microcentrifuge. DNA was precipitated from the aqueous phase by the addition of two 
volumes of 100% ethanol followed by incubation at -20°C for 2 hours. The precipitate 
was collected by centrifugation at 13000ipm for 30 minutes at 4°C, the pellet washed 
with 70% ethanol and then dried for 15 minutes at room temperature. The pellet was 
resuspended in TE and the DNA concentration estimated following agarose gel 
electrophoresis by comparison with DNA samples of known concentration. DNA 
fragments for use as radioactively-labelled probes were stored at 4°C while fragments 
for subcloning were stored at -20°C until required.
b) Glass beads.
Some DNA fragments were purified from agarose using glass beads supplied with a 
chaotropic buffer and wash buffer as "Geneclean" (Stratech Scientific). Following 
electrophoresis the DNA fragment was visualized under ultraviolet light and the agarose 
block containing the fragment excised using a scalpel. The gel slice was cut into 
approximately 2mm cubes and transferred to a microcentrifuge tube. The weight of the 
gel slice was determined and the agarose dissolved by incubation in 2-3 volumes of 
sodium iodide solution at 55°C. An appropriate volume of "Glassmilk" was added to 
the solution (5|il for solutions containing less than 5|ig of DNA with an additional 2pl
48
for every additional 1|xg) which was then mixed gently and incubated on ice for 5 
minutes. The glass beads were pelleted by spinning briefly in a microcentrifuge and 
washed three times with the wash buffer supplied with the "Geneclean" kit DNA was 
then eluted from the glass beads by incubation in an equal volume of TE at 55 °C for 2- 
3 minutes.
2.2.5. Polyacrylamide gel electrophoresis.
Polyacrylamide gel electrophoresis (PAGE) was used for the separation and purification 
of DNA fragments less than 0.5kb in length. Acrylamide solutions were made up from a 
stock solution (Table II.II) to a final concentration of 3.5-12% in TBE and polymerized 
by the addition of 0.06% (w/v) ammonium persulphate and 0.03% TEMED. The gel 
(20cm x 20cm x 3mm) was poured between glass plates and allowed to polymerize for 
1 hour with the well-forming comb in place. After polymerization was completed, the 
well-forming comb was removed and the wells thoroughly flushed with water and TBE. 
DNA samples in loading buffer were loaded onto the gel at up to ljig per 0.5cm well. 
Electrophoresis was performed in vertical gels, using TBE as the running buffer, at 
9V/cm for 4-5 hours or 1.3V/cm overnight. DNA fragments were visualized using 
ultraviolet light following staining of the gel in ethidium bromide and destaining as 
previously described.
DNA fragment sizes were estimated by comparison with the migration distances of 
DNA fragments of known size. For this purpose, 0.5-1.0pg of PhiX174 RF DNA 
digested with the restriction enzyme Haelll (Gibco BRL) were electrophoresed 
alongside each batch of DNA samples.
2.2.6. Purification of DNA from acrylamide gels.
Following PAGE, gel slices containing DNA fragments to be purified were excised 
from the gel, cut into fine pieces and transferred to a microcentrifuge tube. DNA was 
eluted from the gel fragments by incubation in two volumes of 0.5M ammonium 
acetate, ImM EDTA, pH8 at 37°C for 2-16 hours (the longer times being required for 
the elution of larger fragments). The gel pieces were pelleted in a microcentrifuge and 
the supernatant removed. Any remaining acrylamide was removed by extracting the 
solution with an equal volume of phenol followed by an equal volume of chloroform
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containing 4% isoamyl alcohol. The DNA was then precipitated at -20°C after the 
addition of 2 volumes of 100% ethanol. The precipitate was recovered by 
centrifugation, rinsed in 70% ethanol, dried and resuspended in TE.
2.2.7. Denaturing polyacrylamide gel electrophoresis.
Denaturing polyacrylamide gels were used for the electrophoretic separation of 
radioactively-labelled DNA fragments generated by nucleotide sequencing reactions 
(section 2.3.6).
Preparation of denaturing polyacrylamide gels.
Gel plates for the nucleotide sequencing apparatus (Biorad) were prepared by thorough 
washing in phosphate-free detergent, water and finally 100% ethanol. One of the gel 
plates was silicone treated to prevent the polyacrylamide adhering to both plates 
following electrophoresis. Silicone treatment was accomplished by pouring 1ml of 
dimethyldichlorosilane solution onto the plate, wiping the fluid gently over the plate 
and allowing the plate to dry in an extractor hood. This process was repeated twice and 
then the gel mould assembled, using wedge-shaped spacers (0.25-0.53mm thick) to 
form a mould of dimensions 40cm x 20cm.
Electrophoresis was performed in 6% denaturing polyacrylamide gels (Table D.II) using 
TBE as the running buffer. Ten millilitres of the 6 % acrylamide solution was 
polymerized by the addition of 125pl of 10% ammonium persulphate and 27[xl of 
N,N,N\N’-tetramethylethyldiamine (TEMED) and used to seal the base of the gel 
mould. After polymerization of the seal was complete, an additional 40mls of 6% 
acrylamide solution was mixed with 270^1 of 10% ammonium persulphate and 27pl of 
TEMED and poured into the gel mould using a syringe and 19 gauge needle. The well- 
forming comb was inserted and the gel placed at a angle of approximately 2 0 ° to the 
horizontal and allowed to polymerize for 1 hour.
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Electrophoresis of nucleotide sequencing reaction products.
Prior to electrophoresis the well-forming comb was removed and the wells flushed with 
TBE to remove unpolymerized acrylamide. The gel was then placed in a vertical 
electrophoresis apparatus (Biorad) and pre-heated by applying a potential difference of 
1500V across the electrodes for 1 hour prior to loading the DNA samples. The wells 
were flushed again with TBE before loading the gel. The products of the nucleotide 
sequencing reactions (section 2.3.3) were heated to 80°C for 2 minutes then 
immediately placed on ice and 2 pi of each reaction mixture loaded onto the gel.
Electrophoresis was performed at a constant voltage of 1500V and continued for 1-5 
hours, depending on the length of sequence information required. On some occasions, 
in order to obtain the maximum amount of information from each sequencing reaction, 
additional 2|il aliquots of each reaction were loaded onto the gel 2-3 hours after 
commencing electrophoresis of the initial samples.
Autoradiography of the gels.
Following electrophoresis the apparatus was dismantled and the silicone-treated gel- 
plate gently lifted away from the gel and the other glass plate. The gel was then fixed 
and the urea removed from the polyacrylamide by transferring the gel, still attached to 
the glass plate, into a bath containing 10% methanol, 10% acetic acid. After 15 minutes 
the gel and glass plate were removed and the gel transferred onto Whatman 3MM paper 
as follows. Two sheets of Whatman 3MM paper were gently placed on top of the gel, 
smoothed down and then the paper, gel and glass plate inverted. The glass plate was 
lifted away, and the gel covered in Saran Wrap (Dow Chemical Company, Genetic 
Research Instrumentation Ltd.). The 3MM paper and Saran Wrap were trimmed close 
to the edges of the gel and the gel was then dried under vacuum at 80°C for 3 hours in 
an automatic gel drier (Biorad, Model 583) Autoradiography was performed by 
exposing the dried gel to Hyperfilm MP autoradiography film in a metal cassette 
(Dupont) for 48 hours at room temperature.
Following exposure films were developed in a Kodak X-OMAT automatic processor 
(Model ME-3) and the nucleotide sequence determined by comparing the fragment 
sizes obtained in the reaction mixtures containing each dideoxynucleotide triphosphate.
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2.2.8. Purification of radioactively labelled DNA fragments by gel
filtration.
Radioactively-labeUed DNA probes were purified from unincorporated radioactively- 
labelled nucleotides by filtration down a Sephadex-G50 column.
Sephadex-G50 columns were prepared using 20 x 0.5cm Econo-columns (Biorad). 
Sephadex-G50 was made up at 120g/L in TE, autoclaved before use and stored at 4°C. 
The Sephadex-G50 solution was pipetted slowly into the columns, avoiding the 
introduction of air bubbles and the columns were then equilibrated with TE for 1 hour 
to allow settling of the Sephadex-G50.
The mixture of incorporated and unincorporated radioactively-labelled nucleotides 
obtained from the multiprime labelling reaction described in section 2.3.1. was added to 
lOpl of 0.25% Orange-G and the entire volume pipetted onto the top of the column. A 
hand held Geiger counter was used to monitor the filtration process. The most rapidly 
migrating peak of radioactivity was assumed to represent the radioactively-labelled 
DNA fragment, while the unincorporated radioactively-labelled nucleotides migrated 
more slowly down the column, forming a second peak of radioactivity.
The radioactively-labelled DNA fragment was collected in a 500pi volume of buffer. 
The buffer containing the unincorporated labelled nucleotides was discarded. The 
specific activity of the labelled nucleic acid in counts per minute per microlitre was 
estimated by adding lp l of the collected fraction to 5mls of "Ecoscinct" (National 
Diagnostics) and measuring the emitted radiation on a Beckman LS 1801 scintillation 
counter.
2.2.9. Purification of oligonucleotides.
Oligonucleotides for use in the PCR or for nucleotide sequence analysis were obtained 
from an "in house" synthesis facility, employing an automated oligonucleotide 
synthesizer (Model 381 A, Applied Biosystems).
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Following synthesis, oligonucleotides were cleaved from their resin supports by 
flushing the synthesis cartridges with 2mls of 35% ammonia solution over a period of 
2.5 hours. The oligonucleotides were then deprotected by incubation at 55°C in 35% 
ammonia solution for 5-16 hours. The solution volume was made up to 4mls with 
water before further purification steps.
The trityl groups were removed and the oligonucleotides purified using Oligonucleotide 
Purification Cartridges (OPC, Applied Biosystems Ltd.). Each OPC was flushed 
through with 5mls of acetonitrile (Applied Biosystems Ltd.) followed by 5mls 2.0M 
triethylamine acetate (Applied Biosystems Ltd). The solutions were flushed through the 
OPC using 5ml syringes, at a rate of 1-2 drops per second.
The deprotected oligonucleotide was then pushed through the OPC at the same rate, 
repeating the process to ensure efficient binding of the oligonucleotide to the support 
The OPC was flushed with 3 x 5mls of 3.5% ammonia solution, followed by 2 x 5mls 
of water. The oligonucleotide was then detritylated using 2 x 5mls of 2% trifluoroacetic 
acid (Applied Biosystems Ltd.) and washed with 2 x 5mls of water. The detritylated 
oligonucleotide was eluted with 3 x 1ml of 20% acetonitrile. The eluate was divided 
into aliquots, evaporated to dryness by centrifugation under vacuum in a bench-top 
centrifuge (Univap, Uniscience) and redissolved in water as required. Oligonucleotides 
were routinely stored as solids at -20°C.
The concentration of redissolved oligonucleotides was determined by measurement of 
the O.D.26Q, assuming that a solution of 20jig/ml has an O .D ^ q  1«0 (Maniatis etal. 
1982).
2.3. ENZYMATIC MANIPULATION OF NUCLEIC ACIDS.
2.3.1. Radioactive labelling of nucleic acids.
DNA fragments were radioactively labelled to a high specific activity using a procedure 
based on that described by Feinberg and Vogelstein (1983). All reagents for the 
labelling reactions were obtained from Amersham International pic (’'Multiprime 
labelling system").
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Twenty five nanograms of a linear double stranded DNA fragment for use as probe 
were denatured by boiling for 2 minutes and then cooled rapidly on ice. Multiprime 
buffer solution, containing dATP, dGTP and dTTP, and a primer solution, containing 
random hexanucleotides, were added according to the m anufacturers 
recommendations. Three Megabecquerels of {a^pjdCTP (30TBq/mmol) were added 
followed by 2U of DNA polymerase I "Klenow" fragment in a total reaction volume of 
50|il, and the reaction allowed to proceed for 3-5 hours at room temperature. 
Unincorporated radioactively-labelled nucleotides were removed by gel filtration as 
described in section 2 .2 .8 .
2.3.2. Restriction endonuclease cleavage of DNA.
The required amount of DNA in TE buffer was transferred to a microcentrifuge tube. 
Water was added to make the final volume up to 50fil, for digestion of high molecular 
weight DNA, and to 10|Xl for plasmid DNA. One tenth of the final volume of the 
appropriate restriction enzyme reaction buffer (supplied by the manufacturers) was 
added. Spermidine was added to a final concentration of 3mM to reduce the possibility* 
of inhibition by contaminants present in the DNA (Bouche 1981). Two to five units of 
restriction enzyme were added per microgram of DNA, the contents of the tube mixed 
gently and then centrifuged briefly in a microcentrifuge. The reaction mixture was 
incubated at 37°C for 16 hours for the restriction endonuclease digestion of high 
molecular weight DNA and for 1-2 hours for digestion of plasmid DNA.
2.3.4. DNA amplification using the polymerase chain reaction.
Specific amplification of a target DNA sequence was achieved using oligonucleotide 
primers and a thermostable DNA polymerase essentially as described by Saiki et al. 
(1988).
One microgram of high molecular weight DNA was included in a reaction mixture 
containing l^iM primers, 1.5mM magnesium chloride, 50mM potassium chloride, 
lOmM Tris pH 8.2,0.05% NP40,200jiM of each deoxynucleotide triphosphate and 3U 
heat-stable DNA polymerase (Cambio). Amplification was performed in a 
programmable heat block (Perkin Elmer-Cetus Instruments). Target DNA samples were 
initially denatured by heating at 95°C for 6 minutes then subjected to 30 cycles in
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which they were cooled to 55°C over 2 minutes to anneal the primers, heated to 70°C 
over 1 minute and incubated at 70°C for 0.5 minutes to allow primer extension and then 
denatured by heating to 95°C over 1 minute.
Reaction products were visualized on, and purified from, ethidium bromide-stained 
polyacrylamide gels as described in section 2.2.5.
S2.3.5. Cloning of DNA fragments
The plasmid vector and DNA fragment to be ligated were digested with appropriate 
restriction enzymes and size separated on agarose or polyacrylamide gels, as 
appropriate. DNA fragments were purified from agarose gels using DEAE membrane 
(section 2.2.4) and from polyacrylamide gels as described in section 2.2.6. Molar ratios 
of insert to vector of between 10:1 and 2.5:1 were combined in the ligation reactions. 
The insert and vector fragments were mixed to make up a total of 150-200ng of DNA in 
a final volume of 20jxl. DNA ligase reaction buffer (Boehringer Mannheim), 1U of T4 
DNA ligase (Boehringer Mannheim) and 0.5mM ATP (Boehringer Mannheim) were 
included in the reaction mixture.
Control reactions were set up as described above but omitting either insert DNA or 
vector DNA. The former control reaction indicated the frequency at which religation or 
incomplete digestion of vector was occurring. The reaction omitting vector DNA 
permitted the detection of incomplete purification of insert, where the insert was being 
subcloned into a new vector. Ligation reactions were incubated at room temperature for 
4 hours then 5|xl of each reaction and lOjil of a 1:10 dilution of each reaction were used 
to transform an appropriate E.Coli host as described in section 2.5.2.
2.3.6. Nucleotide sequence analysis.
Nucleotide sequencing was carried out using the dideoxy chain termination method 
(Sanger etal. 1977). Double stranded DNA was used as the template and reactions were 
performed using the "T^ Sequencing Kit" manufactured by Pharmacia LKB.
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Template DNA was denatured by adding 2pi of 2M sodium hydroxide to 2jig of DNA 
in 8pl of TE and incubating at room temperature for 10 minutes. The DNA was 
precipitated by the addition of 3jil of 3M sodium acetate (pH4.8), 7|il of water and 60}il 
of 100% ethanol and incubating the mixture on dry ice for 15 minutes. The DNA was 
pelleted by centrifugation at 13000rpm for 10 minutes at 4°C, washed with 70% 
ethanol, centrifuged and dried briefly under vacuum. The denatured template DNA was 
dissolved in lOjxl of water and incubated with appropriate primers in the annealing 
buffer supplied with the kit, at 37°C for 20 minutes. The quantity of each primer added 
was calculated to give a molar ratio of the primer to the template of 10:1. The 
primer/template mix was placed at room temperature for 10  minutes prior to 
commencing the sequencing reactions.
An enzyme premix containing ljxl of water, 3 |il of labelling mix (dATP, dGTP and 
dTTP), 2|xl of T7  DNA polymerase (1.5U/nl) and l|il of [a-35S]dCTP (370MBq/ml) 
was prepared. Primer extension with the mix of deoxynucleotide triphosphates was 
initiated by the addition of 6pl of enzyme premix to the annealed template/primer and 
the labelling reaction continued for 5 minutes at room temperature. Aliquots (2.5pl) of 
the four chain termination mixes containing one dideoxynucleotide triphosphate and the 
remaining three deoxynucleotide triphosphates were prewarmed to 37°C for 1 minute 
and 4.5pl of the labelling reaction added to each of the four mixes. Chain termination 
was allowed to proceed for 5 minutes at 37°C before stopping the reactions with 5|il of 
the stop solution supplied with the kit. Sequencing reactions were analysed by 
denaturing PAGE (section 2.2.7).
2.4. HYBRIDIZATION ANALYSIS OF DNA.
2.4.1. Southern transfer of nucleic acids.
Nucleic acids were transferred to ’Hybond-N’ nylon membranes essentially as 
described by Southern (1975). After photography gels were agitated gently in 0.25M 
HC1 for 2x15  minutes in order to depurinate the DNA molecules as this improves the 
efficiency of transfer of high molecular weight DNA. Gels were rinsed in deionized 
water and the DNA denatured by submerging the gels in alkali buffer (Table n.II) for 1 
hour at room temperature. After a 1 hour submersion in neutralizing buffer (Table M I) 
gels were placed in 10 x SSC (Table M I) prior to transfer.
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Transfer of nucleic acids onto the nylon membrane was assisted by gravity. An 
absorbent pad of tissues was covered first with a layer of filter paper (Whatmann No. 1, 
Scotlab) presoaked in transfer buffer (10 x SSC) and then with "Hybond-N" nylon 
membrane presoaked in deionized water and transfer buffer. Gels were placed onto the 
membrane ensuring that the lower surface of the gel was apposed to the membrane and 
were then covered with a sheet of filter paper presoaked in transfer buffer. A sponge 
soaked in transfer buffer and placed onto the top layer of filter paper was used to 
provide a buffer reservoir and the transfer apparatus was sealed in a plastic bag to 
reduce evaporative loss.
After 16-20 hours the nylon membrane was removed, cut to size and rinsed for several 
minutes in 3 x SSC. The efficiency with which DNA transfer had occurred was checked 
by restaining the gel with ethidium bromide. DNA was irreversibly bound to the 
membrane by baking in an oven at 80°C for 2 hours.
2.4.2. Hybridization of radioactive probes to filter bound DNA.
Detection of specific DNA sequences in filter bound DNA samples was achieved by 
hybridization to radioactive DNA probes labelled by random priming (section 2.3.1).
Filters were presoaked in 0.1% SDS, 3 x SSC and wrapped around the interior of a 
50ml Falcon tube with the side of the membrane onto which the DNA was bound facing 
inside. Care was taken to exclude air bubbles. Filters were prehybridized in 3 mis of 
hybridization buffer (Table H.II) for a minimum of 4 hours at 37°C, with continuous 
rotation. The concentration of formamide in the hybridization buffer was adjusted 
according to the algorithm described by Meinkoth and Wahl (1984) so that the 
stringency of hybridization was appropriate for the mismatch permitted between the 
probe and target sequence. Hybridization was routinely performed at approximately 
25°C below the calculated Tm of the DNA duplex. DNA probes were added to a final 
activity of 10^ counts per minute per ml of buffer and hybridized for 16 hours at 37 °C 
with continuous rotation.
Filters were then rinsed twice for 10 minutes in 2 x SSC, 0.1% SDS at room 
temperature and washed under conditions appropriate for the permitted degree of 
mismatching between probe and target sequences and the length of the probe being
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used Washing was routinely performed in 0.1% SDS, 0.5 X SSC at 65°C except when 
stated otherwise in the description of specific experiments. After a brief rinse in 2 x 
SSC, filters were air dried to dampness, wrapped in Saran wrap and autoradiographed 
by exposing the filters to autoradiography film (Hyperfilm MP) in DuPont metal 
cassettes containing Cronex lightning plus intensifying screens (DuPont). 
Autoradiographs were developed after exposures of 1-21 days as required
2.5. GROWTH AND MANIPULATION OF BACTERIA.
2.5.1. Preparation of competent cells.
Bacterial cells were made competent for the uptake of DNA molecules using calcium 
ions and low temperature, as described by Lederberg and Cohen (1974).
An overnight culture of E. Coli was diluted 1:100 in 50mls of LB or minimal medium, 
as appropriate, and shaken at 225rpm at 37°C until the cell density reached 4-7 x 10^ 
cells/ml. The bacterial cell density was calculated from the O .D .5 5 Q of the solution 
assuming that the approximate O .D .5 5 Q of 5 x 10^ cells is 0.2 with rec- strains, and is 
0.5 with rec+ strains of E.Coli (Maniatis et al. 1982). The bacteria were chilled on ice 
for 10 minutes then pelleted by centrifugation at 4000ipm for 5 minutes at 4°C and the 
supernatant discarded
Bacteria were resuspended in 25mls of an ice cold sterile solution of 50mM calcium 
chloride, lOmM Tris (pH 8.0) and incubated in an ice bath for 15 minutes. The cells 
were centrifuged at 4000rpm for 5 minutes at 4°C and resuspended in 3.3mls of calcium 
chloride solution as above. The bacterial suspension was divided into 0.2ml aliquots in 
prechilled tubes and stored at 4°C for 12-24 hours. The aliquots were then used 
immediately for transformation of plasmids into E. Coli (section 2.5.2) or stored at 
-70°C for future use. Competent bacteria with transformation efficiencies of 10^-10^ 
transformants per microgram of DNA were routinely made using this procedure.
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2.5.2, Transformation of bacterial cells with plasmid DNA.
Competent bacteria were transformed with plasmids essentially according to the method 
described by Hanahan (1983). Frozen competent bacterial cells were made as described 
in section 2.5.1 or purchased from Gibco BRL.
Frozen competent cells were thawed on ice and then aliquoted into lOOjil volumes in 17 
x 100mm polypropylene tubes (Falcon 2059, A. & J. Beveridge). Plasmid DNA was 
added at approximately 4-40ng DNA per lOOjil of cells, mixed briefly and the tubes 
placed on ice for 30 minutes. Bacteria were then heat shocked at 42°C for 45 seconds 
and cold shocked on ice for 1-2 minutes.
Nine hundred microlitres of SOB (Table II.HI) containing 20mM glucose (SOC) were 
added and the bacteria allowed to recover by shaking in an orbital incubator at 225ipm 
for 60 minutes at 37°C. The bacteria were centrifuged at 2500rpm for 5 minutes at 
20°C and washed before resuspending in 150pl of SOC and plating onto LB-agar 
(15g/L of bacto-agar in LB-medium) plates containing the appropriate antibiotic. Plates 
were incubated overnight at 37°C and then stored at 4°C for up to 1 week.
2.5.3. Identification of recombinants.
Bacteria containing recombinant plasmids were identified in one of two ways,
a) Selection by a-complementation.
Plasmid vectors containing the regulatory sequences and coding sequences of the 
amino-terminal region of the p-galactosidase gene (lacZ) were used in some cloning 
experiments. The products of ligation reactions and control reactions were transformed 
into competent bacteria of an E. coli strain capable of expressing the carboxy-terminal 
region of P-galactosidase (E . coli strain DH5a). Bacteria containing the non­
recombinant vector may be identified, as they produce a functional p-galactosidase and 
thus will metabolise 5-bromo-4-chloro-3-indoyl-p-D-galactosidase (X-gal) producing 
blue colonies.
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Transformed bacteria were plated onto LB-agar containing 0.05mg/ml isopropylthio-P- 
D-galactoside (IPTG) and 0.05mg/ml 5-bromo-4-chloro-3-indoyl-p-D-galactoside (X- 
gal). The plates were incubated at 37°C overnight and then placed at 4°C for 3-4 hours 
before examination. Bacteria containing recombinant plasmids were identified as white 
colonies, as insertion of foreign DNA into the cloning site of the vector results in 
disruption of the lacZ gene. The identity of recombinant plasmids was confirmed as 
described below.
b) Restriction endonuclease digestion of small scale preparations of plasmid DNA.
When the choice of plasmid vector and/or the host E.coli strain did not permit use of the 
above protocol, recombinant plasmids were identified by restriction endonuclease 
analysis of plasmid DNA.
Bacteria transformed with the products of ligation reactions were plated onto LB-agar 
and grown overnight at 37°C. The numbers of colonies obtained from bacteria 
transformed with the control ligations and the vector plus insert ligation reactions were 
compared. If a significantly greater number of colonies was obtained from the 
transformation performed using the vector plus insert ligation reaction, compared to the 
control reactions, between 12 and 24 colonies from the former transformation were 
selected for analysis. Plasmid DNA was prepared using the small scale procedure 
described in section 2 .2 .2 . digested with appropriate restriction endonucleases and 
analysed by agarose gel electrophoresis (section 2.2.3).
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CHAPTER THREE.
THE USE OF GENE REARRANGEMENT ANALYSIS FOR THE 
CHARACTERIZATION OF HODGKIN’S AND NON-HODGKIN’S
LYMPHOMAS.
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3.1 INTRODUCTION.
The accurate classification of malignant lymphomas and leukaemias is important both 
clinically, for the selection of appropriate therapies and scientifically, as the 
identification of specific disease entities is a prerequisite for the effective investigation 
of their aetiologies.
The classification of lymphomas and leukemias has been greatly assisted by 
immunophenotyping. For many types of lymphoma determination of the surface 
phenotype of the malignant cells has allowed the identification of their lineage. The 
clonality of proliferative disorders of B-lymphocytes may also be evaluated 
immunophenotypically if expression of IgL is detected. The restricted expression of a 
single IgL isotype by a B-cell population may be used as an indication of clonality 
(Isaacson et al. 1980; Norton and Isaacson 1987). There are no equivalent 
immunophenotypic markers for clonal T-cell populations, though monoclonal 
antibodies (MoAbs) reactive with variable regions of the TCRp (Vp) may be useful in 
a proportion of cases (Clark et a l  1986).
Some lymphoproliferative disorders that are morphologically and clinically 
heterogeneous have proved difficult to characterize immunophenotypically. The 
morphological and clinical heterogeneity of two such disorders, HD and AIL, have been 
described in Chapter 1. The immunophenotypic analysis of diseased tissues from 
persons with these disorders has produced conflicting results. These data are reviewed 
in sections 3.1.3-3.1.4.
Molecular analysis of the configuration of the Ig and TCR genes provides an alternative 
approach to the characterization of lymphoproliferative disorders. This chapter 
describes the results of experiments that use this approach to investigate the lineage and 
clonality of the malignant cells of HD. Samples from patients with AIL were also 
analysed. The following sections describe the organization and rearrangement of the 
IgH and IgL genes and the TCRp chain (TCRP) and TCRy chain (TCRy) genes. The 
use of molecular analysis of these genes for the determination of the lineage and 
clonality of lymphoproliferative disorders is described in section 3.1.2.
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3.1.1 The organization and rearrangement of the TCR and Ig genes.
The organization of the genes encoding the Ig and TCR genes is similar. The 
organization of the genomic loci of the IgH and IgL genes have been recently reviewed 
by Lai etal. (1989). The IgH gene locus consists of clusters of variable (Vjj), diversity 
(Djj) and joining (Jjj) regions and a group of constant region (Cjj) genes (Figure 3.1, 
panel a). The Ig K-light chain (IgK) gene locus is made up from a number of k regions, 
5 Jk regions and a single CA region gene (Figure 3.1 panel b). The IgA,-light chain (IgA) 
gene locus is less well characterized, but contains VA, and J% genes in addition to a 
cluster of CA, genes.
The generation of antibody diversity by rearrangement of the immunoglobulin genes 
during B-cell differentiation has been reviewed by Tonegawa (1983). Rearrangement 
results in the apposition of V, D (where present) and J regions in an arrangement that is 
unique to a given B-cell and its progeny (Figure 3.2). The IgH genes rearrange first, 
followed by IgK gene rearrangement. If IgK gene rearrangement is unsuccesful, i.e. the 
apposition of V k and Jk regions does not produce a functional coding sequence, then 
IgA, gene rearrangement follows.
The antigen receptors of T-cells are formed from heterodimers of TCRa and TCRp 
chains, or of TCRy and TCR8 chains. The organization of the genes for these molecules 
and the generation of diversity through rearrangement of the TCR genes has been 
reviewed by Lai etal. (1989) and Davis and Bjorkman (1988). Molecular analysis of 
the TCRa gene is difficult due to the large size and complexity of the TCRa locus 
(Yoshikai etal. 1985). Molecular analysis of the TCR8 gene is also of limited value due 
to the frequent occurrence of TCR8  gene deletion in mature and malignant T-cells 
(Chein et al. 1987; Foroni et al. 1989). The configurations of the TCRa and TCR8 
genes were not analysed in the studies described in this chapter, thus the organization 
and rearrangement of these genes will not be considered further.
The TCRp and TCRy genes consist of clusters of V regions, D regions (in the TCRp 
gene only) and J regions, as shown in Figure 3.3 (Toyanaga etal. 1985; Lefranc and 
Rabbitts 1985; Quatermous et al. 1986). Rearrangement of the TCR genes occurs at 
discrete stages of T-cell differentiation, creating combinations of V, D (for TCRP 
genes) and J regions that are unique for a given T-cell and its progeny (Toyanaga and 
Mak 1987).
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3.1.2 TCR and Ig gene rearrangement analysis.
Clonal populations of T-cells or B-cells will have identical TCR or Ig gene 
rearrangements, which can be detected by molecular analysis. Rearrangement of the 
TCR or Ig genes causes alterations in the sizes of the restriction endonuclease fragments 
that span the rearranging sequences, as illustrated in Figure 3.4. The altered fragments 
can be detected by Southern hybridization of molecular probes derived from the TCR or 
Ig genes to restriction endonuclease digested DNA.
Ig and TCR gene rearrangement analysis has been extensively applied to lymphoma 
material. In the majority of cases of B-cell NHL clonal rearrangements of the IgH and 
IgL genes are detectable (Arnold etal. 1983; O’Connor 1987). Similarly in the majority 
of cases of T-cell NHL clonal rearrangements of the TCRp and TCRy genes are present 
(Bertness etal. 1985; O’Connor etal. 1985; Griesser et al. 1986a; Minden and Mak 
1986; Toyanaga and Mak 1987). The analysis of lymphoproliferative disorders for the 
presence of Ig and TCR gene rearrangements thus allows the lineage and clonality of 
the proliferating cells to be determined.
Rearrangement of these genes is not completely lineage specific as clonal IgH gene 
rearrangements have been reported in T-cell NHL and TCRP gene rearrangements have 
been detected in B-cell NHL (Pelicci et al. 1985; Waldmann et al. 1985; O’Connor 
1987). Rearrangement of the TCRy genes has been reported in a high proportion of B- 
cell neoplasms and is thus a poor indicator of cell lineage (Griesser etal. 1986a; Pelicci 
etal. 1987a). Rearrangements of the IgH and/or TCRp genes have also been detected in 
leukaemic cells from patients with AML (Boehm et al. 1987a; Foa et al. 1987). The 
detection of Ig or TCRp gene rearrangement in a tumour sample cannot, therefore, be 
taken as definitive proof of its lymphoid origin.
Despite these caveats, the analysis of the configuration of the TCR and Ig genes has 
permitted the more accurate characterization of a variety of lymphoproliferative 
disorders including, for example, hairy cell leukaemia (Cleary et al. 1984) and 
lymphomatoid papulosis (Weiss et al. 1986a). The technique has also proved valuable 
for the investigation of lymphoproliferative disorders that appear to be heterogeneous in 
nature, such as HD and AIL.
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3.1.3 HD: the immunophenotypic analysis of HRS cells.
The use of immunological methods for the characterization of the cell surface 
phenotype of the HRS cells has failed to identify convincingly normal cellular 
counterparts and thus a potential origin for these cells. Many different cell types have 
been proposed as the normal counterparts of HRS cells including B- and T- 
lymphocytes, macrophages, monocytes, myeloid cells, and interdigitating reticulum 
cells (Diexler and Leber 1988).
A lymphoid origin for HRS cells.
The majority of recent studies support a lymphocytic origin for HRS cells. This 
evidence is most convincing for the LP subtype of HD. The HRS cells of LPHD express 
cytoplasmic J chains (Poppema 1980; Stein etal. 1986), the common leukocyte antigen, 
CD45 (Pinkus and Said 1985; Hall et al. 1988) and antigens recognized by the B-cell- 
specific MoAbs LN1 and L26 (Hall etal. 1988; Dallenbach and Stein 1989; Nicholas et 
al. 1990). The HRS cells of cases of other subtypes of HD do not express J chains and 
rarely react with LN1 or L26 (Hall et al. 1988; Dallenbach and Stein 1989; Leoncini ‘et 
al. 1990). Conflicting results have been reported for CD45 expression in NS and 
MCHD (Hsu et al. 1985; Hall etal. 1988; Casey et al. 1989; Leoncini et al. 1990). The 
HRS cells of the majority of cases of LPHD do not express CD 15 and CD30, further 
distinguishing this subtype from the other HD subtypes (Hall etal. 1988; Nicholas etal. 
1990). The results of these studies suggest that LPHD differs from the other subtypes of 
HD in its histogenesis and that LPHD is a B-cell malignancy.
The derivation of the HRS cells in NS, MC and LDHD is more controversial. Many 
studies have reported HRS cell expression of antigens normally associated with 
activated lymphocytes, such as CD30, HLA-DR and CD25 (e.g. Falini etal. 1987; Hall 
etal. 1988; Casey etal. 1989; Dallenbach and Stein 1989). The consistent expression of 
CD 15 by HRS cells was considered initially to be evidence against their lymphoid 
derivation, as CD 15 expression is associated with myeloid cells (Stein etal. 1982a). 
However CD 15 expression by a variety of malignant T- and B-cells has since been 
reported (Lee 1989).
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The use of antibodies to T-cell and B-cell antigens has given conflicting results. In 
some studies the expression of T-cell markers has been detected in a high proportion of 
cases (Falini etal. 1987; Casey et al. 1989; Dallenbach and Stein 1989; Herbst etal.
1989), while others have failed to detect any T-cell antigen expression by HRS cells 
(Hall et al. 1988). The expression of B-cell antigens by HRS cells has been reported 
less frequently (Falini etal. 1987; Casey etal. 1989; Herbst et al. 1989) though Hall et 
al. (1988) found that one third of HD cases (excluding LPHD) expressed B-cell 
antigens. Cases showing expression of both B- and T-cell markers have also been 
reported (Casey etal. 1989; Herbst et al. 1989). However between one third and two 
thirds of cases fail to show detectable expression of either B- or T-cell antigens (Falini 
etal. 1987; Hall etal. 1988; Herbst et al. 1989). Cell lines derived from HD express B- 
or T-cell surface markers, supporting the derivation of HRS cells from T- or B- 
lymphocytes (Drexler et al. 1989; Herbst et al. 1989).
A monocyte/histiocyte origin for HRS cells.
Hsu etal. (1990) have reported that the HD-derived cell lines HDLM-1 and KM-H2 
can be induced to d ifferentiate  into cells that have the m orphological, 
immunophenotypic and functional properties of histiocytes. These authors suggest that 
detection of T- or B-cell markers on HRS cells reflects aberrant antigen expression by 
malignant cells derived from moncytes/histiocytes, or alternatively, surface binding of 
antigens released by adjacent lymphocytes. Limited support for this hypothesis has been 
provided by studies from the same group (Hsu et al. 1985; Hsu and Hsu 1989) and by 
some of the morphological and functional properties of HRS cells (Jones 1987). Hsu 
and Hsu (1989) have in addition shown that CD30, T-cell and B-cell antigens may be 
expressed on some monocyte/histiocyte/myelocyte-related cell lines. However other 
studies have failed to demonstrate the expression of monocyte/histiocyte-associated 
antigens on HRS cells (Stein et al. 1982b; Falini etal. 1987).
Some of the variation in the results obtained in the studies described above may be due 
to technical difficulties encountered because of the scarcity of HRS cells in sample 
material (Casey etal. 1989). In addition the expression of surface antigens by HRS cells 
may be difficult to identify accurately as these cells are usually surrounded by T- 
lymphocytes. However many studies indicate that the immunophenotypes of HRS cells 
are heterogeneous (e.g. Casey etal. 1989; Herbst et al. 1989) and these data have been 
considered as evidence in favour of the notion that HD is an heterogeneous entity.
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3.1.4 Analysis of HP biopsies for rearrangement of the Ig and TCR 
genes.
The analysis of fresh HD material for rearrangements of the Ig and TCR genes has 
permitted further investigation of the lineage and clonality of HRS cells. At the time at 
which the study described in this chapter was commenced a limited number of such 
analyses had been reported in the literature.
Weiss et al. (1986b) analysed tissues from seven cases of NSHD, selected for the 
presence of high numbers of HRS cells. Rearrangements of the IgH and/or IgL genes 
were detected in six cases while the TCRp genes were germline, leading these authors 
to suggest that HRS cells could be derived from B-lymphocytes. However, two other 
published studies produced conflicting results.
Knowles etal. (1986) detected minor clonal Ig and/or TCRP gene rearrangements in 
only 3/18 cases of HD. There was no relationship between the numbers of HRS cells 
and the detection of gene rearrangement. These authors did find a correlation between 
HRS cell numbers and the detection of a pattern of hybridization to the TCRP constant 
region probe that was consistent with the presence of a polyclonal T-cell population. 
Knowles etal. (1986) therefore suggested that HRS cells are a population of polyclonal 
T-cells. These authors further suggested that the absence of significant Ig or TCR gene 
rearrangements in HD could be used to differentiate HD from NHL.
In contrast, Griesser etal. (1986b) reported the detection of TCRp gene rearrangements 
in 4/8 cases of HD.
The results obtained in these studies provide no consensus regarding the following two 
questions.
(a) whether or not significant Ig and/or TCR gene rearrangements are 
detectable in biopsy material from patients with HD,
(b) whether the rearrangements detected are present in the HRS cells.
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In order to investigate these questions, a study combining the molecular analysis of 
tissues from HD patients with the histopathological determination of HRS cell numbers 
was undertaken. This chapter describes the results of the analysis of 35 cases of HD for 
rearrangements of the IgH, IgL and TCRp genes. The numbers of HRS cells present in 
the samples were evaluated by the referring pathologists, to assist in determining 
whether the rearrangements detected were present in the HRS cells.
3.1.5 The immunophenotypic characterization of AIL.
Both the lineage of origin and the neoplastic nature of lesions classified histologically 
as AIL have been the subject of debate. Early reports considered AIL to be a B-cell 
disease (Lukes and Tindle 1975; Nathwani et al. 1978) and some workers have 
identified lesions histologically classified as AIL, that are composed mainly of 
pro liferating  B-cells (Jones et al. 1978; Knecht et al. 1985). H ow ever 
immunophenotypic analysis has indicated  that most cases o f AIL are 
lymphoproliferative disorders of T-cells (Weiss et al. 1986c; Ganesan et al. 1987; 
Namikawa etal. 1987).
Similar results have been obtained from the analysis of lymphomas showing 
histological features of AIL (Watanabe et al. 1980; Weiss etal. 1986c), though B-cell 
derived AIL-like lymphomas have also been identified, following the detection of 
restricted IgL expression by tumour cells (Boros et al. 1981; Bauer et al. 1982; Knecht 
etal. 1985; Pirker etal. 1986).
The controversy over whether AIL should be considered a malignant disease from the 
outset was discussed in Chapter 1 (section 1.3.3). Most studies have distinguished 
between AIL cases lacking features consistent with malignant transformation (ACL) 
and those which show morphological evidence of overt lymphoma (AIL-like 
lymphoma). Clonal cell populations have been detected by karyotypic and 
immunophenotypic analyses of AIL biopsies that lacked morphological evidence of 
lymphoma (Bauer etal. 1982; Kaneko etal. 1982; Godde-Salz et al. 1987). These data 
have provided evidence to support the notion that AIL might be neoplastic from the 
outset
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The availability of molecular techniques for the detection of clonal B- and T-cell 
populations has enabled more detailed investigation of the lineage and clonality of the 
lymphoproliferations characteristic of AIL.
3.1.6 Ig and TCR gene rearrangements in ATI..
When the experiments described in this chapter were commenced, a limited number of 
studies describing the analysis of TCRp and Ig gene rearrangement in AIL had been 
published (Bertness etal. 1985; O’Connor 1986; Weiss et al. 1986c). The results of 
these studies indicated that many cases of AIL contain clonal proliferations of T-cells 
and that many, but not all, cases of AIL-like lymphoma are T-cell neoplasms.
This chapter describes the results obtained from the analysis of samples from patients 
with B- and T-cell NHL for the presence of Ig and TCR gene rearrangement. The 
tissues analysed included 5 samples from patients with AIL. The results obtained are 
discussed in the context of the probable pathogenesis of this disorder.
3.1.7 Gene rearrangement analysis in the differential diagnosis of 
Hodgkin’s and non-Hodgkin’s lymphoma.
The differentiation of HD from NHL is not always straightforward. Particular difficulty 
may be encountered in distinguishing HD from the AIL-like lymphomas and from 
some types of T-cell NHL (Lukes and Tindle 1975; Krajewski et al. 1988). Knowles et 
al. (1986) have suggested that gene rearrangement analysis may be used to differentiate 
HD from NHL, as they were unable to detect significant clonal TCRp or Ig gene 
rearrangements in HD samples. The technique could therefore be useful in cases in 
which routine diagnostic procedures have given equivocal results.
Five of the samples included in this study were referred with differential diagnoses that 
included HD and NHL. The results obtained from the genotypic analysis of these 
samples are compared with those obtained from the analysis of samples from patients 
with HD and NHL. The use of Ig and TCR gene rearrangement analysis for the 
differentiation of HD from NHL is discussed.
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3.1.8 The use of VP-specific MoAbs for the immunophenotypic
detection of clonal T-cell populations in tumour biopsies.
The diagnosis and classification of the peripheral T-cell lymphomas is difficult, in part, 
due to the diverse clinical and morphological features of these tumours (Wright 1986; 
Suchi et al. 1987). T-cell lymphomas are also immunophenotypically heterogeneous 
(Ramsay et al. 1987; Suchi et al. 1987; Krajewski et al. 1988). The difficulty of 
differentiating some T-cell lymphomas from HD has been mentioned above.
The lack of immunohistochemical techniques for the detection of clonality in T-cell 
lymphomas limits the usefulness of immunophenotyping for lymphoma diagnosis. The 
development of immunological reagents for the detection of clonal T-cell populations 
would, therefore, be of considerable diagnostic value.
Recently clonotypic MoAbs, that react with the TCRP expressed by the T-cell lines 
HPB-ALL and Jurkat, have been described (Moretta etal. 1985; Carrel etal. 1986). 
These MoAbs also react with 2-4% of thymoctyes and with 0.5-13% of PBMCs in 
healthy humans (Moretta etal. 1985; Borst etal. 1986). Cloned T-cells, derived by 
selection for reactivity with the MoAb specific for the HPB-ALL TCR, have been 
shown to express TCRps with identical or closely related VP (Borst et al. 1987). These 
variable regions are members of the Vp5 family (Kimura etal. 1986; Borst etal. 1987). 
Jurkat T-cells express a TCRp containing a member of the Vp8 family (Siu et al. 1984; 
Kimura et al. 1986). MoAbs directed against the TCRp expressed by HPB ALL and 
Jurkat T-cells have been used by Clark et al. (1986) to identify clonal T-cell 
populations in tissue sections.
There are at least 16 families of Vp, each of which contains a small number of members 
(Concannon etal. 1986; Kimura etal. 1986). Thus the Vp-specific MoAbs are likely to 
be useful only in a small number of cases. In addition, the specificity of the anti- 
HPBALL and anti-Jurkat MoAbs for the Vp5 and Vp8 regions has not previously been 
confirmed in tumour samples.
The T-cell NHL samples that were analysed for Ig and TCR gene rearrangements 
included four samples that showed reactivity with clonotypic antibodies directed against 
the Vp5 and/or VP8 region of the TCRp. The specificity of these MoAbs for the Vp 
expressed by the tumour cell populations in these samples was investigated using 
molecular probes for the VP gene segments.
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3.1.9 R earrangem ent of the bcI-2 locus in NHL and HD.
Non-random chromosomal abnormalities have been reported in a number of 
histological subtypes of NHL (Yunis et al. 1982; 1983). Translocations involving the 
IgH gene locus on chromosome 14(q32) have been described in a significant proportion 
of follicular and diffuse large cell B-cell lymphomas, BLs, B-cell chronic lymphocytic 
leukaemias and have also been identified in T-cell leukaemias (Baer etal. 1987; Weiss 
et al. 1987a; Aisenberg et al. 1988). Such translocations may be detected as 
rearrangements of the IgH gene locus if the translocation breakpoint occurs within the 
restriction fragment containing the DNA sequences used as the IgH gene probe.
The t(14;18)(q32;q21) involving the IgH heavy chain locus and the bcl-2 gene has been 
observed in 60-69% of follicular lymphomas and 20-40% of diffuse large cell 
lymphomas (Lee et al. 1987; Lipford 1987a; Weiss etal. 1987a). These studies have 
shown that in the majority of cases the breakpoint on chromosome 18 occurs within a 
4.3kb Hindin fragment at the 3* end of the bcl-2 gene, the major breakpoint cluster 
region (MBR). DNA sequence analysis of the cross over point on the der (14) 
chromosome in seven cases has shown that the breakpoints on chromosome 18 
occurred within 460bp of each other, while the breakpoints on chromosome 14 were 
located at the 5* ends of J h ^ H ^  (Bakshi et al. 1985; Cleary and Sklar 1985; 
Tsujimoto etal. 1985; Cleary etal. 1986). The Hindin restriction fragment overlapping 
the translocation breakpoint on the der (14) chromosome would therefore be predicted 
to be approximately 4.5-6kb in a majority of cases.
The results of IgH gene rearrangement analysis showed that in a significant proportion 
of the lymphoma samples, the rearrangements detected were giving rise to restriction 
fragments of similar sizes. The possibility that this could be due to the t(14:18) 
translocation involving the IgH gene locus and the bcl-2 gene on chromosome 18q22 
was investigated.
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3.2. MATERIALS AND METHODS.
3.2.1. Clinical cases.
Samples from 35 non-selected cases of HD were obtained from three referral centres. 
Cases were classified according to the Rye classification (Lukes etal. 1966) following 
histological review. HRS cells were identified on the basis of morphology in 
haemotoxylin and eosin-stained sections and their relative frequency estimated.
Samples from patients with NHL were obtained from three referral centres. The 
classification of NHL cases was based on a combination of clinical features, 
morphological assessment of haemotoxylin and eosin-stained paraffin sections and the 
results of immunophenotyping. Samples from 5 cases with differential diagnoses of HD 
and NHL were obtained from the Department of Pathology at Edinburgh University 
Medical School.
3.2.2 DNA probes.
Ig gene probes: The locations of the Ig gene probes relative to the coding sequences of 
the Ig gene loci are shown in Figure 3.1. The IgH probe, pHj, was a 3.3kb EcoRI- 
HindQI fragment which includes 2.2kb of the 3’ joining region (Jjj) sequences (Erikson 
et al. 1982). The K light chain probe, Ck, was a 2.5kb EcoRI fragment containing the 
constant region (Rabbitts et al. 1984). A probe for the k  deleting element, Kde, was 
used to evaluate k gene loss (Siminovitch et al. 1985). This probe detects the deletion 
of K gene sequences. B-cells producing ^-chains usually delete both k genes, more 
rarely, K gene rearrangement is detected (Heiter et al. 1981). However it may be 
difficult to detect evidence of deletion of both k  genes when using the C k  probe for the 
analysis of tumour biopsies. The detection of germline IgLK genes in a sample may 
reflect the presence of non-neoplastic cells in the tumour tissue. In order to determine 
whether IgL gene rearrangement has occurred in such cases, either the Kde probe or 
probes for the X gene locus may be used. Use of the Kde probe avoids the problems 
associated with polymorphic sites within the X locus when using IgL X chain probes 
(Brinker et al. 1987).
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TCRp gene probes. The TCRp constant region probe was derived from a cDNA clone, 
C91p, of the p chain isolated from the HTLV-I infected cell line C91PL (Gledhill e ta l
1990). Sequence analysis of C 9ip revealed an Xhol site located precisely at the 
junction between the joining and constant regions (R. Jarrett unpublished results). The 
1.3kb fragment can be excised from the pGEM4 vector with EcoRI, thus simultaneous 
digestion with Xhol may be used to generate a constant region probe, Cp, containing all 
coding sequences and the untranslated 3’ sequences of the second constant region. The 
derivation of the Cp probe is shown schematically in relation to the TCRP locus in 
Figure 3.3. The TCRy gene probe was a 700bp fragment of genomic DNA 
encompassing the TCRy joining region (Lefranc and Rabbitts 1985). The origin of the 
TCRy probe is illustrated in Figure 3.3.
Variable region probes: The Vp8 probe for the Vp gene segment expressed by the 
Jurkat cell line was derived from pYTJ2 (Siu et a l 1984). Double digestion of the 
plasmid with PstI and PvuII produces a 256 bp fragment, which corresponds to bases 
100-356 of the published sequence of YT35 (Yanagi et a l  1984) and includes Vp 
sequences only. The Vp5 probe for the Vp gene segment expressed by the HPB-ALL 
cell line was obtained from Dr. M. Owen and is a 120bp fragment which hybridizes 
with members of the Vp5 family (Dr. M. Owen, personal communication).
Bcl-2 probes: The probe for the bcl-2 gene on chromosome 18q21 was obtained from 
Dr. S.J. Korsmeyer and is a 4.3kb Hindlll fragment (H4.3) from the bcl-2 exon 3 
(Bakshi et a l 1987). For some experiments this fragment was further digested with 
EcoRI and either the 2.8kb EcoRI-HindlH fragment (RH2.8) containing the major 
breakpoint cluster region (MBR), or the 1.5kb HindDI-EcoRI fragment (HR1.5), 5* to 
the MBR, was used as a probe. Figure 3.5 illustrates the relationships between these 
probes, and their use for the detection of the t( 14; 18) translocation.
3.2.3 Molecular analysis.
For IgH gene analysis DNA samples were digested with the restriction enzymes 
BamHI, EcoRI and Hindlll, and electrophoresed on 0.8% agarose gels. The size 
separated DNA samples were transferred to nylon membranes and hybridized to the 
radioactively labelled Jjj  probe. Washing was performed at high stringency in 0.5 x 
SSC and 0.1% SDS at 65°C. TCRP genes were analysed as described above, but in 
addition samples were digested with EcoRV. In order to detect TCRp gene
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rearrangement it was necessary to run some of the EcoRI and EcoRV digested DNA 
samples on 0.7% agarose gels. Analyses of the IgL and TCRy genes were performed 
using BamHI digested DNA samples. Hindin digested DNA samples were used for the 
analysis of bcl-2 gene rearrangement.
Vp genes were analysed using BamHI, EcoRI and Hindin digested DNA samples. In 
order to permit hybridization of the Vp probes with related Vp regions washing was 
performed under lower stringency conditions, at 60°C in 1 x and 3 x SSC. These 
conditions were selected as described below, to accommodate a 25% mismatch between 
the probe and the target sequences as Vp regions are assigned to families on the basis of 
a greater than 75% homology.
Meinkoth and Wahl (1984) have reviewed the parameters affecting the stability of DNA 
hybrids. The melting temperature (Tm) of duplex DNA under the conditions employed 
for hybridization and washing may be calculated from the formula:
Tm = 81.5 + 16.61ogM + 0.41(%G+C) - 500/n - 0.61(%F)
Where M is the ionic strength of the solution (moles/L), (%G+C) is the percentage of G 
and C residues in the target sequence, n is the average length of the probe in nucleotides 
and (%F) is the percentage of formamide in the solution.
The Tm of the Vp probes hybridized to a perfectly matched target sequence may be 
estimated at 87°C and 84°C for Vp8 and VP5 respectively, when washed in 3 x SSC. 
The G+C content was assumed to be 40% (similar to the average for mammalian 
DNA), while the average probe lengths were assumed to be 128 and 60 nucleotides for 
VP8 and Vp5 respectively. The Tm of a DNA duplex has been estimated to decrease 
by 1°C for every 1% of base pairs that are mismatched (Meinkoth and Wahl 1984). 
Hybridization of the VP8 and VP5 probes to target sequences that diverge by up to 25% 
would produce duplexes with Tm of 62°C and 59°C respectively. A washing 
temperature approximately equal to the calculated Tm was selected.
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Densitometry of rearranged bands.
In order to evaluate the relationship between the number of HRS cells in HD biopsies 
with the proportion of cells estimated to contain a clonal gene rearrangement, the 
intensity of rearranged bands was measured using densitometry. To obtain a linear 
relationship between the quantity of radioactivity present on membranes following 
hybridization and the intensity of the film response, autoradiography was performed 
using preflashed X-ray film (Laskey and Mills 1975; 1977). Film was preflashed using 
a photographic flash unit at a distance of 3m, in order to increase the absorbance of 
developed film by 0.1-0.2 units. The intensity of rearranged bands were measured on a 
Molecular Dynamics densitometer and analysed using ImageQuant software.
The use of this method to estimate the proportion of cells with a clonal gene 
rearrangement was validated using reconstitution experiments. DNA derived from the 
leukaemic cells of a patient with B-cell CLL was mixed with DNA extracted from 
placenta. Analysis of DNA extracted from the leukaemic cells using the IgH probe 
showed an absence of germline fragments, thus any germline fragments detected in the 
mixed samples could be assumed to derive from the placental sample.
The DNA from both sources was digested with the restriction enzyme Hindlll, 
precipitated in ethanol and resuspended in TE. The DNA concentration of the solutions 
was determined using spectrophotometry as described in Chapter 2 (section 2.2.1). The 
two solutions were combined in various proportions such that between 2  and 100% of 
the total sample was derived from leukaemic cell DNA.
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3.3 RESULTS.
3.3.1 HD cases
Table ELI summarizes the clinical features, diagnoses and results of genotypic analysis 
for the HD cases. Thirty five HD cases were analysed, including twenty four cases of 
nodular sclerosing (NS) HD, six cases of mixed cellularity (MC) HD, two cases of 
lymphocyte predominant (LP) HD and one case of lymphocyte depleted (LD) HD. In 
two additional cases no consensus was reached as to the correct diagnosis following 
histological review. Case 72 was referred to us as NSHD but was considered by one of 
the reviewing histopathologists to be classifiable as MCHD. For case 210 the 
possibility of sclerosing mediastinal B-cell lymphoma was raised, but NSHD was not 
excluded as a differential diagnosis. Cases 167 and 168 were referred with differential 
diagnoses that included HD and T-cell NHL. Following genotypic analysis and 
histological review final diagnoses of HD were reached for both cases, as described in 
section 3.3.3. Cases 167 and 168 have therefore been included in the group of HD 
samples.
Nine cases of HD had rearranged IgH genes (Figure 3.6), seven of these cases also had 
rearranged IgL genes. Figure 3.7 shows representative results obtained from Southern 
blot analysis of the IgLK genes. IgH rearrangements were detected in 6 cases of NSHD 
(including case 210, for which a differential diagnosis of B-cell NHL was given), 2 
cases of MCHD and 1 case of LDHD. The rearranged bands detected in these cases 
were faint compared to germline bands, but were readily visible on autoradiography. 
TCRP gene rearrangement was detected in none of the thirty five cases. No TCRy gene 
rearrangements were detected in the ten cases analysed.
Ig gene rearrangements and HRS cell numbers.
Figure 3.8 illustrates the relationship between the detection of IgH gene rearrangements 
in the HD cases, and the numbers of HRS cells identified in the tissue sections. In seven 
of the cases in which IgH gene rearrangements were detected the HRS cell numbers 
were estimated to form more than 8% of the total population. Six HD samples with 
more than 8% HRS cells showed germline Ig genes. IgH gene rearrangement was 
detected in one case in which HRS cell numbers were estimated at less than 3% of the
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Table III.I. B, B-cell NHL; 6 , germline; ND, not done; NK, not known; 
R, rearranged; *, the percentage of cells containing the IgH gene 
rearrangement as estimated by densitometry; + + + , more than 8%; 
+ + , 3-8%; +, less than 3%; -, less than one HRS cell per high power 
field; *, the differential diagnoses are shown for cases 72 and 210; 
# , the results shown for case 382 are from the analysis of a  lymph 
node biopsy with the histological appearance of a  reactive node (see 
text). The final column of the table indicates the results obtained 
from the analysis of the sam ples by Southern hybridization for the 
presence of Epstein-Barr virus (EBV) genom es (Gledhill et al. in 
press). These data are discussed in section 3.4.1.
Table lll.l. Clinical features, diagnoses and the results of 
molecular analyses for the HD cases.
Patient
No.
Age/Sex HD
subtype
% HRS 
ceils
Gene rearrangements 
TCR B TCRy IgH* igL
EBV
70 36/M LP _ G G G +
71 22/M NS + G G G -
72 21/M NS/MC + G G G +
74 20/M MC ND G G G -
75 24/M NS ND G G G -
76 19/M NS + G G G -
78 31/F NS + + + G R + + + R K -
79 48/F MC + G G G +
167 35/M NS + + G G G G -
168 69/M NS - G G G +
210 50/F NS/B + + + G R + + + R K +
237 25/M MC + + + G G G G -
289 43/F NS + + + G G G G -
373 66/M NS + + + G G R + + + R Kde +
3 8 2 # 23/M NS - G G R + + + R Kde -
384 28/F NS + G G G G -
385 31/M NS + G G G G -
386 80/M MC + + + G G R + + + R K +
387 14/M MC + G G G G +
390 68/F NS + + + G G G G +
420 19/M LD + + + G R + + + RK
430 67/M NS + + + G R + + + R K
923 24/M NS + + G G G
924 19/M NS + + G G G
925 77/M MC + G R + + G +
926 26/M NS + + G G G
927 13/M NS + + G G G +
928 19/M NS + + + G G G
929 17/M LP - G G G
930 32/M NS + + G G G
931 42/M NS + + G G G
932 25/F NS + + + G R + + + G
933 26/M NS + + + G G G
934 21/F NS + + + G G G
935 15/NK NS ND G G G
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total. In sample 382 Ig gene rearrangements were detected in a lymph node biopsy 
considered to be reactive following histology and immunophenotyping. Some 
lymphoblasts were identified in the sections, but no classical RS cells were seen. This 
sample is indicated with an open circle in Figure 3.8.
No gene rearrangements were detected in a spleen sample showing features of NSHD 
which was also obtained from this patient. Karyotypic analysis also indicated the 
presence of a clonal cell population in the "reactive" node (Banks etal. 1991).
Densitometric analysis of IgH gene rearrangements.
Figure 3.9 shows the detection of IgH gene rearrangements by Southern blot analysis 
of samples reconstituted from known proportions of leukaemic cell and placental DNA. 
The densitometric estimations of the proportion of the reconstituted DNA samples 
containing the clonal IgH gene rearrangements are also shown in Figure 3.9. The results 
showed good agreement with the estimations based on quantitation of the placental and 
leukaemic cell DNA samples prior to mixing.
The results obtained from the densitometric analysis of IgH gene rearrangements 
detected in the HD samples are given in Table III.I. In eight cases the intensity of the 
rearranged bands indicated that the cells containing the clonal rearrangement formed 
more than 8% of the total population. The numbers of HRS cells in paraffin sections 
from seven of these samples were also estimated to represent more than 8% of the total 
cell numbers. No RS cells were seen in the paraffin sections from the lymph node 
biopsy obtained from patient 382, as discussed above. Sample 925 was estimated to 
contain more than 3% HRS cells on the basis of morphology in paraffin sections, while 
densitometry indicated that the clonal IgH gene rearrangement was present in 3-8% of 
the cell population.
77
Fi
gu
re 
3.
13
. 
DN
A 
sa
m
pl
es
 
we
re 
di
ge
ste
d 
wi
th 
Ba
m
HI
 (
pa
ne
ls 
a,b
,e 
an
d 
f) 
or 
Ec
oR
I 
(p
an
els
 
c 
an
d 
d) 
an
d 
an
al
ys
ed
 
us
ing
 
the
 
CI
3, 
VI3
5 
or 
VI3
8 
pr
ob
es
, 
as 
in
di
ca
ted
 
be
lo
w “O CD 0  -C
COo 0p.E 0  
0  -Q
CO S '  0 ^
?  =0 ^  
-O Co |
I "E £
a *0
O
LU
0  x: h-
CO-4—*c  
0
jo  CD 
Q . ~
E E 
o  0M- O) 
"O 03
I ’8
0  0  
N 
‘0
0  x:
<Z
O
T3
C0
0 i ®
C  
0  
0  
0  0
0
0
£
0
0
0
Eo
0c
0L_
0
"O c  
0  
-Q Ep
JD C  
0
« * 
i— o. T3
2 i
0  XD 
XI °
.9
> 0  
T3 JD 
0  O-£2 I—
0  Q_
00 "o S
.£ >  
0  0  
0
0  o■Q 
C  
0  n
<  O)
1-T3 CL
0  Vr■4—' O0 c0 ED) >»
5 &
1
E 
0
c  _  
C g
s a0  ^
0
0
TO
C
0
_Q
X3
CM
cvi
0
T3
0
N
T3
Co
° .0  
CL ®
"q5cco .9  
clx:
8 1
T3 
O) >,C SZ 
0
O0)
CO
X
CO
0
_QO
CO
CO
>
0
XI-4—>
D)c
’0D
0
0
CC
_ 0
0c
0
T3
0  ■4—• 
0  
0  
CD
■D
0  0  ^  
->* lO > 0 CO o  c
C  0  
0  r-g»S
tr\ ^
o>
0
Q. "U v
0
CD
CD [ I
Figure 3.8. The scatter diagram shows the number of 
sam ples with germline IgH genes on the left hand side (IgH 
G) and the number of samples in which IgH gene 
rearrangements were detected on the right hand side (IgH R). 
Each sample is indicated by a circle. The number of samples 
in which HRS cell numbers were estimated at more than 8% 
of the total is shown in the top panel (+ + + ); the middle two 
panels indicate the numbers of samples in which the HRS 
cell numbers were estimated at 3-8% (++), or less than 3% 
of the total (+); the bottom panel indicates the number of 
sam ples in which less than 1 HRS cell was seen per high 
power field.
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Figure 3.8. Comparison between the detection of IgH
gene rearrangements and the numbers of abnormal 
cells in samples from patients with HD.
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•  •  •
•  •  •  •
•  •  •
•  •  •  •
•  •  •  
• •  •
IgH G IgH R
33.2  NHL cases.
The diagnoses and clinical details of the 15 patients with NHL are shown in Table HLII. 
This table also shows the results of genotypic analysis of the samples obtained from 
these patients.
T-cell NHLs.
The results obtained from the histological and immunophenotypic analysis of the 
samples obtained from the majority of this group of patients have been described 
previously (Krajewski etal. 1988).
Three immunoblastic T-cell lymphomas and two cutaneous T-cell lymphomas showed 
germline Ig genes and rearrangement of the TCRp gene(s) (Figure 3.10). In cases 200 
and 201 TCRp gene rearrangements were detected only following restriction digestion 
with EcoRV, or following electrophoresis of EcoRI digested DNA in 0.7% agarose gels 
(Figure 3.10). Four of the cases also showed rearranged TCRy genes (Figure 3.11).
Five cases classified as AIL were analysed. In samples 107,112 and 347 TCRP gene 
rearrangement was detected and IgH genes were germline (Figure 3.12). A sample from 
case 204 showed IgH and IgLK gene rearrangement and germline TCRp genes. The 
IgH gene rearrangement detected in this sample is shown in Figure 3.12. Sample 383 
showed TCRp gene rearrangement in addition to IgH and IgL gene rearrangement 
(Figure 3.12). Immunophenotyping of cases 204 and 383 indicated that B-cells formed 
20-30% of the cellular infiltrate. Restricted expression of IgL was not detected in either 
case. In the sample obtained from patient 383 there was additional evidence to indicate 
the presence of a clonal T-cell population in the lymph node biopsy as tumour cells 
showed reactivity with the clonotypic antibody MX11. However no rearrangements 
were detected in this sample using the Vp8 probe. Four of the samples were analysed 
for TCRy gene rearrangements. Two rearrangements were detected in sample 107, 
these are shown in Figure 3.11 (panel a). TCRy gene rearrangements were not detected 
in samples 347 and 383. Multiple faint rearranged bands were detected in EcoRI 
digested DNA from sample 204 (Figure 3.11, panel b). This result indicates the 
presence of a polyclonal T-cell population in the sample (Boehm et al. 1987b).
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VP region rearrangements.
Three cases of T-cell NHL in addition to case 383, discussed above, showed reactivity 
with the T-cell clonotypic antibodies MX11 or 421C1. Figure 3.13 shows the results of 
Southern blot analysis of these three cases using the Vp probes. The rearrangements 
detected using the Vp probes are shown alongside the results obtained from Southern 
blot analysis using the Cp probes, in order to demonstrate comigration of the Vp and 
Cp containing rearranged fragments.
Case 200 showed reactivity with antibody 421 C l in over 90% of tumour cells and 
TCRP gene rearrangement was detected using the Vp5 probe (Figure 3.13, panel b). No 
rearrangement was detected in BamHI digested DNA from this sample using the Cp 
probe (Figure 3.13, panel a). This was due to comigration of the rearranged fragment 
with the germline fragment, as shown by the location of the rearranged band that was 
detected with the Vp5 probe in the adjacent panel of Figure 3.13 (panel b). Sample 347 
showed reactivity with MX 11 and a rearrangement was detected with the Vp8 probe 
which comigrated with one of the rearrangements detected using the CP probe (Figure 
3.13, panels c and d). In sample 464, which was obtained from a patient with mycosis 
fungoides, approximately 70% of tumour cells reacted with MX11 while most of the 
remaining tumour cells stained with 421 Cl. A rearrangement was detected with the 
VP8 probe and this comigrated with the rearrangement detected in BamHI digested 
DNA using the CP probe. However no rearrangement was detected using the VP5 probe 
to analyse this sample.
B-cell NHLs.
In 5/6 cases of B-cell NHL rearrangements of the IgH and IgL genes were detected 
(Figures 3.14 and 3.15). In 4/5 cases with rearranged Ig genes monotypic IgL 
expression was reported. Samples 236 and 238 showed IgLK gene rearrangement 
(Figure 3.15, panel a) and were reported to show IgLK light chain restriction. In sample 
238 a rearrangement was also detected using the Kde probe (Figure 3.15, panel c), 
indicating that deletion of one IgLK gene had occurred prior to successful 
rearrangement of the second gene. In samples 171 and 239 rearrangement of the Kde 
locus was detected (Figure 3.15, panels b and c) and both samples showed IgLX light 
chain restriction. In sample 239 both Ck alleles were deleted, however in sample 171 
only germline fragments were detected using the Ck probe, most probably reflecting
79
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the presence of non-tumour cells in the biopsy. In case 228, a follicular lymphoma, no 
IgH or IgL chain expression had been detected on immunophenotyping, however 
rearrangements were detected with the Jjj  and Kde probes (Figure 3.14, panel b; Figure 
3.15, panel c). No TCRp gene rearrangements were detected in these samples.
Case 169 was classified as a T-cell predominant B-cell lymphoma. Immunophenotypic 
analysis indicated that the lymph node was infiltrated by small lymphocytes with T-cell 
markers (90% CD3+, CD4+ and 10% CD8+) and 1-2% blast cells including a small 
number of multinucleated cells. The blast cells expressed B-cell markers (CD19 and 
CD22) and monotypic IgLK. No Ig or TCRp gene rearrangements were detected in the 
sample from this case (Figures 3.14 and 3.15). Ig gene rearrangements were detected 
only on prolonged autoradiograph exposure in reconstituted DNA samples in which 2% 
of the total DNA was known to contain a clonal gene rearrangement (see previous 
section and Figure 3.9). It is therefore likely that the neoplastic cell population in 
sample 169 was too small for the detection of any gene rearrangements that might be 
present in this population.
3.3.3 Diagnostically difficult cases.
The biopsies from  the patients in this group were histo logically  and 
immunophenotypically heterogeneous. The clinical features, diagnoses and the results 
of immunophenotypic and genotypic analysis are shown in Figures 3.16-3.12 together 
with photomicrographs of tissue sections.
Case 124: NSHD or B-cell NHL?
Case 124 presented with an anterior mediastinal tumour, which when biopsied showed 
sheets of large mononuclear blast cells, with small numbers of multinucleated cells 
surrounded by collagenous septae (Figure 3.16). Morphologically the differential 
diagnoses included NSHD and sclerosing mediastinal B-cell lymphoma. The blast cells 
were CD45-, CD15+, CD30+, HLA-DR+ and CD25+ and did not express T- or B-cell 
antigens. On the basis of the tumour phenotype, histology and clinical presentation, a 
working diagnosis of NSHD was made.
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Figure 3.16. Results of histological, immunophenotypic and 
genotypic analysis for case 124. The photograph is of an 
haemotoxylin and eosin-stained section and shows an 
infiltrate of large blast cells with a  small number of 
multinucleated cells. G, germline; ND, not done; NSHD-2, 
NSHD type II; R1, one allele rearranged ; R2, two alleles 
rearranged; <5% positive cells; + + , >50% positive cells. 
The histological and immunophenotypic analyses were 
performed by Dr. A.S. Krajewski.
Figure 3.16. Case 124.
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Molecular analysis of the biopsy from Case 124 showed rearrangement of the IgH and 
IgLK genes (Figure 3.21). No TCRp gene rearrangements were detected.
Case 167: MCHD or T-cell NHL?
The initial biopsy obtained from case 167 was an extradural tumour (frontal lobe). The 
biopsy contained a mixed infiltrate of small lymphocytes with small numbers of larger 
mononuclear blast cells, but no RS cells (Figure 3.17). A diagnosis of pleomorphic T- 
cell lymphoma was made. The patien t subsequently developed axillary 
lymphadenopathy and a lymph node biopsy was considered to show features of MCHD, 
with numerous RS cells expressing CD 15 and CD30.
Unfortunately no tissue from the extradural tumour was available for genotyping. 
Analysis of the lymph node biopsy showed germline IgH (Figure 3.21), IgL and TCRP 
genes, though the hybridization pattern observed with the CP probe was consistent with 
the presence of a polyclonal T-cell population.
Case 168: NSHD or T-cell NHL?
Case 168 presented with lymphadenopathy and a pulmonary infiltrate. A lymph node 
biopsy showed infiltration by small and medium-sized lymphocytes, predominantly T- 
cells, with B-cells expressing either IgLK or IgLA present in small residual follicles. No 
RS cells were seen, though small numbers of large mononuclear cells expressing CD15 
and CD30 were present A second lymph node biopsy showed a similar infiltrate to the 
first biopsy, with complete effacement of normal node architecture, capsular fibrosis 
and collagenous septae dividing the lymph node (Figure 3.18). No typical RS cells were 
seen. The differential diagnosis included NSHD and T-zone lymphoma and despite the 
lack of RS cells, a diagnosis of HD was considered most likely on the basis of the 
histological findings.
The second biopsy was analysed for gene rearrangements and showed germline IgH, 
IgL and TCRp genes.
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Figure 3.17. Results of histological, immunophenotypic and 
genotypic analysis for case 167. The photograph is of an 
haemotoxylin and eosin-stained section and shows several 
typical Reed-Sternberg cells. G, germline; +, 5-50% positive 
cells; + + , >50% positive cells; # , positive staining of large 
mononuclear cells and RS-like cells. The histological and 
immunophenotypic analyses were performed by Dr. A.S. 
Krajewski.
Figure 3.17. Case 167.
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Figure 3.18. Results of histological, immunophenotypic and 
genotypic analysis for case 168. The photograph is of an 
haemotoxylin and eosin-stained section and shows an 
infiltrate of lymphocytes and plasma cells with a single 
binucleated cell. G, germline; ND, not done; +, 5-50% 
positive cells, + + ; >50% positive cells; # , positive staining 
of large mononuclear cells and RS-like cells. The 
histological and immunophenotypic analyses were 
performed by Dr. A.S. Krajewski.
Figure 3.18. Case 168.
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Case 172: MCHD or AIL?
Case 172 had a prodromal history of fever and malaise for 2 years, and presented as an 
emergency with right upper quadrant pain, pneumonia and splenomegaly. A lymph 
node biopsy showed obliteration of the lymph node architecture (Figure 3.19) and 
replacement with a mixed cellular infiltrate mostly composed of T-cells (80% CD8+, 
CD3+ and 10% CD4+, CD3+). There were small numbers (less than 1%) of 
multinucleated cells, which were CD30+ and showed fine granular CD 15 staining, but 
no typical RS cells were seen. Some B-cells showing polytypic IgL expression were 
present in small residual follicles. Plasma cells, eosinophils and prominent high 
endothelial vessels were also present. In this case the histological features and high 
numbers of CD8+ cells were considered to be more consistent with AIL, though MCHD 
could not be excluded.
A rearrangement of the IgH gene locus was detected in the sample from patient 172, 
though the rearranged band was very faint and only detectable following prolonged 
exposure of the filters to autoradiographic film (Figure 3.21). TCRP genes and TCRy 
genes were germline, though the hybridization pattern detected using the Cp probe was 
consistent with that of a polyclonal T-cell population.
Case 196: LPHD or T-cell NHL?
Case 196 had a history of night sweats and fatigue for 4 months prior to presentation 
with massive hepatomegaly and splenomegaly. Samples obtained from spleen, 
abdominal lymph nodes and liver showed a diffuse infiltrate of small lymphocytes, 
many showing nuclear irregularity, occasional macrophages and 1-2 % blast cells 
(Figure 3.20). No multinucleated cells were identified. Over 90% of the cells were 
CD3+ and CD4+, less than 5% were CD8+ and 1% expressed B-cell markers. 
Morphologically, many of the features were consistent with nodular lymphocyte and 
histiocyte predominant HD and this possibility was raised clinically. However, the 
immunophenotypic findings, the lack of RS cells and the pleomorphic nature of the 
lymphoid infiltrate was considered to be more consistent with T-lymphocytic, or small 
cell pleomorphic, T-cell NHL.
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Figure 3.19. Results of histological, immunophenotypic and 
genotypic analysis for case 172. The photograph is of an 
haemotoxylin and eosin-stained section and shows an 
infiltrate of small to large blast cells with occasional 
multinucleated cells (top right). G, germline; R1, one allele 
rearranged; + , 5-50% positive cells, + + ; >50% positive 
cells; # , positive staining of large mononuclear cells and 
RS-like cells. The histological and immunophenotypic 
analyses were performed by Dr. A.S. Krajewski.
Figure 3.19. Case 172.
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Figure 3.20. Results of histological, immunophenotypic and 
genotypic analysis for case 196. The photograph is of an 
haemotoxylin and eosin-stained section and shows an 
infiltrate of small lymphocytes with occasional blast cells. G, 
germline; R1, one allele rearranged; <5% positive cells; 
+ + ; >50% positive cells. The histological and
immunophenotypic analyses were performed by Dr. A.S. 
Krajewski.
Figure 3.20. Case 196.
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Genotypic analysis of the sample from case 196 showed an IgH gene rearrangement 
(Figure 3.21) and germline TCRp and TCRy genes. The hybridization pattern seen with 
the constant region probe suggested that there was a significant population of 
polyclonal T-cells present.
3.3.4 Bcl-2 gene analysis.
In each of the 5 B-cell lymphomas in which IgH gene rearrangement was detected, one 
of the rearranged fragments detected in Hindlll digested DNA appeared to be between 
5kb and 5.6kb in size (Figure 3.14). The size distribution of rearranged IgH Jjj 
fragments detected in Hindin digested DNA in other samples analysed was evaluated.
The rearrangements detected in the HD and AIL samples described in sections 3.3.1 
and 3.3.2 and those detected in an additional 12 B-cell lymphomas and 1 unclassified 
lymphoma (sample number 369) were included in the analysis. A total of 45 rearranged 
fragments were detected in 29 lymphomas. The size distribution of rearranged bands 
detected following Hindin digestion is shown in Figure 3.22. Twenty two of a total of 
forty five rearranged fragments were between 4.0 and 6.0kb in size.
In order to determine whether the consistent size of these rearranged fragments was 
related to the t(14; 18)(q32;q21) chromosomal translocation that is present in a 
substantial proportion of follicular and diffuse B-cell NHLs, selected samples were 
analysed using the bcl-2 probes. Fourteen samples with rearranged fragments of 
between 4.0 and 7.0kb in size were analysed with either the H4.3 probe or both the 
HR1.5 and RH2.8 probes. Three additional samples were analysed using the RH2.8 
probe only (Table m ill).
Rearrangements of the bcl-2 locus were detected in two B-cell NHLs (cases 228 and 
352) as shown in Figure 3.23. In both cases one of the rearranged bands detected using 
the bcl-2  probes comigrated with a rearranged band that was detected with the Jjj - 
probe.
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Figure 3.22. The size distribution of rearranged JH region 
fragments detected in Hindlll digested DNA samples.
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DNA samples were digested with the restriction enzyme Hindlll 
and hybridized with the JH probe. The sizes of rearranged 
fragments were estimated using the fragments of 
Hindlll-digested phage lambda DNA as standards.
Table lll.lll. Southern blot analysis of lymphoma
samples for rearrangements of the major 
breakpoint cluster region of the bcl-2 gene.
Patient
No.
Diagnosis Size of rearranged 
Hindlll fragments 
hybridizing to pHj
Configuration 
of bcl-2 (*)
51 B (LG) 4.5 G (c)
53 B (Foil) 5.5, 19 G (c)
59 B (Foil) 2.7, 5.4 G (c)
62 B (CC) 2.8, 4.5 G (c)
124 HD/B 5.8, 8.0 G (a,b)
171 B (Foil) 5.1, 8.4 G (a,b,c)
204 AIL 5.4, 6.0 G (a,c)
228 B (Foil) 5.2, 13 R (a,b)
236 B (Foil) 5.6, 6.8 G (a,b,c)
238 B (CB) 5.4, 18 G (a,b)
239 B (CC) 5.0, 15 G (a,b)
352 B (CB) 4.9, 6.6 R (b)
373 HDNS 1.7, 4.7 G (b)
386 HDMC 6.0 G (a,b,c)
413 B (CB) 4.7, 5.8 G (c)
430 HDNS 4.8, 7.4 G (b)
433 B (Foil) 5.0, 5.4 G (a,b,c)
B, B-cell NHL; CC, centrocytic; CB, centroblastic; Foil, 
follicular; G, germline; L, low grade; R, rearranged (*) 
the probes used for bcl-2 gene rearrangement analyses 
are indicated in parenthesis; (a), HR1.5; (b), RH2.8; (c), 
H3.4.
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3.4 DISCUSSION.
3.4.1 Hodgkin’s Disease.
As part of a study into the aetiology and pathogenesis of HD, 35 unselected cases of 
HD were analysed for the presence of Ig and TCR gene rearrangements.
Ig gene rearrangements in HD.
Ig gene rearrangements were detected in approximately one quarter (9/35) of the cases, 
while none of the cases showed TCRP gene rearrangement. These data indicate that 
clonal cell populations showing genotypic features of B-cells may be found in a 
significant proportion of HD biopsies. The data are in agreement with a number of other 
reports, in which Ig gene rearrangements but not TCRp gene rearrangements were 
detected in HD samples (O’Connor etal. 1986; Weiss etal. 1986b; Brinker etal. 1987; 
Raghavachar etal. 1988) (Table III.IV). In two of the HD cases with rearranged IgH 
genes, IgL gene rearrangement was not detected, suggesting that the clonal cell 
population has been expanded at an early stage in B-cell differentiation. IgL gene 
rearrangement was not detected in cases without rearranged IgH genes, though this has 
been reported by others (Weiss et al. 1986b; Brinker etal. 1987; Herbst et al. 1989).
TCRp gene rearrangements in HD.
No TCRP gene rearrangements were detected in the 35 cases analysed in this study and 
no TCRy gene rearrangements were detected in the 10 cases analysed with the TCRy 
gene probe. Griesser etal. (1987) found TCRP and TCRy gene rearrangements in 4/22 
and 15/22 HD samples respectively, while Herbst et al. (1989) detected TCRp gene 
rearrangement in 6/39 cases of HD. In addition Dallenbach and Stein (1989) have 
reported that in 30% of HD cases the RS cells express TCRp. However in the majority 
of other reports TCRp gene rearrangements were not detected in HD samples (Table 
DI.IV). The reasons for the variations in the findings of different groups are obscure. 
Sundeen etal. (1987) suggested that technical problems may have been responsible for 
the high number of TCRy gene rearrangements reported by Griesser et al. (1987).
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Difficulties may be encountered in differentiating HD from some T-cell lymphomas, in 
particular the T-zone lymphomas, including those classified as AIL (Lukes and Tindle 
1975; Krajewski et al. 1988). Thus differences in lymphoma classification in different 
centres could explain some of the variations in the reported results.
Gene rearrangements in different subtypes of HD.
In this study IgH gene rearrangements were detected in cases of NS, MC and LDHD. 
These results combined with data from other groups show that IgH gene rearrangements 
may be detected in the NS, MC and LP subtypes of HD at similar frequencies (using 
the test, p>0.5) (Table m.V). The number of cases of LDHD are too small to 
include in this analysis. However comparison of the frequency of gene rearrangements 
detected in LDHD relative to the frequency detected in all other subtypes combined 
again shows no significant difference (Fisher’s exact test, two tailed, p=0.16). The cases 
analysed by Brinker et al. (1987) and Weiss etal. (1986b) have been excluded from the 
analyses, as these cases were selected on the basis of high HRS cell numbers.
These data do not support the suggestion that LPHD is a distinct B-cell disorder. 
However the criteria used for the diagnosis of LPHD have recently altered (Nicholas et 
al. 1990). The summarized data is therefore likely to include cases that would no longer 
be classified as LPHD. In addition HRS cells are usually very scarce in LPHD, thus if 
the Ig gene rearrangements are present in the HRS cells the data do not provide 
convincing evidence against the hypothesis. The two cases of LPHD analysed in this 
study were estimated to contain less than 1% HRS cells, thus clonal Ig gene 
rearrangements present in these cells would not be detectable.
Are the Ig gene rearrangements present in HRS cells?
HD biopsies contain a variety of different cell populations in addition to HRS cells. In 
order to draw any conclusions about the lineage and clonality of HD from the results of 
gene rearrangement analysis it is necessary to determine whether the rearrangements are 
present in the HRS cells. The detection of Ig gene rearrangements in a minority of cases 
of all subtypes of HD, may reflect the low numbers of HRS cells present in most 
tumour biopsies. HRS cells frequently make up less than 2% of the total cell population
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Table III.V. Detection of TCR and Ig gene rearrangements 
in samples from patients with different subtypes of HD.
Subtype No. of 
cases
Ig gene 
rearrangements
TCR gene 
rearrangements
IgH igL TCRB TCRy
NS 111 19 15/98 7 7/46
MC 44 5 1/38 3 4/33
LP 21 3 0/16 1 3/14
LD 13 4 1/5 0 3/9
The data presented in this table are summarized from the 
reports by Knowles et al. (1986); Weiss et al. (1986); 
Brinker et al. (1987); Griesser et al. (1987); Sundeen et al. 
(1987); Raghavachar et al. (1988); Roth et al. (1988); 
Herbst et al. (1989) and this study. The cases of NSHD 
analysed by Weiss et al. (1986) and the cases analysed by 
Brinker et al. (1987) were selected on the basis of high 
HRS cell numbers. The study of Brinker et al. (1987) 
included two cases of NSHD and one case of MCHD for 
which differential diagnoses including LDHD were given. 
These cases have been classified in the table as NS or 
MCHD, all three cases had IgH gene rearrangements. The 
results obtained by Sundeen et al. (1987) from the 
analysis of unfractionated sam ples have been included in 
the table.
in HD biopsies and this is close to the limit of sensitivity of gene rearrangement 
analysis. However a number of authors have suggested that the gene rearrangements 
detected in HD samples may be present in lymphoid cell populations unrelated to HRS 
cells (Knowles etal. 1986; Griesser et al. 1987; Raghavachar et al. 1988).
A correlation between the detection of Ig gene rearrangement and HRS cell numbers 
was observed in this study. Seven of the nine HD cases in which Ig gene 
rearrangements were detected had more than 8% HRS cells (Figure 3.8). Some other 
reports have also described a correlation between HRS cell numbers and the detection 
of Ig and/or TCR gene rearrangement. Weiss et al. (1986b) detected Ig gene 
rearrangements in 7/8 cases of NSHD selected on the basis of high RS cell numbers. 
Sundeen etal. (1987) analysed HD samples enriched for HRS cells, and were able to 
detect Ig gene rearrangements in the enriched fractions of 3/6 samples, but not in the 
original material. Herbst etal. (1989) also evaluated HRS cell numbers on the basis of 
CD30 positivity, and found that Ig/TCR gene rearrangements were detected more 
frequently in HD cases with large numbers of HRS cells.
The relationship between HRS cell numbers and the cells containing clonal Ig gene 
rearrangements was evaluated for the nine cases in which rearrangements were 
detected. The proportion of cells containing a clonal gene rearrangement was estimated 
from densitometric measurement of the intensity of the rearranged band detected 
following autoradiography. The numbers of cells estimated by densitometry to contain 
clonal gene rearrangements were similar to the numbers of HRS cells (as assessed 
morphologically) present in eight of the nine samples. The result obtained from sample 
382 is discussed further below.
Additional indirect evidence suggesting that the Ig gene rearrangements detected in 
case 386 are present in the HRS cells is provided by the results of karyotypic analysis. 
Detailed karyotyping was performed on 5 of the cases analysed in this study, cases 237, 
382,384,385,386 and 387 (Banks et al. 1991). Abnormal karyotypes were detected in 
cases 382 and 386, both of which showed IgH and IgL gene rearrangement. No 
karyotypic abnormalities and no Ig gene rearrangements were detected in the other 
three cases. Teerenhovi et al. (1988) found that the abnormal clonal karyotypes 
detected in 2 cases of HD were restricted to the HRS cells. If this finding can be 
extrapolated to other cases, the results suggest that the Ig gene rearrangements and
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karyotypic abnormalities detected in case 386 were present in the same cell population, 
probably the HRS cells. The results obtained for case 382 are not consistent with this 
interpretation, as no HRS cells were observed in the biopsy in which Ig gene 
rearrangements and kaiyotypic abnormalities were detected.
The above data offer support for the hypothesis that the Ig gene rearrangements 
detected in HD biopsies are present in the HRS cells.
Are there HRS cells with germline Ig genes?.
Some HD cases with large numbers of HRS cells do not have detectable Ig gene 
rearrangements. In this study Ig gene rearrangements were not detected in 6 cases in 
which HRS cell numbers were estimated to be over 8% and 7 cases in which HRS cell 
numbers were estimated to be 3-8% (Figure 3.8). Others have reported similar findings 
(Knowles etal. 1986; O’Connor et al. 1987; Sundeen et al. 1987; Herbst etal. 1989).
There are two possible interpretations of the data. The results are consistent with the 
possibility that HRS are derived from lymphocytes at varying stages of differentiation. 
Alternatively clonal B-cell populations unrelated to HRS cells may be present in a 
minority of HD biopsies.
Restricted expression of IgL on B-cells in HD biopsies has not been reported, 
suggesting that the latter interpretation is unlikely to be correct (Brinker etal. 1987; 
Herbst et al. 1989). Restricted IgL expresssion was not observed on B-cells in the HD 
biopsies with IgH and IgL gene rearrangements included in this study.
Case 382.
The results obtained for patient 382 offer some support for the hypothesis that Ig gene 
rearrangements are present in a cell population distinct from HRS cells. IgH and IgL 
gene rearrangements were detected in a lymph node biopsy that was classified 
histologically as "reactive", but were not detected in a spleen sample showing features 
of NSHD. Alternatively this result could be due to differences in the extent of disease 
involvement in the parts of the lymph node sent for genotypic and histological analysis.
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It should also be noted that some lymphoblasts were present in the "reactive" lymph 
node. A clonal karyotypic abnormality was also detected in this sample (Banks etal. 
1991), suggesting that this latter explanation may be correct. Other investigators have 
shown that karyotypic abnormalities in HD are restricted to the HRS cells (Teerenhovi 
e ta l  1988).
The detection of EBY genomes in HD.
The 35 HD cases included in this study were also analysed for the presence of EBV 
genomes in a parallel investigation (Gledhill etal. in press). EBV DNA was detected by 
Southern hybridization in 11 of the 35 HD cases included in this study. These data have 
been included in Table DLL In the 10 EBV positive cases analysed, the viral episomes 
were shown to be monoclonal in origin implying that the virus-infected cell has 
undergone clonal expansion. Similar results have been reported by a number of other 
groups (Weiss et al. 1987b; 1989; Anagnostopoulos et al. 1989; Boiocchi et al. 1989; 
Staal etal. 1989; Uccini et al. 1989).
The expression of EBV antigens has been shown on HRS cells in some of these cases 
(numbers 79,210, 386, 387 and 390; R.F. Jarrett and A. Armstrong, unpublished 
results). EBV has also been shown to be present in HRS cells of HD biopsies using in 
situ hybridization (Anagnostopoulos et al. 1989; Uccini etal. 1989; Weiss etal. 1989). 
The results of these studies have demonstrated that HRS cells are clonal in origin.
It seems probable that the clonal Ig gene rearrangements detected in case 386 are also 
present in the EBV infected, clonal HRS cells. However in cases 390 and 927 which 
were EBV positive, no Ig gene rearrangements were detected although HRS cell 
numbers were estimated at 3-8% and 8% respectively. Similar results were reported by 
Weiss etal. (1987b) and Herbst etal. (1989). In these cases the virus may have infected 
a cell at an early stage of differentiation prior to the rearrangement of Ig/TCR genes. In 
support of this possibility, Gregory et al. (1987) have shown that EBV will infect and 
immortalize lymphocytes at varying stages of maturity. An alternative explanation is 
that polyclonal rearrangements of the Ig and/or TCR genes have occurred in EB V- 
infected cells following transformation.
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The results described in this chapter provide support for the hypothesis that HRS cells 
are derived from lymphoid cells at various stages of differentiation. The characteristic 
morphologic and phenotypic features of HRS cells may develop as a result of a common 
event occurring as part of the transformation process. Evidence from a number of 
groups suggests that in some cases of HD the mechanism of transformation is related to 
EBV infection (Anagnostopoulos et a l  1989; Uccini e ta l  1989; Weiss et al. 1989; 
Gledhill e ta l  in press).
3.4.2 AIL.
TCR and Ig gene rearrangement in AIL-like lymphomas and AIL.
Analysis of the configuration of the TCR and Ig genes in 5 cases of AIL-like lymphoma 
demonstrated that this disease is not associated with a consistent pattern of TCR/Ig gene 
rearrangement The results indicate that clonal T-cell populations (cases 106, 112,347 
and 383) or clonal B-cell populations (cases 204 and 383) may be detected in affected 
tissues. In case 383 the data suggest that more than one clonal population is present, as 
although IgH gene rearrangement has been described in T-cell lymphomas, IgL gene 
rearrangement has been reported very infrequently in non-B-cell tumours (Pelicci e ta l  
1985; Ha Kawa e ta l  1986; O’Connor et a l 1987). It is unlikely that the TCRp gene 
rearrangement detected in this sample was present in the clonal B-cell population, as the 
presence of a T-cell clone was also indicated by reactivity of tumour cells with MoAb 
MXD, which is specific for the Vp region of the TCR.
AIL-like lymphoma has been included in the updated Kiel classification as a low grade 
T-cell NHL (Stansfeld e ta l  1988). Most studies have reported the detection of TCRp 
gene rearrangements in the majority of cases of AIL-like lymphoma, supporting this 
classification (Watanabe et a l  1986; Weiss e ta l  1986c; Suzuki et a l  1987; Tobinai et 
al. 1988). However, in agreement with the data reported in this study, some samples 
have been shown to have rearranged Ig genes, while others have germline Ig and TCR 
genes (Weiss et a l  1986c; Suzuki e ta l  1987; Tobinai et a l  1988). Evidence for the 
occasional presence of multiple clonal cell populations in AIL-like lymphoma has also 
been derived from karyotypic and gene rearrangement analysis (Fuiita e ta l  1986; Story 
e ta l  1987; Kaneko e ta l  1988).
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The results that have been obtained from the analysis of AIL samples lacking 
morphological evidence of overt lymphoma do not differ markedly from those 
described above (O’Connor et al. 1986; Weiss et al. 1986c; Lipford et al. 1987b; 
Suzuki et al. 1987; Kaneko et al. 1988). From the above and previous discussions 
(sections 1.3.3 and 3.1.5) it is apparent that the results of immunophenotypic, molecular 
and karyotypic analyses do not suggest that a clear distinction may be drawn between 
AIL and AIL-like lymphoma.
Frizzera etal. (1989) have proposed a classification system for AIL and related lesions, 
in which the histological and immunophenotypic features are considered in the context 
of the results of molecular and karyotypic investigations. The results described in this 
chapter suggest that monoclonal T- or B-cell populations were present in samples from 
cases 112, 204 and 347. These cases would be classified, on these and on 
morphological grounds, as AIL-like-lymphomas as suggested by Frizzera et al. (1989). 
Clonal TCRp and TCRy gene rearrangements were also detected in the sample from 
case 107, however this case subsequently resolved spontaneously. Frizzera etal. (1989) 
have suggested that such cases, in which evidence of sequential changes in the 
predominant clonal cell population(s) are found, could be classified as AIL-like 
dysplasias. The clinical usefulness of this classification may be limited, however, by the 
requirement for sequential investigations. Case 383, in which evidence for the presence 
of multiple clonal cell populations was detected, would also be classified as AIL-like 
dysplasia.
The pathogenesis of AIL.
O’Connor et al. (1986) suggested that one possible interpretation of their data is that 
AIL is initially a polyclonal disease of B- and T-lymphocytes, in which monoclonal cell 
populations were likely to arise as secondary events. Lipford et al. (1987a) propose a 
similar model of disease pathogenesis, with expansion of clonal B- or T-cell 
populations occurring in the context of an underlying disorder of immune regulation. In 
the latter study changes in the predominant clonal lymphocyte population were detected 
in sequential samples. Similar findings were reported by Kaneko et al. (1988). Lipford 
etal. (1987b) make the observation that the presence of clonal lymphocyte populations 
in AIL biopsies does not necessarily imply overt malignancy. The spontaneous 
resolution of disease seen in patient 107 is consistent with this notion.
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According to this model AIL, AIL-like dysplasia and AIL-like lymphoma represent 
overlapping stages in disease pathogenesis. Polyclonal or oligoclonal lymphocyte 
proliferation may be the first stage in a multistep pathogenic process, followed by the 
expansion of a single predominant clone. The occurrence of additional transforming 
events in cells of this clone may, in some cases, give rise to the development of an 
overt lymphoma.
3.4.3. Analysis of Vp rearrangement in samples reacting with T-cell 
clonotvpic antibodies.
Molecular probes for the Vp regions used by rearranged TCRp genes in the Jurkat and 
HPB-ALL cell lines were used to analyse biopsies showing reactivity with the 
clonotypic antibodies MX 11 and 421C1, which were raised against these cell lines. 
Rearrangement of the VP5 locus was demonstrated in 1/2 cases showing reactivity with 
MoAb 421 C l, while rearrangements of the Vp8 locus were detected in 2/3 cases 
showing reactivity with MoAb MX11.
These results support the use of these antibodies for the identification of monoclonal T- 
cell populations in tumour biopsies, but suggest that the antibodies may have a wider 
range of specificities that the relevant DNA Vp probes. It is possible that the antibodies 
may react with epitopes that are conserved between more than one Vp family.
Jack etal. (1990) have recently reported that the tumour cells of a high proportion of 
CTCLs show reactivity with a MoAB reactive with TCRp containing Vp8 regions. 
These authors suggest that proliferation and transformation of T-cells expressing a 
particular Vp could arise from immune stimulation by a specific antigen. A similar 
model of leukaemogenesis has been described in Chapter 1 (section 1.4.2). Jack etal. 
(1990) also raise the possibility that v p 8 -containing TCRp could be functioning as 
receptors for an oncogenic virus.
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In order to assess the significance of results such as those obtained by Jack etal. (1990), 
it is important that the specificity of the Vp-reactive MoAbs are accurately determined 
A PCR strategy similar to those recently described by d ’Auriol et al. (1989) and 
McCarthy et al. (1990) for the detection of TCRy and IgH gene rearrangements 
respectively could be used to resolve this question. A similar study would also be useful 
to confirm the specificities of the additional Vp-specific MoAbs that have recently 
become available commercially (Laboratory Impex Limited).
3.4.4. The use of gene rearrangement analysis for lymphoma 
diagnosis.
Gene rearrangement analysis has been extensively used for the investigation of the 
lineage and clonality of lymphoma material, as in the study of HD described above. 
This has allowed a number of conditions with defined clinical and pathological features 
to be classified as B- or T-cell neoplasms. However the results of genetic analysis in 
individual cases which prove difficult to classify on clinical and pathological criteria 
may be more difficult to interpret. We analysed the configuration of the Ig and TCR 
gene loci in 5 cases in which difficulty had been encountered in reaching a diagnosis 
following routine examination.
The 5 cases analysed had differential diagnoses which included HD and NHL. Knowles 
et al. (1986) have suggested that the detection of significant gene rearrangements in 
lymphoma material may be used to exclude a potential diagnosis of HD. However the 
detection of significant gene rearrangements in HD cases in these studies and those of 
others (Brinker etal. 1987; Griesser etal. 1987; Herbst etal. 1989) indicates that this is 
not a useful criterion for distinguishing NHL and HD. Failure to detect Ig or TCR gene 
rearrangements in such cases would be significant supportive evidence for a diagnosis 
of HD, provided that adequate numbers of the presumptive neoplastic cells were present 
for detection. The importance of the latter point is illustrated by the lack of detectable Ig 
gene rearrangement in case 169, a T-cell predominant B-cell lymphoma, in which the 
numbers of neoplastic cells were estimated at less than 2%.
Thus in cases 26 and 27, for which the differential diagnoses included HD and T-cell 
NHL, the lack of TCRp gene rearrangements is more consistent with a diagnosis of HD. 
Case 29 also had a differential diagnosis which included HD and T-cell NHL. The 
detection of an IgH gene rearrangement in this case and the lack of TCRp and TCRy
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gene rearrangement are more consistent with a diagnosis of HD. However no typical RS 
cells were observed in biopsies from this patient and the histological and 
immunophenotypic features were considered to be more consistent with a diagnosis of 
T-cell NHL. This case is difficult to classify with any degree of certainty as occasional 
cases of T-cell NHL lacking TCRp gene rearrangements have been reported (O’Connor 
etal. 1987) and rearranged IgH genes have been described in such cases (Ogawa etal. 
1986: Weiss et al. 1988).
The differential diagnosis for case 28 included HD and AIL. Our results and those of 
others indicate that lymphomas classified as AIL may show a variety of genotypes 
(section 3.4.2). Detection of a clonal IgH gene rearrangement in this sample does not 
resolve the diagnostic difficulty, as Ig gene rearrangements may be detected in both HD 
and AIL.
A similar problem is encountered with sample 25, in which IgH and IgL gene 
rearrangements were detected. The diagnosis for this case lay between HD and B-cell 
NHL, but as discussed earlier, Ig gene rearrangements may be detected in HD samples. 
The results of genetic analysis of case 25 did not therefore assist in making a definite 
diagnosis.
This series of cases suggests that the analysis of TCR and Ig genes may be useful for 
lymphoma samples in which immunophentotyping and histology have been 
inconclusive. However because variation in genotype may be seen in certain groups of 
conditions the results of genetic analysis may not be helpful in every case. In order to 
ensure that gene rearrangements are not missed it is essential that individual samples are 
subject to extensive analysis. In some of the cases included in this study analysis with 4 
restriction enzymes and electrophoresis on low percentage agarose gels was required for 
the detection of TCRp gene rearrangement (see Figures 3.10). In addition, care is 
necessary in the interpretation of results if the putative malignant cells are present in 
small numbers. In spite of these potential problems, genotypic analysis should form a 
useful adjunct to routine diagnostic procedures as long as the results are assessed in the 
context of histological and immunophenotypic findings.
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3.4.5 Bcl-2 gene rearrangement analysis.
Analysis of 29 lymphoma samples with the Jjj probe showed that nearly half (22/45) 
the rearranged fragments detected in Hindlll digested DNA were between 4.0 and 6.0kb 
in size. In order to determine whether detection of Hindin restriction fragments of this 
size indicated the presence of a t(14;18)(q32;q21), HindTH digested DNA from 17 of 
these samples was analysed with probes for the MBR on chromosome 18. 
Rearrangements of the MBR were detected in 1/6 follicular lymphomas and 1/3 
centroblastic B-cell lymphomas. The results indicate that detection of a restriction 
fragment of this size with the IgH J-region probe in Hindin digested DNA is not a good 
indicator of the presence of a translocation involving the bcl-2 MBR on chromosome 
18, even in follicular and diffuse B-cell NHL. In addition the incidence of 
rearrangements of the MBR was low relative to that described in other studies (Lee et 
al. 1987; Lipford et al. 1987a; Weiss et al. 1987a). In a recent study, translocations 
involving the MBR of the bcl-2 gene and the Jjj region of the IgH gene were detected 
in 32% of HD samples using the PCR (Stetler-Stevenson et al. 1990). However bcl-2 
gene rearrangements were not detected in three HD cases analysed in this study, or in 
case 124, one of the diagnostically difficult cases discussed earlier. The low numbers of 
MBR rearrangements detected in this study may reflect the small number of samples 
included in the analysis.
3.4.6. Conclusions.
The results obtained from the analysis of Ig and TCR gene rearrangement in HD are 
consistent with the derivation of HRS cells from lymphocytes at various stages of B- 
cell differentiation. Definitive proof that the Ig gene rearrangements are present in the 
HRS cells will be important for the development of an accurate model for the 
pathogenesis of HD. This must account for the evidence indicating that EBV may play 
a role in the aetiology of HD. The epidemiological and serological evidence supporting 
a viral aetiology for HD is discussed further in the following chapter.
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Molecular analysis of the TCR and Ig genes in samples from patients with AIL 
provides an opportunity to study different stages in a multistep pathogenic process. The 
emergence of dominant clonal cell populations from a background of abnormally 
proliferating lymphoctyes may arise as a result of an underlying immunological 
abnormality. A variety of mechanisms by which viruses could induce immune 
dysfunction and thus contribute to lymphomagenesis were discussed in Chapter 1 
(section 1.4.2). The possibility that virus infection could be involved in the 
pathogenesis of AIL is explored further in Chapter 4.
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CHAPTER FOUR.
THE MOLECULAR ANALYSIS OF TUMOUR BIOPSIES FOR THE 
PRESENCE OF HUMAN HERPESVIRUS TYPE 6 (HHV-6) DNA
SEQUENCES.
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4,1. INTRODUCTION.
Human herpesvirus-6  (HHV-6), initially designated human B-lymphotropic virus, was 
firs t iso lated  from 6  patients with a variety o f lym phoproliferative and 
immunosuppressive disorders (Salahuddin et al. 1986). This report stimulated interest 
in the possib ility  that HHV -6  could be involved in the pathogenesis of 
lymphoproliferative disease. The study described in this Chapter was designed to 
investigate the molecular association between HHV-6  and lymphoid malignancy and 
was commenced immediately following the initial isolation of the virus. At this time 
little information about the structure or biology of HHV-6  had been reported.
The following sections provide a brief review of subsequently published studies that 
have investigated the structure, biology and disease associations of HHV-6 .
4.1.1. Virus structure and genomic organization.
HHV-6  shows typical herpesvirus morphology when visualized with an electron 
microscope (Figure 4.1). The virions are enveloped, have a diameter of approximately 
200 nm and contain a nucleocapsid with icosahedral symmetry (Salahuddin etal. 1986).
Early studies did not detect evidence of serological cross-reactivity or of nucleic acid 
homology with other animal or human herpesviruses (Josephs et al. 1986). 
Subsequently limited regions of DNA sequence homology with MDV (Kishi et al. 
1988) and HCMV (Efstathiou etal. 1988) were identified.
HHV -6  was in itially  considered to be a gammaherpesvirus because of its 
lymphotropism and the lack of evidence indicating a close relationship with any other 
human herpesviruses (Kishi et al. 1988; Lopez et al. 1988). Recently nucleotide 
sequence analysis of a 22kb region of the HHV-6  genome has revealed a closer 
resemblance to HCMV than to the other human herpesviruses (Lawrence etal. 1990). 
Lawrence et al. (1990) have therefore suggested that HHV-6  would be more 
appropriately classified with HCMV, as a betaherpesvirus.
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4.1.2. Seroepidemiology.
The seroprevalence of HHV-6  in healthy adult populations exceeds 50% and 
seroconversion appears to occur early in childhood for the majority of individuals 
(Briggs etal. 1988; Knowles etal. 1988; Clark et al. 1990). The virus therefore appears 
to be ubiquitous and readily transmitted.
Seroconversion has been reported in association with exanthem subitum, a febrile 
disease of children (Knowles etal. 1988; Takahashi etal. 1988; Yamanishi etal. 1988). 
HHV-6  has also been isolated from the peripheral blood of children with exanthem 
subitum and has been linked to the aetiology of this disease (Yamanishi etal. 1988). 
Seroconversion has also been reported in a number of additional clinical syndromes, 
including an infectious mononucleosis-like illness (Kirchesch etal. 1988; Irving and 
Cunningham 1990); hepatitis (Irving and Cunningham 1990) and febrile illnesses 
following renal transplants (Moms et al. 1989).
Serological studies have identified an association between high seroprevalence and high 
antibody titres to HHV-6 and a number of lymphoproliferative disorders, including HD, 
ALL and Burkitt’s lymphoma in Africans (Ablashi et al. 1988). An increased 
seroprevalence to the virus was also detected in patients with sarcoidosis, high grade 
NHL and SjOgrens syndrome (Ablashi et al. 1988; Biberfeld et al. 1988). However 
neither of these studies were case-controlled and thus the significance of the findings is 
uncertain.
A case-controlled study of the seroepidemiology of HHV-6  in patients with leukaemia 
and lymphoma was performed in parallel to the experiments that are described in this 
Chapter (Clark etal. 1990). Clark et al. (1990) found that HHV-6  seroprevalence and 
antibody titres were higher in patients with acute myeloid leukaemia, high-grade NHL 
and HD compared to controls.
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4.13. In vitro and in vivo tropism.
HHV-6  can infect a number of different cell types in vitro, including B- and T- 
lymphocyte cell lines, a megakaryocyte cell line and glioblastoma cells (Ablashi etal. 
1987). Lusso etal. (1988) have shown that when cultures of PBMCs are infected with 
HHV-6 , the virus is preferentially tropic for immature CD4+ T-cells. HHV-6  has a 
cytopathic effect in culture, characterized by the appearance of large refractile cells 
which express viral antigens (Salahuddin et al. 1986; Downing etal. 1987; Tedder et al. 
1987).
The in vivo tropism of HHV-6 may not be the same, though the virus has been detected 
by PCR in the PBMCs of healthy individuals (Gopal etal. 1990; Jarrett etal. 1990). 
Reports that HHV-6 may be isolated from cell-free and unfractionated saliva samples 
from healthy individuals (Pietroboni etal. 1988a; Harnett etal. 1990; Levy etal. 1990) 
suggest that the oropharynx is a site of viral replication in vivo. This has been supported 
by the detection of viral DNA sequences in saliva samples from healthy persons by the 
PCR (Gopal et al. 1990; Jarrett etal. 1990). In addition Fox et al. (1990) have reported 
the detection of HHV-6 DNA in salivary gland tissue using in situ hybridization.
4.1.4. Interactions between HHV-6 and HIV.
The possibility that interactions between viruses may be important in the pathogenesis 
of lymphoproliferative disease was discussed in Chapter 1 (section 1.4.2). A number of 
lines of evidence suggest that interactions between HHV-6  and HTV are likely to occur 
in vivo and may contribute to the development of HTV-associated disease.
Co-infection of CD4+ T-cells with HTV and HHV-6 results in increased HIV replication 
and an increased rate of cell death (Lusso et al. 1989). HHV-6  infection of T-cells has 
been shown to result in trans-activation of the HIV LTR, providing a possible 
mechanism for the effect on viral replication (Horvat etal. 1989). HHV-6 infection of 
CD4- T-cells has been reported to upregulate CD4 expression, rendering the cells 
susceptible to HIV infection (Lusso etal. 1991). HHV-6  may thus increase the number 
of potential target cells for HTV infection in vivo.
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It is also possible that HHV-6  replication may be increased in HIV-infected persons, as 
HHV-6  has been isolated frequently from the peripheral blood of patients with HTV 
infection (Downing etal. 1987; Tedder et al. 1987; Lopez et al. 1988; Peitroboni et al. 
1988b). However seroepidemiological studies have failed to detect any differences in 
HHV-6  antibody titres between HIV antibody-negative, HIV antibody-positive and 
HIV-p24 antigenaemic persons (Brown et al. 1988; Fox et al. 1988; Spira et al. 1990). 
The importance of HHV-6  as a cofactor in the pathogenesis of HIV-associated disease 
is therefore uncertain.
4.1.5. The oncogenic potential of HHV-6.
Cell transformation has not been reported following HHV-6 infection in vitro. However 
in a recent study transfection of HHV-6  genomic DNA or a subclone, pZVH14, into 
NIH3T3 cells resulted in morphological transformation of the cells (Razzaque 1990). 
The transformed cells were tumorigenic in nude mice, however viral DNA sequences 
were not detected in transformed or tumour cell lines in all cases. Genomic fragments of 
a number of other human herpesviruses have been shown to induce rodent cell 
transformation in vitro (Sugden 1986; Galloway et al. 1986), as discussed earlier 
(Chapter 1, section 1.2.1). However the relevance of these findings to virus infections in 
vivo remains to be established.
In order to investigate the role of HHV-6 in the pathogenesis of lymphoproliferative 
disease, the molecular association between the virus and a variety of lymphoid 
malignancies was investigated. This chapter describes the results of molecular analysis 
of tissues from patients with a variety of lymphoproliferative disorders for the presence 
of HHV-6 specific sequences. Disorders that had been previously linked to HHV-6  in 
serological studies were of particular interest, thus a large group of samples from 
patients with HD were examined. A parallel study into the involvement of EBV in HD 
was also performed using this material (Gledhill et al. in press; Jarrett etal. manuscript 
submitted). Samples from patients with sarcoidosis and Sjogren’s syndrome were also 
selected for investigation.
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4.2. MATERIALS AND METHODS.
4.2.1. Clinical samples.
Samples from patients with a variety of diseases were collected from a number of 
clinical centres. Sample material was categorized into three groups. The first group 
included samples from patients with lymphomas and leukaemias. This group included 
53 samples from patients with NHL and 47 samples from patients with HD. The cases 
were classified by the referring pathologists according to the Working formulation as 
detailed by the Non-Hodgkin’s lymphoma Pathologic classification project (Rosenberg 
1982). A second group, designed as a control group, contained 26 biopsies from 
patients with non-lymphoid disorders and included reactive nodes, secondary 
neoplasms and non-lymphoid primary tumours. The third group included material from 
9 patients with sarcoidosis or SjOgren’s syndrome, conditions which had been 
associated with HHV-6 in early seroepidemiological studies.
4.2.2. Viral isolates.
The A72 isolate of HHV-6  was obtained from Dr. R. Tedder and was originally isolated 
from the PBMCs of a Gambian patient with HIV-2-associated AIDS (Tedder etal. 
1987). The 1102 isolate of HHV-6 was a gift from Dr. R.G. Downing and was obtained 
from the cultured PBMCs of a Ugandan patient with AIDS (Downing et al. 1987).
4.2.3. Molecular analysis.
DNA samples were digested with the restriction enzymes EcoRI or HindlH unless 
otherwise indicated, size separated on 0 .8% agarose gels, transferred to nylon 
membranes and hybridized to radioactively-labelled DNA probes as described in 
Chapter 2.
The HHV-6  probe used was the insert from the pZVH14 plasmid, which consists of 9kb 
of viral DNA and does not cross-react with sequences from any other known 
herpesvirus (Josephs etal. 1986). This probe was obtained from the prototype isolate of
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HHV-6 , HHV-6q s  (Salahuddin et al. 1986). Probes for the 5’ and 3* regions of the 
clone, pZVH 5’H/E and pZVH 3’E/H, respectively, were prepared by purification of 
fragments following double digestion of the plasmid with Hindin and EcoRI (Figure 
4.2).
Selected samples were also analysed for rearrangements of the TCRP and IgH genes as 
described in Chapter 3.
4.2.4. Pulse field gel electrophoresis.
Pulse field gel electrophoresis (PFGE) was used to analyse virus-infected cells and 
HHV-6  positive samples, in order to investigate the size and state of the viral genome.
Cells were lysed in agarose, as follows, to avoid shearing long DNA molecules. 
Cultured cells, or cell suspensions prepared from disrupted tissues (as described in 
section 2.2.1) were washed once in phosphate-buffered saline (PBS; 144mM sodium 
chloride, 16mM sodium phosphate, dibasic, 4mM sodium phosphate, monobasic, pH 
7.4), then resuspended in PBS at between 5 x 10^ and 10^ cells per ml. An equal 
volume of 1% low melting point agarose (BRL) in PBS was added and lOOpl aliquots 
dispensed into prechilled moulds (LKB). The agarose blocks were allowed to set for 
more than 10 minutes then removed from the moulds and incubated in 10 volumes of 
lysis buffer (0.5M EDTA, 1% sarcosyl, 2mg/ml proteinase K [Boehringer Mannheim]) 
at 50°C for 48 hours. The blocks were rinsed twice at 50°C in TE containing 40p,g/ml 
of phenyl methyl sulfonyl fluoride and stored at 4°C in 0.5M EDTA (pH8.0).
DNA molecules were separated by the application of a contour clamped hexagonal 
electrophoretic field (CHEF), using an apparatus obtained from Dr. D. Green (MRC 
Human Cytogenetics Unit, Edinburgh). Optimum conditions for the separation of DNA 
molecules of 50-250kb in length were established in experiments with phage lambda 
concatemers. Agarose blocks containing the lysed cells were loaded into preformed 
wells and sealed in place with molten low melting point agarose. Electrophoresis was 
performed at 4.5 V/cm for 48 hours with a pulse time of 30 seconds. Samples were 
electrophoresed in 1.0% agarose gels made up in 0.5 x TBE. The running buffer (0.5 x 
TBE) was constantly recirculated and maintained at 12°C.
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4.2.5. Preparation of phage lambda concatemers.
Concatemers of phage lambda were prepared using the lysogenic bacterial strain 
N1323, containing phage lambda (strain Cj857). A single colony was inoculated into 
25mls of L-broth and incubated at 30°C overnight Twelve millilitres of the overnight 
culture was inoculated into 500mls of L-broth containing 0.01M magnesium sulphate 
and incubated at 33°C until the optical density at 600nm was 0.35 (approximately 3 
hours). Replication of phage lambda in the bacterial culture was induced by incubation 
at 43°C for 15 minutes and the culture was then incubated for a further 2.5 hours at 
39°C. The bacteria were pelleted by centrifugation at 7000rpm for 10 minutes at 4°C 
and resuspended in 8.8mls of TE. Phage particles were released by lysing the bacterial 
cells with 0.5mls chloroform and shaking the culture at 37°C for 15 minutes. 
Ribonuclease A (Boehringer Mannheim) and Deoxyribonuclease I (Boehringer 
Mannheim) were added to final concentrations of 20pg/ml and the incubation continued 
for a further 15 minutes. Bacterial debris was removed by centrifugation at lOOOOrpm 
for 15 minutes at 4°C. The supernatant was mixed with an equal volume of 1% low 
melting point agarose and poured into prechilled moulds. The phage particles were 
lysed in agarose blocks as described above. Concatemerization of the phage lambda 
genomes was encouraged by incubating the blocks at 50°C in 0.1M EDTA for 72 hours
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4,3. RESULTS.
4.3.1. Analysis of biopsy material for HHV-6 DNA.
A total of 135 cases were analysed for the presence of HHV-6  DNA sequences by 
Southern hybridization (Table IV.I). Viral sequences were detected in 2/53 patients 
with NHL. HHV-6  was not detected in 47 biopsies from patients with HD, or in 35 
biopsies from patients with other conditions. The two positive cases were patient 112, 
who had a diagnosis of AIL which had progressed to T-zone lymphoma, and patient 
287, who had a gastric lymphoma and a history of Sjdgren’s syndrome.
4.3.2. Clinical histories and molecular analysis of HHV-6-positive 
cases.
Case 112.
This patient was a 52 year old white female who first presented in 1979 with 
generalized lymphadenopathy and hepatosplenomegaly. These symptoms had been 
preceded by an influenza-like illness which had been associated with a skin rash on the 
arms and legs. At presentation the patient was profoundly anaemic, she had a normal 
WBC count with 30% abnormal leukocytes and plasma-like cells and showed Bence- 
Jones proteinuria. A lymph node biopsy showed partial effacement of the normal node 
architecture by a polymorphic infiltrate containing numerous large immunoblasts and 
an arborizing vascular network. The biopsy was not considered to indicate the presence 
of overt lymphoma. A diagnosis of AIL was made. Therapy was commenced with 
chlorambucil and prednisolone. The patient also received a blood transfusion.
Over the next few years the patient experienced repeated episodes of lymphadenopathy, 
involving different lymph node groups. She reported intermittent influenza-like 
symptoms and periods of extreme tiredness. These episodes were treated with steroids 
and several courses of more aggressive chemotherapy. The patient developed Coombs- 
positive haemolytic anaemia on three occasions and was treated with blood 
transfusions. Protein electrophoresis revealed the presence of an IgGA, band.
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Table IV.I. Samples analysed for the presence of 
HHV-6-specific sequences.
Clinical Condition Number
analysed
HHV-6 +
B cell lymphomas
Lymphocytic, plasmacytoid 6 0
Follicular
Small cell and mixed 7 0
Predominantly large cell 1 0
Diffuse
Small cleaved 4 0
Mixed cell 3 0
Large cell 6 1
Immunoblastic 3 0
Lymphoblastic 1 0
Burkitt’s 1 0
Unclassified 3 0
Hodgkin’s disease 47 0
T-cell lymphomas
Lymphocytic 1 0
T-zone and pleomorphic 9 1
Immunoblastic 4 0
Lymphoblastic 1 0
Unclassified 3 0
Nonlymphomatous
Reactive nodes 10 0
Secondary neoplasms 3 0
Primary neoplasms 4 0
Sarcoidosis 7 0
Sjogren’s  syndrome 2 0
Miscellaneous 9 0
Total 135 2
Early in 1987 her condition deteriorated. She had systemic symptoms of increased 
tiredness and sweating. W hen exam ined, she had cervical and axillary 
lymphadenopathy. A cervical lymph node biopsy revealed expansion of the paracortex 
and infiltration of the cortex by a diffuse proliferation of large clear cells. The original 
features of AIL could still be discerned. Cells in the paracortical area of the node 
reacted with T-cell antibodies (CD3, CD4 and CD8), while the cortical areas contained 
a mixture of CD3+, CD4+, CD8+, CD5+, CD7+ and CD21+ cells. A diagnosis of T- 
zone lymphoma was made.
Southern blot analysis of the cervical node biopsy showed the presence of HHV-6  DNA 
(Figure 4.3, panel a, lane B). The results obtained from the analysis of the lymphoma 
biopsy from this patient for the presence of TCRP and Ig gene rearrangements have 
been described in Chapter 3 (section 3.3.2). A clonal rearrangement of the TCRp gene 
was detected (Figure 4.3, panel b, lane B), while the IgH genes were germline.
The patient was treated with ifosfamide, dexamethasone, and vincristine, followed by 
radiotherapy, but failed to respond and died in July 1987. Disseminated lymphoma was 
reported on post-mortem examination.
Multiple tissues were obtained at autopsy and were analysed for the presence of HHV-6  
DNA by Southern hybridization. Viral DNA was detected in all tissues analysed (Figure
4.3, panel a). Duplicate filters were hybridized with the TCRp gene probe (Figure 4.3, 
panel b). The intensity of the rearranged band detected in EcoRI digested DNA using 
the Cp probe permits the extent of tumour infiltration of the tissue to be assessed. In the 
three lymph node samples an intense rearranged band is observed at approximately 
8.5kb (Figure 4.3, panel b, lanes B-D) indicating substantial replacement of the lymph 
nodes by lymphoma. A faint band at the same position can be observed in samples from 
spleen and parotid salivary gland (Figure 4.3, panel b, lanes F and I), suggesting that 
small numbers of tumour cells have infiltrated these tissues. The rearranged EcoRI 
fragment is a similar size to that of a frequently detected partial digestion product. 
However the 8.5kb fragments detected in these samples were considered to represent 
TCRp gene rearrangements, as similar results were obtained from the analysis of 
BamHI-digested DNA.
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Figure 4.3. DNA samples were digested with the restriction 
enzyme EcoRI. DNA was extracted from placenta, as a negative 
control (lane A) and from a cervical lymph node biopsy (lane B) 
obtained from patient 112. The other DNA samples were 
extracted from tissues obtained at autopsy and included hilar 
lymph node (lane C), retroperitoneal lymph node (lane D), liver 
(lane E), spleen (lane F), bone marrow (lane G), kidney (lane H), 
parotid salivary gland (lane I) and brain (lane J). Duplicate filters 
were hybridized with the HHV-6 probe, pZVH14 (panel a) or the 
TCRI3 gene probe, CI3 (panel b).
Figure 4.3. Southern blot analysis of multiple tissues
from patient 112.
A B C D E F G H I  J
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The amounts of DNA present in different lanes on the filter were assessed using the 
intensity of the 4kb band observed in EcoRI digested DNA hybridized to the Cp probe, 
as this fragment is not altered by TCRP gene rearrangement. The intensity of this band 
is similar across all lanes of the filter, thus the amount of viral DNA detected in the 
samples is not dependent on the extent of tumour infiltration, but appears to be 
equivalent in all the tissues examined.
Lymph node biopsies from 4 additional patients with AIL-like lymphomas were 
examined, all were negative for HHV-6 DNA sequences.
Case 287.
This patient, a 77 year-old white female, had a longstanding history of Sjdgren’s 
syndrome and Raynaud’s phenomenon. She also had seropositive rheumatoid arthritis, 
fulfilling the American Rheumatoid Association criteria, from the age of 35 years. 
Biopsies obtained from the left and right parotid glands in 1963 and 1965 respectively, 
revealed histological features consistent with Sjogren’s syndrome. Her recent clinical 
history included the onset of acute right parotitis in 1980, followed by intermittent 
swelling of the left parotid gland. Over this period she had progressively worsening 
pulmonary interstitial fibrosis. She had received numerous courses of steroidal and non­
steroidal anti-inflammatory agents.
In August 1987 she presented with progressive weight loss, decreasing appetite and 
lymphadenopathy. A prepyloric ulcer close to the lesser curvature was detected on 
endoscopy and biopsied. Histological and immunophenotypic examination resulted in a 
diagnosis of diffuse large cell NHL with a B-cell phenotype. The patient received 
therapy with chlorambucil and prednisolone.
Repeat gastric biopsies were obtained in December 1987, but revealed no evidence of 
tumour infiltration though inflammatory cells were present. DNA extracted from these 
samples was positive for HHV-6  sequences (Figure 4.4, panel a). IgH gene 
rearrangement was not detected in EcoRI digested DNA from this sample, though there 
was insufficient DNA for analysis with additional restriction enzymes.
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A lymph node biopsy was obtained in May 1988. Analysis of DNA extracted from this 
sample showed the presence of HHV-6  sequences (Figure 4.4, panel b). A clonal 
rearrangement of the IgH gene was also detected in EcoRI digested DNA from this 
sample (Figure 4.4, panel e). This result shows that the initial biopsy analysed was 
predominantly non-tumour tissue, as indicated by histology, as insufficient numbers of 
tumour cells were present for the detection of the IgH gene rearrangement
Biopsies from two additional patients with Sjogrens syndrome were included in this 
study, neither of these patients had lymphomas. HHV-6  DNA sequences were not 
detected in these samples and IgH and TCRp genes were germline in both cases.
4.33. Characterization of HHV-6 genomes.
The pZVH14 homologous sequences in cases 112,287 and in the A72 and 1102 
isolates of HHV-6  were compared with the pZVH14 clone itself, using multiple 
restriction enzyme digestions.
Hybridization of the pZVH14 probe to sequences present in J JHAN cells infected with 
the A72 and 1102 isolates of HHV-6  and to viral sequences present in cases 112 and 
287 was detected using stringent conditions. The data indicate that there is a high level 
of homology between the prototype HHV-6q $  isolate and the A72 and 1102 isolates 
over the region spanned by the pZVH14 probe (Downing et al. 1987; Tedder et al. 
1987). The viral sequences present in cases 112 and 287 also show a high degree of 
homology to the pZVH14 clone.
Differences in the restriction enzyme cleavage pattern between the sequences present in 
case 112 and the three viral isolates were detected when DNA was cleaved with each 
enzyme (Figure 4.5). Differences between the viral sequences obtained from all four 
sources were detected with Haelll, which recognizes a four-base-pair restriction site 
(Figure 4.5, panel d). The EcoRI restriction pattern demonstrates that the three internal 
EcoRI sites and the 5* flanking site are conserved in the viral sequences present in case 
112 (Figure 4.5, panel c). Hybridization of EcoRI-digested DNA samples with the 
pZVH 3’E/H probe shows that the 3’ flanking fragment is replaced by a doublet (Figure 
4.6, panel a). Hybridization of the pZVH14 clone to HindlH-EcoRI double digested 
DNA samples demonstrates the absence of the 5* 1.8kb Hindni/EcoRI fragment and the 
5* internal 2.1kb EcoRI fragment in the 112 virus (Figure 4.6, panel b).
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Figure 4.7. Ethidium bromide stained DNA samples 
from HHV-6-infected cells and tissues following PFGE.
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(lanes A an d  N), 107 J JHAN cells (lanes B an d  M), 5 x 
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(lanes E and  L) J JHAN cells infected with th e  A72 
isolate of HHV-6,107 cells from the brain of patien t 112 
(lane F), 107 (lane G) an d  108 (lane H) cells from the  
sp leen  of patient 112 an d  5 x 107 cells from the brain of 
patient 112 (lane I). The approxim ate s izes (in kb) an d  
migration d is tan ces  of co n ca tem ers  of p h a g e  lam bda 
are  given on the  right of the  panel. The arrow ind icates 
the  location of a  band  of approxim ately 160kb which is 
se e n  in HHV-6 infected J  JHAN cells (lanes D, E, K an d
L).
Figure 4.8. Southern  blot analysis of HHV-6-infected
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These results indicate that the 112 virus lacks the 5* HindlH site present in the pZVH14 
clone and has an extra H indlll site between the 5* internal EcoRI sites. The 
pZVH3’E/H probe hybridizes to an extra fragment of approximately 5.5kb in DNA 
digested with HindHI and EcoRI, demonstrating that the extra EcoRI fragment detected 
with this probe is not a product of an EcoRI restriction site polymorphism in the 3* 
flanking sequences. The data suggest that there are sequences elsewhere in the viral 
genome that hybridize to the pZVH14 probe.
Detailed analysis of the viral genome present in case 287 was not possible due to the 
limited availability of material. Analysis of the HHV-6  DNA sequences present in the 
lymph node biopsy from patient 287 showed that the restriction fragments detected in 
BamHI and HindHI digested DNA were identical to those detected in case 112 (Figure
4.4, panels b and c). Thus the virus present in case 287 appears to lack the HindHI site 
that defines the 5* end of the pZVH14 clone and has an extra HindlH site, similar to that 
detected in the virus present in case 112. In addition one of the internal EcoRI 
fragments of the virus present in case 287 appears to be absent (Figure 4.4, panels a and 
d).
4.3.4. Analysis of the viral genome bv PFGE.
Separation of viral DNA from cellular DNA was achieved, using PFGE to analyse 
HHV-6A72  infected JURKAT (J JHAN) cells. In lanes containing lysed virus-infected 
cells a band of approximately 160kb was visualized on ethidium bromide stained gels 
(Figure 4.7). No bands were seen in this position in lanes containing uninfected cells, 
thus this band is likely to represent HHV-6  DNA. Lanes G-J of the gel illustrated in 
Figure 4.7 were Southern blotted and hybridized to the pZVH14 probe. Intense 
hybridization was seen along the length of lane J, with the most intense hybridization 
visible in the 160kb region (Figure 4.8). Hybridization of the pZVH14 probe along the 
length of this lane is likely to reflect entrapment of HHV-6  DNA in chromosomal 
DNA, which has undergone partial degradation. Evidence of DNA degradation was 
visible on the ethidium bromide stained gel, in lanes containing higher numbers of 
virus-infected cells (Figure 4.7, lanes D, E, K and L). A similar finding was reported by 
Harris and Bentley (1988), who used PFGE to separate EBV genomes from infected 
cells.
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Figure 4.9. S outhern  blot analysis of HHV-6 
DNA. purified following PFGE.
I -
x
>
N
q. a  co
8.2 —
1 .2 -*  « •
DNA sam p les  w ere from th e  pZVH14 plasm id, 
p lacen ta  (P) an d  J  JHAN cells infected with the  
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In order to confirm that the 160kb band did represent HHV-6  DNA, the ethidium 
bromide stained bands in lanes D, E, K and L were excised from the gel and the DNA 
extracted using glass beads, as described in Chapter 2 (section 2.2.4). The extracted 
DNA was digested with EcoRI, electrophoresed on a 0.8% agarose gel and Southern 
blotted as described in Chapter 2. Hybridization with the pZVH14 probe revealed the 
presence of the three internal EcoRI fragments and two flanking fragments (Figure 4.9).
A number of tissues obtained at autopsy from patient 112 were analysed by PFGE 
under the same conditions. No discrete bands were observed in ethidium bromide 
stained gels, but there was evidence of considerable DNA degradation in lane H, which 
contained 10** spleen cells (Figure 4.7). Hybridization with the pZVH14 probe showed 
a barely detectable signal at approximately 160kb in this lane (Figure 4.8).
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Figure 4.5. DNA samples were from the insert of the pZVH14 
plasmid (lane A), J JHAN cells infected with the A72 isolate of 
HHV-6 (lane B), J  JHAN cells infected with the 1102 isolate of 
HHV-6 (lane C) and the spleen of patient 112 (lane D). Samples 
were digested with the restriction enzymes Hindlll (panel a), 
BamHI (panel b), EcoRI (panel c) and Haelll (panel d). All filters 
were hybridized with the pZVH14 insert. Internal fragments of 
the pZVH14 insert are indicated with arrows and flanking 
fragments are indicated with lines, the sizes of the fragments are 
shown in kb.
Figure 4.5. Restriction enzyme analysis of HHV-6 DNA 
seq u en ces using the pZVH14 probe.
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4.4. DISCUSSION.
The involvement of HHV-6  in human lymphoid malignancies was investigated by 
analysing tumour tissues for the presence of viral DNA. HHV-6 -specific sequences 
were detected in samples from 2 of 135 cases.
4.4.1. Characterization of HHV-6 genomes.
PFGE enables large DNA molecules to be separated according to size and was therefore 
used in this study to investigate the size and state of the HHV-6  genome in infected 
cells.
The size of the viral genome.
Analysis of the cells infected with the A72 isolate of HHV-6  by PFGE indicated that 
the size of the viral genome was approximately 160kb. It is likely that this represents 
linear viral DNA. Josephs et al. (1986) had previously estimated the size of the HHV- 
6q s  genome as greater than 1 lOkb. Subsequently published estimates of the length of 
HHV-6  viral DNA, derived by summation of the lengths of restriction enzyme 
fragments (Josephs et al. 1988b; Lawrence et al. 1990) have shown good agreement 
with the result obtained by PFGE in the experiments described here.
The state of the viral genome in cells infected in vitro.
Analysis of DNA samples from CMV and HSV-infected cells by PFGE has shown that 
linear viral genomes are the predominant forms of viral DNA visible on ethidium 
bromide-stained gels (van den Berg et al. 1988). Multimeric forms of CMV genomes 
were also detected by these workers, who suggest that their presence may reflect a 
rolling-circle mechanism of viral replication. High molecular weight forms of EBV and 
of herpesvirus saimiri, thought to represent circular or concatameric forms, have also 
been detected using field inversion gel electrophoresis to analyse virus-infected cells 
(M.R. Gopal, personal communication). No multimeric forms of HHV-6  were detected
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in virus-infected cells analysed on ethidium bromide-stained gels in this study. This 
may reflect differences in the replication cycles of CMV and HHV-6  or alternatively, 
technical differences in the experimental procedures used. The results of Southern 
hybridization analysis did not permit an assessment of whether higher molecular weight 
forms of HHV-6  were present. However no evidence for the presence of circular or 
multimeric forms of HHV-6 in infected cells has been found by others (M.R. Gopal, 
personal communication).
The state of the viral genome in cells infected in vivo.
PFGE was used to analyse the state of the HHV-6  genome in tissues from patient 112. 
The results were technically unsatisfactory, but suggested that linear viral genomes 
were present in the tissue analysed. Evidence for the presence of viral episomes was not 
detected, however this could not be excluded due to technical difficulties. Evidence of 
considerable DNA degradation in the samples also suggests that the results of these 
experiments should be interpreted with caution.
The ability of herpesviruses to establish latent infections in host cells has been 
described in Chapter 1 (section 1.2). Herpesvirus genomes are maintained in circular, 
concatameric or linear forms in latently infected cells (Lindahl et al. 1976; Gardella et 
al. 1984; Rziha et al. 1986; Mellerick and Fraser 1987), however the form in which 
HHV-6  genomes are maintained has not yet been determined. Further characterization 
of HHV-6  DNA may permit an assessment of whether the state of the viral genome in 
the tumour tissues from patients 112 and 287 is indicative of latent infection or active 
replication.
Restriction enzyme polymorphisms in HHV-6 genomes.
The viruses present in patients 112 and 287 show a high level of DNA sequence 
homology to the prototype HHV-6q§ over the region defined by the pZVH14 probe. 
DNA sequences that hybridized to the HHV-6 1 1 0 2 -derived probe, p9.1 were also 
detected under stringent conditions in DNA extracted from the same samples (Jarrett et 
al. 1989). However restriction enzyme site variation relative to the HHV-6q $  was 
detected in the region covered by the pZVH14 probe. A variant pattern of Hindin sites 
was detected in the viruses present in both patients.
I l l
Previous isolates had shown restriction maps similar to the prototype isolate when 
hybridized to the pZVH14 probe (Downing et al. 1987; Tedder et al. 1987), though 
Josephs et al. (1988a) found evidence of genomic differences in HHV-6  isolates 
elsewhere in the virus. Becker etal. (1989) have subsequently reported the detection of 
a similar HindHI restriction pattern to that found in the viruses present in cases 112 and 
287 following the analysis of additional virus isolates using the pZVH14 probe. The 
variant pattern was detected in isolates made from 4 patients of diverse ethnic origin 
(Becker et al. 1989). The data indicate that the HHV-6  genome is polymorphic and 
suggest that the variant HindHI pattern detected with the pZVH14 probe in this study is 
due to a common polymorphism.
4.4.2. The association of HHV-6 with AIL and AIL-Iike lymphoma.
HHV-6  DNA sequences were detected in tissues obtained from a patient with AIL 
which had progressed to T-zone lymphoma. One of the original HHV-6  isolates was 
made from the cultured PBMCs of a patient with AIL (Salahuddin etal. 1986). Thus 
AIL has been previously associated with HHV-6  infection.
An additional 4 AIL-like lymphomas analysed in this study were negative for HHV-6  
DNA sequences, while Josephs et al. (1988a) did not detected viral DNA in 7 AIL 
biopsies included in their study. These data indicate that the presence of detectable 
HHV-6  DNA sequences is not consistently associated with either AIL or AIL-like 
lymphomas.
In patient 112 the analysis of multiple tissues demonstrated that there was no correlation 
between the extent of infiltration by tumour and the amount of HHV-6  DNA present. 
These results demonstrate that the virus is not present exclusively in the tumour cells in 
this patient Unfortunately no tissue was available for in situ hybridization so it was not 
possible to determine the identity of the virus-infected cells.
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The clinical and morphological features of AIL that are suggestive of a viral aetiology 
have been described in Chapter 1 (section 1.3.2). Viral involvement in the pathogenesis 
of AIL and AIL-like lymphoma was also discussed briefly in Chapter 3 (section 3.4.6). 
The data described in this chapter do not support a direct role for HHV-6  in the 
pathogenesis of AIL or AIL-like lymphomas. The possibility that HHV-6  may be 
playing an indirect role in disease pathogenesis is discussed further in section 4.4.4.
4.4.3. The association between HHV-6 and lymphomas occurring in 
the context of Sjogren’s syndrome.
HHV-6  DNA sequences were detected in a patient with a B-cell lymphoma occuring in 
the context of Sjdgren’s syndrome. Samples from an additional 5 patients with 
Sjdgren’s syndrome, 2 of which had lymphomas, were found to be negative for HHV-6 
DNA sequences (R.F. Jarrett, unpublished data). Josephs et al. (1988a) reported the 
detection of HHV-6  DNA sequences in 3 of 82 B-cell lymphomas analysed. One of the 
HHV-6-positive B-cell lymphomas had developed in a patient with a 10 year history of 
SjOgren’s syndrome. Samples from an additional 97 patients with a variety of 
neoplastic and non-neoplastic disorders were negative for HHV-6 specific sequences. 
Six of the HHV-6-negative patients had SjOgren’s syndrome-associated lymphomas. 
Thus HHV-6  is not consistently associated with lymphomas occurring in the context of 
SjOgren’s syndrome.
However if the data from the two studies are combined, HHV-6-specific sequences 
were detected in a total of 5/218 patients with lymphoma, whereas 2/10 patients with 
SjOgren’s syndrome-associated lymphoma were positive. The increased frequency of 
detection of HHV-6  in lymphomas occurring in patients with SjOgren’s syndrome 
relative to other lymphomas is statistically significant (p<0.05 by Fisher’s exact test).
In patient 287 viral DNA was detected in a biopsy showing no molecular or histological 
evidence of tumour infiltration. Virus infection was not, therefore, restricted to tumour 
cells. Josephs etal. (1988a) analysed multiple tissues from one of their HHV-6-positive 
patients and did not find viral DNA sequences in non-tumour tissues. However in this 
patient, HHV-6  DNA was not detected in the peripheral blood, which did appear to 
contain tumour cells. Thus the analysis of multiple tissues in three HHV-6  positive 
cases has shown that the virus is not exclusively or consistently associated with the 
presence of tumour cells.
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The data do not indicate that HHV-6  is directly involved in the aetiology of lymphomas 
occurring in the context of SjOgren’s syndrome. However the possibility that the virus 
may be playing an indirect role in the pathogenesis of these lymphomas remains and is 
discussed further in the following section.
4.4.4. Does HHV-6 plav an indirect role in lvmphomagenesis?
AIL and SjOgren’s syndrome have a number of features in common. The clinical and 
pathological features of AIL have been described previously. The clinical features of 
SjOgren’s syndrome have been described by Bloch et al. (1965) and Morrow and 
Isenberg (1987). SjOgren’s syndrome is an autoimmune disorder characterized by 
xerostomia and keratoconjuncitivitis sicca and is frequently associated with other 
autoimmune diseases such as rheumatoid arthritis and systemic lupus erythrematosus. 
The disease is associated with a 44-fold increase in the incidence of lymphoma, the 
majority of which are of B-cell type (Kassan et al. 1978; Zulman etal. 1978)
Both AIL and SjOgren’s syndrome are characterized by the presence of immunological 
abnormalities, including polyclonal B-cell activation and T-cell dysfunction (Whaley 
and Buchanon 1971; Azevedo and Yunis 1985; Honda et al. 1985). In addition the 
lymphoid proliferation that occurs in both disorders shows a similar pattern of clonal 
evolution. The notion that AIL and AIL-like lymphoma represent stages in the 
evolution of a polyclonal lymphoproliferation into a monoclonal disorder has been 
discussed in Chapter 3. A similar pattern of disease progression has been described in 
SjOgren’s syndrome.
Zulman etal. (1978) reported the progression from an unrestricted to a restricted pattern 
o f IgL expression in sequential salivary gland biopsies from SjOgren’s syndrome 
patients. Schmid et al. (1982) and Isaacson and Hyjek (1987) detected restricted IgL 
expression by B-cells in salivary glands that lacked histological evidence of lymphoma; 
some of these patients subsequently developed overt lymphomas. Oligoclonal and 
monoclonal Ig gene rearrangements have also been detected in salivary glands lacking 
histological evidence of overt lymphoma (Fishleder et al. 1987; Freimark and Fox
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1987). The analysis of sequential biopsies has suggested that different clonal B-cell 
populations may emerge and predominate over time (Fishleder etal. 1987). In the latter 
study the detection of clonal B-cell populations was not invariably associated with 
clinical features of malignancy.
Thus both AIL and SjOgren’s syndrome appear to be characterized by the progression 
of polyclonal or oligoclonal lymphoproliferations to monoclonal disorders, which in 
some cases progress to overt lymphoma. It is therefore likely that the pathogenetic 
mechanisms involved in these two diseases will share common features. Indeed there 
are a number of reports describing the development of both AIL and SjOgren’s 
syndrome in the same patient (Moore et al. 1976; Bisson et al. 1978; Le Charpentier et 
al. 1978; Aizawa et al. 1979; Pierce et al. 1979; Bauer et al. 1982). It is possible that 
HHV -6  could play a role in the induction of the underlying polyclonal 
lymphopioliferation observed in AIL and SjOgren’s syndrome.
A number of indirect mechanisms by which viruses could be involved in 
lymphomagenesis were described in Chapter 1 (section 1.4.2). The possibility that 
chronic stimulation of the immune system by HHV-6  could be be involved in the 
pathogenesis of lymphomas occurring in the context of SjOgren’s syndrome and AIL 
seems worthy of further investigation.
a)Sjogren’s syndrome.
Chronic stimulation of the immune system could form the pathogenetic mechanism 
underlying both the autoimmune phenomena and the lymphomas occurring in SjOgren’s 
syndrome. The evidence indicating that HHV-6  replicates in salivary glands has been 
reviewed in section 4.1.3. The detection of HHV-6  antigen expression in the salivary 
gland epithelium of healthy adults indicates that viral replication at this site is not 
normally associated with pathological consequences. However it is conceivable that in 
certain circumstances expression of viral antigens in salivary gland could induce 
chronic stimulation of the immune system.
Alternatively chronic immune stimulation could result from aberrant antigen expression 
by virus infected salivary gland epithelial cells. Baboonian eta l. (1989) have 
suggested that altered antigen expression following virus infection of salivary gland 
could be involved in the pathogenesis of Sjogren’s syndrome. These authors found that
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adenovirus infection of human cell lines induces the relocalization of a nuclear protein, 
La, to the cell surface membrane. Antibodies to La are detected in 50-70% of cases of 
SjOgren’s syndrome (Morrow and Isenberg 1987). Baboonian et al. (1989) also found 
that EBV and CMV infection of cell lines resulted in altered distribution of the La 
antigen.
The involvement of other human herpesviruses, including HCMV and EBV in the 
pathogenesis of SjOgren’s syndrome has been previously proposed (Lemer etal. 1981; 
Shillitoe et al. 1982; Fox et al. 1986). The evidence for the involvement of HCMV is 
limited. Shillitoe etal. (1982) reported elevated antibody titres to HCMV in SjOgren’s 
syndrome patients relative to matched controls, though these results were not confirmed 
by others (Venables etal. 1985).
A more substantial body of evidence implicates EBV as a potential aetiological agent 
Lemer et al. (1981) found that the La antigen binds to EBV-encoded RNAs and suggest 
that this interaction could lead to autoimmunity. Salivary glands are known to be a site 
of replication of EBV (Venables et al. 1989). The rapid onset of SjOgren’s syndrome 
following IM has been reported (Pflugfelder et al. 1987) and in addition EBV DNA 
sequences have been detected in a lymphoma occurring in the context of SjOgren’s 
syndrome (Fox et al. 1989). It is possible that both EBV and HHV-6  may play a role in 
the pathogenesis of SjOgren’s syndrome via one of the mechanisms described above.
b)AIL
Chronic antigenic stimulation due to herpesvirus infection may be involved in the 
pathogenesis of AIL. HHV-6  DNA has been detected in lymph nodes of patients with 
lymphoproliferative disorders by in situ hybridization (Kreuger et al. 1989). In this 
study increased numbers of HHV-6  infected cells were detected in nodes showing 
histo logical features of m alignant lymphoma and "atypical polyclonal 
lymphoproliferation" than were present in "reactive" nodes. HHV-6  DNA was not 
detected in the tumour cells of lymphomatous nodes, but was present in scattered small 
lymphocytes, suggesting that any role that the virus might be playing in the 
pathogenesis of these disorders is likely to be indirect.
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AIL has also been associated with infection by EBV; the occurrence of AIL in persons 
with evidence of active EBV infection has been reported (Viielizier et al. 1978). EBV 
DNA has been detected in AIL-like lymphomas (Bomkamm et al. 1976; Richel et al. 
1990). In the study reported by Richel etal. (1990) EBV gene expression was localized 
to the tumour cells, however the clonality of the EBV genomes was not determined so 
the possibility that EBV infection had occurred subsequent to lymphoma development 
was not excluded.
4.4.5. Herpesvirus reactivation.
An alternative explanation for the detection of HHV-6 in the two patients described in 
this Chapter is that reactivation of HHV-6 is occurring due to the immune dysfunction. 
An additional speculative possibility is that HHV-6  reactivation in these cases may be 
an indicator of underlying retrovirus infection. These two possibilities are discussed 
further below.
a) Disseminated herpesvirus infection associated with immunosuppression.
It is possible that the detection of HHV-6 DNA sequences in the tissues of patients 112 
and 287 is an indication of disseminated herpesvirus infection. Herpesvirus infection is 
a frequent complication of AIL and pneumonia caused by HCMV is a common cause 
of death in AIL patients (Frizzera et al. 1975; Nathwani et al. 1978; Pangalis et al.
1983). Fatal herpesvirus infection has also been reported in Sjdgren’s syndrome 
(Asherson etal. 1987). Thus the detection of HHV-6 and EBV in lymphomas occurring 
in the context of SjOgren’s syndrome may reflect frequent herpesvirus reactivation in 
this disease.
The recent data obtained by Lawrence et al. (1990) showing that HHV-6  is closely 
related to HCMV is of interest in this context It is possible that HHV-6  will share some 
biological properties with HCMV, which is a common cause of disease in 
immunosuppressed persons (Griffiths and Grundy 1987). However, as discussed earlier, 
(section 1.2) herpesviruses that are closely related on the basis of genome organization 
and DNA sequence homology may show widely divergent biological behaviour.
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The detection of HHV-6  DNA sequences in multiple tissues obtained from both the 
virus positive-patients identified in this study is consistent with dissemination of virus 
infection due to profound immunosuppression. It should be noted, however, that HHV- 
6  was not detected in samples from a number of cases in which immune function was 
likely to be severely compromised.
b) Interaction with a retrovirus.
Most of the reported isolations of HHV-6  from the cultured PBMCs of adults have been 
made from retrovirus-infected persons (Salahuddin etal. 1986; Downing et al. 1987; 
Tedder et al. 1987; Lopez et al. 1988). This suggests that retroviruses may reactivate 
latent HHV-6  infection in vivo. Evidence that retroviruses may activate herpesvirus 
replication or expression has been reported. HTV appears to induce EBV to commence 
productive replication (Emberg 1989), while preliminary evidence that the HTLV-I tax 
protein can trans-activate an EBV promoter has been reported (Pagano etal. 1988). Tax 
expression has also been shown to activate the HCMV enhancer in cotransfection 
experiments (M. Campbell, personal communication).
The involvement of retroviruses in the aetiology of both AIL and SjOgren’s syndrome 
has been suggested (Ganesan et al. 1987; Garry et al. 1990). Sera from patients with 
AIL or Sjdgren’s syndrome have been shown to cross react with human retroviral core 
proteins (Nunley etal. 1987; Szabo et al. 1987; Talal et al. 1990b).
AIL and HIV-associated AIDS show some clinical and morphological similarities 
(Azevedo and Yunis 1985; Steinberg et al. 1988). HIV-infection and AIL are both 
characterized by hypergammagloblinaemia and T-cell dysfunction (Steinberg et al.
1988). In addition AIL-like lymphomas have been reported in persons with HIV 
infection and/or AIDS (Blumenfeld and Beckstead 1983; Lust et al. 1989).
Some clinical manifestations of HIV infection also overlap with features characteristic 
of Sjogren’s syndrome, including lymphocytic infiltration of the salivary and lachrymal 
glands, with associated dry eyes and mouth (Itescu et al. 1989). In addition transgenic 
mice expressing the tax gene of HTLV-I have been reported to show salivary gland 
lesions typical of Sjogren’s syndrome (Green et al. 1989).
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The associations between HHV-6  and AIL and Sjdgren’s syndrome described above 
could, therefore, reflect stimulation of herpesvirus replication due to an underlying 
retrovirus infection.
4.4.6. The involvement of HHV-6 in HD.
The hypothesis that HD has an infectious aetiology has been discussed in Chapter 1 
(section 1.3.2). The data are most convincing for HD occurring in younger age groups, 
and have led to the suggestion that HD in younger persons may arise as an unusual host 
response to a common transmissable agent acquired relatively late in life.
Members of the human herpesvirus family have been identified as candidate infectious 
agents. Many studies have shown an association between elevated antibody titres to 
EBV antigens and HD (Henle and Henle 1973; Hesse etal. 1977; Evans and Gutensohn
1984). A number of serological studies have reported a higher antibody prevalence to 
HHV-6  in patients with HD (Ablashi et al. 1988; Biberfeld et al. 1988). In a recent 
case-control study performed by Clark et al. (1990) higher antibody titres were found 
in HD patients compared to controls. In addition HHV-6  seroprevalence and antibody 
titres were found to be greatest in HD patients aged 15-34 years who lacked siblings.
Forty-seven cases of HD were analysed for the presence of HHV-6  genomes in this 
study, all were negative. Over 23 cases of HD occurring in persons less than 35 years 
old were included in the analysis. These data do not support a role for HHV-6  as a 
candidate transmissable agent responsible for HD in younger persons, and do not 
support a direct role for HHV-6  in the pathogenesis of HD in any age group. The 
possibility that HHV-6  infection could play an indirect role in the development of HD 
remains. An alternative explanation proposed by Clark etal. (1990) for their serological 
data is that the higher antibody prevalence and titres to HHV-6  detected in young HD 
patients lacking siblings are purely a marker of a lack of early social contact. Late 
infection with other common viruses, one or more of which may be involved in the 
aetiology of HD, is also likely to have occurred in this group.
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4.4.7. Conclusions.
HHV-6-specific sequences were detected in 2/135 samples from patients with a variety 
of lymphoproliferative disorders and non-lymphoid neoplasms. The HHV-6  positive 
samples were from a patient with AIL-like lymphoma and a patient with B-cell NHL 
occuring in the context of SjOgren*s syndrome. Both of these conditions have been 
previously associated with HHV-6 . Precise cellular localization of the viral DNA in 
these samples would be of considerable value in assessing the potential role of HHV-6 
in the aetiology of these lymphomas.
The data described here suggest that HHV-6  is present in some non-tumour cell type, 
but do not exclude the possibility that the virus is also present in the tumour cells. The 
detection of HHV-6 DNA in tumour and non-tumour tissues in both patients suggests 
that HHV-6  did not play a direct role in the pathogenesis of these lymphomas. The 
possibility remains that HHV-6 may be indirectly involved in the lymphoproliferative 
processes underlying both AIL and Sjogren’s syndrome. Alternatively the detection of 
HHV-6  DNA sequences in the biopsy material may reflect reactivation and 
dissemination of herpesvirus infection occurring as a consequence of the severe 
immunosuppression seen in these two patients. A final possibility is that HHV-6 
reactivation is occurring due to the presence of an underlying retroviral infection. The 
two latter alternatives do not exclude the possibility that HHV-6  is contributing to 
disease progression in these patients.
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CHAPTER FIVE.
IDENTIFICATION OF THE IMMUNOREACTIVE 
B-CELL EPITOPES OF THE P19 CORE PROTEIN OF HTLV-L
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5.1. INTRODUCTION.
Following the isolation of the first oncogenic human retrovirus, HTLV-I, and the 
identification of this virus as the aetiological agent of adult T-cell leukaemia/lymphoma 
(ATL), the search for aetiological associations between retroviruses and other human 
haematological malignancies has intensified. The use of molecular and serological 
approaches for searching for viruses related to known leukaemogenic viruses was 
discussed in Chapter 1 (section 1.5). A variety of techniques have been utilized and/or 
described for searching for retroviruses related to HTLV-I. These include low 
stringency DNA hybridization using probes derived from HTLV-I sequences (Manzari 
et al. 1987), amplification of viral sequences using conserved DNA sequences as 
primers in the PCR (Bangham etal. 1988) and screening serum samples using a variety 
of assays for the detection of antibodies that react with HTLV-I proteins (Ranki and 
Krohn 1987; Sanders et al. 1990; Srivastava et al. 1990).
A number of studies have reported the detection of antibodies that react with HTLV-I 
core proteins in Western blots (WB) in sera from persons who do not appear to be 
infected with HTLV-I (Koprowski etal. 1985; Ohta etal. 1986; Ranki and Krohn 1987; 
Starkebaum et al. 1987; Schupbach et al. 1988; Sanders et al. 1990; Srivastava et al. 
1990). In these studies, antibodies that cross-react with HTLV-I core proteins were 
identified in serum samples from healthy persons and persons with a variety of diseases. 
The authors of these reports have suggested that these persons may be infected with 
retroviruses related to HTLV-I.
In section 5.1.2 the evidence in favour of this suggestion and possible alternative 
explanations for the data are discussed. An experimental approach to the investigation 
of the origin and significance of cross-reactivity with HTLV-I proteins in HTLV-I 
negative sera was described in Chapter 1 (section 1.5.3). This chapter describes the 
results of experiments to identify the regions of HTLV-I core proteins that bind to 
antibodies present in cross-reactive sera. The data obtained could be used to test the 
hypothesis that persons whose sera show cross-reactivity with HTLV-I core proteins are 
infected with HTLV-I related retroviruses.
The assays that are currently available for the detection of HTLV-I antibodies are not 
sufficiently sensitive and specific to be used in isolation. The problems encountered in 
the serological diagnosis of HTLV-I infection and the requirement for more specific
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assays are discussed in the following sections. This chapter describes the results of 
preliminary experiments that may be of value in the rational design of second 
generation assays for the detection of HTLV-I-specific antibodies.
5.1.1. Serological diagnosis of HTLV-I infection.
A variety of assays have been used for the detection of antibody to HTLV-I. Many "in 
house" assays have been developed and have been used for seroepidemiological studies. 
The variation in the sensitivity and specificity of such assays causes difficulties when 
comparing and collating studies from different laboratories. Recently a number of 
diagnostic assays have become commercially available though none of these is suitable 
for use in isolation.
In areas of Japan endemic for HTLV-I infection, screening programs for the detection 
of HTLV antibodies in donated blood have been in place for some years. Initially 
immunofluorescence (IF) using HTLV-I producing cell lines was employed (Hinuma et 
al. 1981), more recently a tiered approach has been adopted (Inaba et al. 1989). 
Samples are screened with a sensitive gelatin particle agglutination (GPA) method 
which uses gelatin particles coated with virus antigens (Serodia-ATLA, Fujirebio Inc.). 
Positive sera are tested by IF, and GPA positive, IF negative sera are also tested by WB. 
The use of WB permits the identification of antibodies to specific viral proteins, as 
illustrated in Figure 5.1.
Screening of blood donations for HTLV antibody is now also performed routinely in 
the USA. The US Food and Drug administration (FDA) have recommended a tiered 
approach to testing (US Public Health Service Working Group 1988). The assays used 
differ from those employed in Japan in that ELIS As employing whole virus as the target 
antigen are used for screening. Serum samples which show reactivity greater than a 
predefined cutoff are retested in duplicate and if positive in either of the duplicates are 
defined as repeatedly reactive (RR). RR samples are then analysed using more specific 
serological tests capable of identifying antibody to specific viral proteins.
Suitable confirmatory tests include WB and radioimmunoprecipitation assays (RIPA) 
using whole disrupted virus as the target antigen. According to the confirmatory 
criteria adopted by the FDA "a specimen must demonstrate immunoreactivity to the gag 
gene product p24 and to an env gene product (gp46 and/or gp61/68) to be considered
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Figure 5.1. The proteins that react with HTLV-I 
antibody-positive sera on western blot (WB) analysis 
(central panel) are gag or env gene products, as indicated. 
P53 is the gag protein precursor and is cleaved to give the 
viral structural proteins p19, p24 and p15 (Yoshida et al. 
1985). These correspond to MA, CA and NC respectively, in 
the nomenclature of Leis et al. (1988). Antibodies to all 
these proteins are readily detected by HTLV-I WB analysis.
The env gene codes for a  46kDalton precursor (p46) which 
is glycosylated to give gp62. The glycoprotein is then 
cleaved to produce the transmembrane protein (p20E) and 
the envelope glycoprotein (gp46). The two latter proteins 
correspond to TM and SU respectively, according to the 
nomenclature of Leis et al. (1988). Antibodies to envelope 
proteins are only weakly detected on WB analysis, as 
shown (see section 5.1.1 for additional discussion).
Additional proteins on HTLV-I WB strips also react with 
HTLV-I antibody-positive sera. A protein corresponding to 
p36 has been shown to react with a p19-specific 
monoclonal antibody (Palker et al. 1985), however tan ak a  
et al. (1986) reported evidence that a  p36 was a gag protein 
precursor, containing p24 and p15. P32 has been identified 
as a  possible degradation product of p53 and reacts with 
both p24- and p19-specific monoclonal antibodies 
(Schupbach and Kalyanaraman, 1989). P28 has been 
shown to react with a  p19-specific monoclonal antibody 
(Palker et al. 1985).
Figure 5.1. Detection of HTLV-l-specific antibodies 
by w estern blot analysis.
g a g  p o l  e n v  ta x
i —  .. i i
glycosylation
"positive". Serum specimens not satisfying these criteria but having immunoreactivities 
to at least one suspected HTLV-I gene product (such as pl9 only, pl9 and p28, or pl9 
and env) are designated "indeterminate". Serum specimens with no immunoreactivity to 
any HTLV-I gene products in additional, more specific tests are designated "negative".
The tiered approach adopted in both screening programs is necessitated by the relatively 
low specificity of the screening assays and the complexity and expense of the 
confirmatory assays. The three ELIS As licensed by the FDA were estimated to provide 
a sensitivity of 97.3-100% (p=0.05) and a specificity of 99.3-99.9% (p=0.05) (US 
Public Health Service Working Group 1988). When used in populations with a low 
incidence of HTLV infection, however, tests with this degree of specificity may have a 
low positive predictive value. Large scale studies of blood donors in populations with a 
low incidence of HTLV-I associated disease have found that between 32% and 37% of 
RR samples confirm as HTLV positive using RIPA and/or WB (Fang et al. 1989; 
Hartley etal. 1990). Indeterminate results (IR) are obtained in 30%-37% of RR sera and 
negative results in 30%-32%.
Anderson et al. (1989) have assessed the relative sensitivities of WB and RIPA for the 
detection of antibody to specific viral gene products. They found WB to be more 
sensitive than RIPA for the detection of antibody to the core proteins, p24 and p i9, 
though the difference was not statistically significant for p24. RIPA was significantly 
more sensitive than WB for the detection of env-encoded proteins. Similarly results 
obtained during mass screening studies indicate that for approximately two thirds of 
RR sera RIPA is required in addition to WB to obtain a reliable result (Fang etal. 1989; 
Hartley et al.. 1990, Lee et al. 1990).
The US Public Health Service Working Group (1988) have recommended that donors 
whose sera are RR but not HTLV positive on more than one occasion should be 
deferred indefinitely and informed that they have inconclusive test results. Thus the 
lack of specificity of available screening assays has deleterious consequences in terms 
of both the loss of HTLV negative units of blood and the difficulty of counselling 
persons with inconclusive test results. Two additional problems encountered as a result 
of the testing protocols used are the interpretation of IR and the inability to distinguish 
between HTLV-I and HTLV-II infection.
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5.1.2 Indeterminate reactivities (IR).
Significant numbers of sera give IR on HTLV-I testing. The significance and origin of 
these reactivities is at present unclear. Seroepidemiological studies are difficult to 
compare as IR have been defined differently depending on the serological assays that 
have been used. Many studies have used only WB for the confirmatory analysis of RR 
sera. This has probably resulted in the classification of some HTLV positive sera as 
indeterminate. The definition of an IR that has been used throughout this text is a 
serum sample which shows reactivity to one or more of the core proteins of HTLV-I on 
WB but which does not confirm as being HTLV-I positive when analysed with one or 
more of the following confirmatory assays; RIPA, vesicular stomatitis virus (HTLV-I) 
pseudotype neutralization or competition ELISA.
There are a number of possible explanations for sera with IR.
(a) Early seroconversion or low titre antibody to HTLV.
Few incidences of seroconversion to HTLV-1 have been documented. Following HIV 
infection anti-core protein antibodies are the first to appear and may precede full 
seroconversion by several months (Ranki et al. 1987). It is possible that a similar 
sequence might follow infection by HTLV-I. Gout et al. (1990) detected an 
indeterminate pattern of reactivity by WB in serum from a woman following 
(probable) sexual transmission of HTLV-I. IgG antibody to pl9 and related proteins 
(Pr53, p36, p28, p26) appeared 10 months before antibody to p24. A more recent study 
by Chen etal. (1990a) found that 8 HTLV-I infected individuals had antibodies to both 
gag- and env- encoded proteins within 1-3 years of seroconversion. Further studies are 
required to determine whether these findings can be confirmed in more recently 
seroconverted persons.
Low viral load has been suggested as a possible explanation for IR by Kwok et al. 
(1990b), who detected HTLV-II DNA using PCR in uncultured PBMCs of a patient 
whose sera was ELISA, RIPA and IF negative but reacted with p24 on HTLV-I WB.
Other evidence suggests that early seroconversion or low viral load are likely to be 
infrequent explanations of IR. S sequential testing of sera from persons with IR failed to 
show subsequent appearance of antibody to other viral proteins (Hartley et al. 1990)
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and PCR analysis of PBMCs from the majority of persons with IR failed to detect 
HTLV-I or -II DNA (Kwok et al. 1990a; 1990b). A study of recipients of blood 
products from persons whose sera gave IR failed to show seroconversion to HTLV-I, 
providing indirect evidence that the donors were not infected with the virus (van der 
Poel e ta l  1989). HoweverInaba etal. (1989) have suggested that blood with low titre 
HTLV-I antibody may contain low viral loads and is likely to be of low infectivity.
(b) HTLV-II infection.
IR have been reported in some individuals in which HTLV-II and not HTLV-I infection 
has been identified by amplification of viral DNA using PCR (Lee etal. 1989; Kwok et 
al. 1990a). This is likely to be an infrequent explanation for IR as the majority of 
HTLV-II positive sera do show reactivity with HTLV-I gag and env proteins on WB 
and/or RIPA (Anderson etal. 1989; Lee et al. 1989).
(c) Non-specific reactivity.
Non specific reactions caused by the presence of autoantibodies, circulating immune 
complexes or high levels of Ig have been suggested as a cause of IR (Agius etal. 1988). 
However there appears to be no direct evidence to support any of these suggestions. 
Immune complex levels in serum and antibody titre to P. falciparum correlated with 
reactivity in HTLV-I and HIV ELIS As in an African population (Biggar etal. 1984;
1985). However the positive control used in the immune complex assay and sera from 
other areas endemic for malaria did not react in the ELISAs (Biggar et al. 1985). Thus 
the high levels of reactivity detected in the African sera were not considered to result 
from the presence of immune complexes or high Ig levels in the samples. The authors 
suggest that polyclonal B-cell proliferation due to P. falciparum  infection could 
enhance detection of true retrovirus positivity, or that unknown serum factors could be 
responsible for nonspecific reactions in these sera.
The non-confirmed reactivities observed using HTLV-I ELISAs in these populations 
may be unrelated to IR obtained on WB, though evidence suggests that sera reactive on 
ELISA show an high incidence of apparent reactivity with HTLV-I proteins on WB 
(Schupbach etal. 1988; Bolton et al. 1989).
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No studies appear to have specifically examined the correlation between HTLV-I IR on 
WB and serum levels of immune complexes, Ig or autoantibodies. However studies of 
patients with a variety of autoimmune diseases have failed to detect antibodies to 
HTLV proteins using HTLV-I and/or HTLV-II WB (McDougal et al. 1985; 
Starkebaum et al. 1987; Agius et al. 1988). These studies do not, therefore, support a 
link between autoantibody or immune complex levels and IR.
(d) Reactivity with non-viral proteins present on WB strips.
Cellular antigens in the viral lysates used for WB strips may react with antibodies in test 
sera, producing bands that may be confused with virus-specific bands. Henderson etal. 
(1987) have described the presence of human leukocyte antigens (HLA) in HIV viral 
lysates. HLA are also likely to copurify with HTLV virions. Based on the known sizes 
of HLA, reactions on WB may give rise to bands at 34-36kD, 30-32kD and 25kD 
(Henderson et al. 1987; Kwok etal. 1990b). Reactivity with these antigens should not 
be confused with reactivity to viral core proteins, with the possible exception of p36 
and p32. The relationship of these proteins to the other gag-encoded proteins of HTLV- 
I has been discussed in the legend to Figure 5.1. Other cell surface proteins present in 
the viral lysates could migrate with viral core proteins and react with autoantibodies in 
test sera. There is however no direct evidence to support this possibility.
(e) Cross reactivity between viral and non-viral proteins.
HTLV-I proteins may share immunogenic epitopes with non-viral proteins. Antibodies 
directed against such non-viral proteins could be responsible for IR in virus-negative 
sera.
Some monoclonal antibodies to HTLV-I pl9 cross react with tissues not infected with 
HTLV-I indicating that pl9 shares an epitope or epitopes with one or more cellular 
proteins. A monoclonal antibody (MoAb), 12/1-2, which reacts with pl9  (Robert- 
Guroff etal. 1981) has been shown to bind to a thymic epithelial cell antigen acquired 
during ontogeny and to the basal layer of tonsillar, adenoidal and oesophageal 
squamous epithelium (Haynes et al. 1983). Reactivity with fresh thymic epithelial cells
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occurred with a cell surface rim pattern. Suni et al. (1984) found that MoAb 12/1-2 
reacted with syncytiotrophoblasts from first trimester pregnancies and placental 
tumours, producing a diffuse cytoplasmic staining pattern. Immunoblots using proteins 
extracted from two choriocarcinoma cell lines identified a 28kD polypeptide as the 
target antigen.
Ralfkier et al. (1986) reported staining of the cytoplasm of basal keratinocytes of 
normal epithelia, benign dermatoses and CTCL by MoAb 12/1-2. The antibody also 
reacted in dot blots with conventionally extracted keratin proteins. The distribution of 
12/ 1-2 reactivity in epithelia was different to that of antibodies against a variety of 
keratin classes thus the authors suggest that 12/ 1-2 may be reacting with an associated 
molecule rather than directly with intermediate filaments.
Two additional monoclonal antibodies directed against HTLV-I pl9, aHTLV-2 and 
aHTLV-4 have been shown to react with non-virus-infected tissues and cell lines. 
aHTLV-2 reacted with the majority of tissues tested, including thymus, kidney tubules, 
liver, pancreas, prostate adenocarcinoma, melanoma, breast carcinoma and a variety of 
HTLV-uninfected T- and B-cell lines. aHTLV-4 reacted with kidney glomeruli, 
prostate adenocarcinoma, melanoma and breast carcinoma (Palker etal. 1985).
These results suggest that at least three p l9  epitopes may cross react with epitopes 
present on cellular antigens as the patterns of cross reactivity seen with MoAbs 12/1-2, 
aHTLV-2 and aHTLV-4 are different. In addition MoAb 12/1-2 reacts with p22 of 
HTLV-II on WB, while aHTLV-2 and aHTLV-4 do not react with HTLV-II proteins 
on WB or RIPA (Palker et al. 1985), indicating that these MoAbs are reacting with 
different epitopes on pl9.
Cross reactivity with malarial antigens has been considered a possible explanation for 
the correlation between antibody titres to P. falciparum and reactivity with HTLV 
ELISAs in African sera (Biggar et al. 1984; 1985). However this was considered an 
unlikely explanation as HTLV reactiv ity  by ELISA did not correlate with 
seroprevalence of P. falciparum in this population. Studies in Papua New Guinea where 
malaria is also endemic have not detected a relationship between reactivity in HTLV-I 
screening assays and malarial prevalence or antibody titre (Kazura etal. 1987; Babona 
and Nurse 1988; Weber et al. 1989).
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Sanders etal. (1990) found no correlation between the detection of IR using WB and 
RIPA and Plasmodium species parasitaemia in sera from persons living in Papua New 
Guinea. Reactivity with HTLV-I proteins on WB has been detected in sera from Papua 
New Guinea in a number of additional studies (Asher etal. 1988; Hardy etal. 1989; Re 
et al. 1989; Weber et al. 1989). The possibility that the results were due to cross 
reactivity between HTLV-I and P. falciparum antigens was not investigated in any of 
these studies, but in three of the reports reactivity was apparently detected to more than 
one viral core protein. Thus two immunoreactive epitopes on P. falciparum antigens 
would have to cross react with epitopes on separate HTLV-I core proteins in order to 
fully explain the recorded reactivities.
(f) Cross reactivity with endogenous viral proteins.
The human genome is known to contain a number of endogenous retrovirus-related 
sequences (HERV) many of which are defective (e.g. Steele et al. 1984; Callahan etal. 
1985; Kroger and Horak 1987; Mager and Freeman 1987; Bangham et al. 1988; Perl et 
al. 1989). Some of the families of HERVs are related on the basis of sequence 
homology to the type C oncoviruses and homology with the HTLVs has been reported 
for a small number of HERV (Mager and Freeman 1987; Perl etal. 1989). It is possible 
that antibodies directed against HERV antigens with homology to HTLV-I proteins 
could give rise to IR in HTLV-I negative sera.
Mager and Freeman (1987) described a family of HERV which have a histidine tRNA 
primer binding site (RTVL-H) and found that one member of the family (RTVL-H2) 
contained sequences with homology to the HTLV gag genes. Translating the nucleotide 
sequence of the homologous region of RTVL-H2 gave 55% homology with HTLV-I 
pl5 and 61% with the pl2 NC protein of BLV. However no evidence for expression of 
this sequence was reported and the homologous coding sequence of RTVL-H2 is 
interrupted by a termination codon.
Perl et al. (1989) identified a transcriptionally active HTLV-related endogenous 
sequence, HRES-1/1, which contained sequences with homology to the LTRs and gag 
genes of HTLV-I and -II. An open reading frame in HRES-1/1 which could encode a 
25kD protein (HRES-1/1 p25) showed regions of homology to HTLV-I pl9 and p24. 
Translation of the coding sequences identified a region of HRES-1/1 p25 with 32% 
homology to amino acids 92-122 near the C-terminus of HTLV-I pl9. A different
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region of HRES-1/1 p25 showed 25% homology with HTLV-I p24 amino acid 
sequences. Transcription of the mRNA encoding HRES-1/1 p25 was detected in 
leukaemic cell lines, in EBV-transformed human peripheral blood lymphocytes and in 
human placenta. This last observation is of particular interest in relation to the cross­
reactivity of the pl9-specific MoAb 12/1-2 with human placental tissues and 
precipitation of a 28kD protein from choriocarcinoma cell lines by the MoAb (Suni et 
al. 1984). Confirmation that the HRES-1/1 p25 protein is itself expressed and shows 
serological cross-reactivity with HTLV-I core proteins would permit further evaluation 
of the possibility that antibodies to HRES-1/1 p25 may be a cause of IR.
(g) Infection with a novel HTLV related retrovirus.
Infection with a novel retrovirus related to HTLV has been advanced as a possible 
explanation for the presence of antibodies to HTLV-I core proteins in sera from patients 
with CTCL (Ranki and Krohn 1987; Srivastava et al. 1990) multiple sclerosis 
(Koprowski etal. 1985; Ohta et al. 1986), and large granular lymphocytic leukemia 
(Starkebaum et al. 1987). The finding by Schupbach et al. (1988) that 30-40% of 
Swiss blood donor sera showed reactivity with one or more HTLV-I core proteins on 
WB casts some doubt on the significance of these reports. However the relatively high 
concentration of sera used in this study makes comparison with data from other groups 
difficult, and could have increased the possibility of non specific reactions. In the 
following sections these data are discussed in the context of any additional or 
conflicting evidence for the involvement of retroviruses in these diseases.
Cutaneous T-cell lymphoma (CTCL)
The possibility that a retrovirus related to HTLV-I might be involved in the aetiology of 
CTCL was discussed in Chapter 1 (section 1.3.4). Serological evidence supporting this 
notion has been reported by a number of groups.
Ranki and Krohn (1987) studied Finnish patients with MF and large plaque 
parapsoriasis (PPs) using HTLV-I WB. They detected reactivity with HTLV-I pl9 or 
p24 in 15/27 sera from patients with MF or PPs, 4/42 control sera from patients with 
dermatological disease and 0/33 control sera from healthy persons. The authors suggest 
that their results may indicate involvement of a retrovirus related to HTLV-I in MF.
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Srivastava et al. (1990) also considered that infection with an HTLV-I related virus 
could be responsible for the reactions with multiple HTLV-I proteins on WB observed 
in sera from 3/6 MF patients.
Lange-Wantzin et al. (1986) detected antibodies to HTLV-I by ELISA in 11.4% of 
CTCL patients from Scandinavia and west Germany. In this study a competitive ELISA 
and absorption with HTLV-I infected cells were used to confirm the positive results. 
The low titre of antibodies detected and their presence in a small proportion of patients 
was suggested to indicate infection with a related retrovirus rather than HTLV-I 
(Saxineer et al. 1985; Lange-Wantzin et al. 1986).
Additional supportive evidence for the involvement of retroviruses in CTCL has come 
from ultrastructural analyses. A number of groups have reported the detection of 
retroviral like particles in the cytoplasm of Langerhans cells and related cells of patients 
with MF, PPs and other premycotic lesions (van der Loo etal. 1979; Fullbrandt etal. 
1983; Slater et al. 1985). Saal et al. (1989) have also reported the detection of C-type 
retroviral particles in cultures of PBMCs and lymph node obtained from patients with 
CTCL. Two studies have reported the detection of reverse transcriptase activity 
associated with particles of similar density to retroviruses (van der Loo et al. 1979; 
Saal etal. 1989). However electron microscopic evidence may be difficult to interpret 
and most reports have described only intracytoplasmic particles, not typical of 
mammalian C-type retroviruses.
Manzari etal. (1987) have reported the isolation of a novel retrovirus related to HTLV- 
I, from a patient with CTCL. The virus, named HTLV-V, was isolated from cultured B- 
cells derived from the peripheral blood of a leukaemic patient with CD4+, CD25- 
CTCL. Hybridization to HTLV-I probes was detected under low stringency conditions, 
while HTLV-II and HTV probes did not hybridize. Hybridization at high stringency was 
observed using a probe derived from a virus present in a patient with T-cell leukemia. 
This virus was originally described as HTLV-Ic (Pandolfi et al. 1985). HTLV-Ic 
differed from HTLV-I in lacking an internal BamHI site, but otherwise appeared to be 
closely related by hybridization analysis and restriction enzyme mapping (Pandolfi et 
al. 1985; Manzari et al. 1984). Related sequences were detected by Manzari et al. 
(1987) in another seven patients with CD4+, CD8-, CD25- CTCL.
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A number of features differentiated these cases from typical ATL cases. They did not 
all appear to have aggressive disease, the neoplastic cells did not express CD25 and 
patient sera showed only borderline positivity in HTLV-I ELISAs and gave faint 
reactions with HTLV-I p24 on WB. However it should be noted that HTLV-I associated 
malignancies do not always run an aggressive course, as discussed in Chapter 1 (section 
1.3.4). In addition restriction enzyme site variation has been previously reported in 
HTLV-I isolates (Fukasawa etal. 1987).
This report has a number of confusing features and little additional information about 
HTLV-V has been published. At present the potential role of HTLV-V in CTCL 
remains to be established.
Multiple Sclerosis (MS)
The association between MS and an HTLV-I related retrovirus is controversial. 
Koprowski etal. (1985) reported increased levels of antibodies to HTLV-I p24 in the 
serum and CSF of MS patients, relative to patients with other neurological disease 
(OND) and healthy controls. Ohta etal. (1986) detected low titre antibodies to HTLV-I 
core proteins by WB in 11/46 sera from MS patients. Eleven sera from healthy controls 
and nine sera from patients with OND were negative. A number of groups found that 
MS sera gave negative results in assays for HTLV-I antibody (Hauser et al. 1986; 
Karpas etal. 1986; Ohta etal. 1986; Koike etal. 1988). However Ohta etal. (1986) and 
Koprowski et al. (1986) suggest that the negative results obtained with MS sera may 
reflect the low sensitivity of the assays employed in some of these studies.
Koprowski etal. (1985) detected HTLV-I-related RNA sequences in cells from the CSF 
of MS patients by in situ hybridization but these results could not be confirmed by 
Hauser et al. (1986). Recently Reddy et al. (1989) used the polymerase chain reaction 
(PCR) to amplify HTLV-I nucleotide sequences from DNA extracted from the PBMCs 
of 6  patients with MS. However the detection of a similar sequence in one of their 
control samples and the similarity between the detected sequence and the sequence of 
the virus infecting the MT-2 cell line used as a positive control raises the possibility that 
these results were due to contamination of sample material. Other groups have failed to 
confirm these results (Bangham et al. 1989; Richardson etal. 1989), thus these data 
remain controversial.
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While a number of features of MS suggest that a viral aetiology is likely, and the 
association between retroviruses and neurological disease in animals and humans 
identifies them as candidate viruses, the evidence for the involvement of a retrovirus 
related to HTLV-I in MS is conflicting and inconclusive.
Large granular lymphocytic leukemia (LGLL)
The evidence for involvement of an HTLV related retrovirus in LGLL comes from two 
reports. Starkebaum et al. (1987) detected antibodies to pl9 or p24 (and in one case 
additional proteins) of HTLV-I by WB in 6/12 sera from LGLL patients. Control sera 
from patients with Felty’s syndrome, rheumatoid arthritis, other connective tissue 
disorders and healthy individuals were negative. Pandolfi etal. (1987) analysed sera 
from 27 patients with LGLL; 4 were positive in an HTLV-I ELISA, while antibodies to 
HTLV-I core proteins were detected by WB in 7 sera. These results were not 
confirmed by Imamura et al. (1988) who obtained negative results with sera from 11 
patients with LGLL analysed by GPA, IF, ELISA and WB for antibodies to HTLV-I.
Papua New Guinea.
Infection with a retrovirus related to HTLV-I has also been suggested as an explanation 
for IR detected in sera from Papua New Guinea (PNG) (Weber et al. 1989; Sanders et 
al. 1990). Studies of sera from a number of populations in PNG have detected a 
variable incidence (0-45%) of antibodies to HTLV-I by ELISA (Kazura et al. 1987; 
Asher et al. 1988; Re et al. 1989).
Kazura etal. (1987) detected very high antibody titres (>1:900) in nearly half the sera 
titrated using a commercial ELISA. The HTLV-I specificity of the reactions obtained in 
44/47 of their positive sera was confirmed using a competitive ELISA employing 
sheep polyclonal antisera to compete out specific antibody. The specificity of this 
competitive ELISA has been questioned (Weber et al. 1989). Data indicating that 
different species produce antibodies of differing specificity when inoculated with the 
same antigens (Getzoff et al. 1988) suggest that the use of heterologous antisera in 
competition assays may not be justified. Re etal. (1989) analysed the specificity of 72
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ELISA positive sera by preadsorption with a commercial virus preparation and 
confirmed their positive results in 71 of the samples. When tested with WB these sera 
showed a variety of patterns of reactivity, from pl9 only to pl9, p24, and multiple gag 
protein precursors. Both Re et al. (1989) and Kazura et al. (1987) consider that their 
data indicate the presence of HTLV-I in the populations tested.
In support of this possibility, Yanagihara etal. (1990a) recently reported the serological 
confirmation of HTLV-I infection in 16/61 members of a PNG population. The positive 
sera contained antibodies reactive to gag encoded proteins and to a recombinant 
transmembrane protein in WB. Additional confirmation that the serological data 
indicated true HTLV-I infection was obtained following the isolation of HTLV-I from 
the peripheral blood lymphocytes of a member of the same population group, the 
Hagahai (Yanagihara et al. 1990b). In addition to the sera in which HTLV-I infection 
was confirmed, i.e. those in which antibodies to both env and gag encoded proteins 
were present, high numbers of sera with IR were detected. The authors suggest that 
these may indicate early seroconversion, or may be due to infection with an HTLV-I 
related retrovirus.
Evidence from other studies suggests that the antibodies detected in PNG sera using 
HTLV-I assays may not be to HTLV-I itself but rather to a related retrovirus. Asher et 
al. (1988) found that 24/49 of their sera showed reactivity to HTLV-I pl9, p24 and p53 
on WB and some sera reacted weakly to gp46 and gp68. However when thirty of these 
sera were tested in HTLV-I/VSV pseudotype neutralization assays none showed 
neutralization, leading the authors to suggest that these individuals might be infected 
by strains of HTLV-I with antigenically variant envelope proteins.
Weber et al. (1989) studied sera from four populations in PNG using a variety of 
assays, including GPA, competitive ELISA, an "in house" IgG antigen capture 
radioimmunoassay, IF and WB, and failed to find convincing evidence for infection 
with HTLV-I. Thirty five of three hundred and fifty seven sera were positive in a 
commercial ELISA (DuPont), but these samples were negative in a competitive ELISA 
and did not neutralize vesicular stomatitis virus (HTLV-I) pseudotypes. Three of the 
thirty five ELISA positive sera showed weak reactivity with HTLV-I core proteins on 
WB. The authors suggest their data indicate that high levels of false positive results 
may be obtained when using ELISAs to detect HTLV-I antibody in sera obtained from 
populations in PNG. They suggest that the weak reactivity with core proteins detected 
in some sera may indicate cross reactions with an HTLV-related retrovirus.
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Sanders eta l. (1990) used ELISA, WB and RIPA to analyse sera from villagers living 
in PNG. Reactivity to p l9  and/or p24 was detected using HTLV-I WB in 14/15 sera 
that had shown evidence of reactivity with HTLV-I proteins in ELISA or IFA. One 
sample reacted in addition to a recombinant transmembrane protein. Reactivity to the 
gp46 envelope protein was not detected in any sera, thus the authors suggest that 
infection by a variant strain of HTLV-I may give rise to the IR in these sera.
ATL and TSP have not been reported in PNG (Babona and Nurse, 1988). Although it is 
possible that these diseases could be under-reported this does suggest that HTLV-I is 
unlikely to be prevalent in this area at the levels suggested by Kazura et al. (1987) and 
Re et al. (1989).
5.1.3. Distinguishing between HTLV-I and HTLV-II infection.
HTLV-II shares approximately 57% DNA sequence homology with HTLV-I, while the 
structural proteins show 55-85% amino acid sequence homology (Seiki et al, 1983; 
Shimotohno et al. 1985). Sera from HTLV-II infected persons show cross reactivity 
with HTLV-I antigens and will give positive results with HTLV-1 screening assays. 
Confirmatory assays are also unable to distinguish between antibodies to the two 
viruses. HTLV-II positive sera react with HTLV-I gag proteins on WB and with 
HTLV-I gag and env encoded proteins in RIPA (Hartley etal. 1990).
For the counselling of HTLV positive persons identified during testing accurate 
identification of the specific infecting virus is important, as HTLV-II has not been 
identified as an aetiological agent of disease. Seroepidemiological studies of HTLV 
infection have also been complicated by the lack of distinction between HTLV-I and 
HTLV-H.
A number of assays able to distinguish between infection with HTLV-I and HTLV-H 
have been developed. A virus neutralization assay using vesicular stomatitis virus 
pseudotypes utilizes differences in the immune response to HTLV-I and -H proteins 
(Clapham et al. 1984), but is technically complex and therefore not suitable for 
widespread application. A variety of competition ELISAs have been developed. Tedder 
etal. (1984) used a known HTLV-1 positive human serum standard to compete out 
reactivity to disrupted whole virus, in a study which identified IVDA as a population
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with increased risk of HTLV-H infections. Saxinger et al. (1984) have described a 
similar assay which uses sheep anti-HTLV antisera, this assay has also been used by 
Lange-Wantzin etal. (1986) and Kazura et al. (1987). The problems associated with 
the use of antisera from heterologous species for confirmation of antibody specificity 
were discussed in the previous section. Robert-Guroff et al. (1986) used antigens from 
HTLV-I and HTLV-H producing cells to compete out reactivity to HTLV-I p24. The 
discrim inatory ability of this assay is questionable, as HTLV-I p24 shows 
approximately 85% homology to the equivalent protein of HTLV-II and HTLV-H 
positive sera show strong reactivity with HTLV-I p24 in Western blots (Shimotohno et 
al. 1985; Wiktor et al. 1990). A competition ELISA does offer the potential for 
widespread use, however none of these assays is at present commercially available.
Molecular analysis of the virus present in PBMCs provides an alternative to serological 
assays. HTLV-I and HTLV-II may be distinguished by Southern hybridization with 
viral probes but this is time consuming and requires relatively large numbers of virus 
infected cells. DNA amplification using PCR permits rapid analysis of large numbers of 
samples and requires only small numbers of cells. A number of groups have developed 
PCR strategies for distinguishing between HTLV-I and HTLV-H. Sequences conserved 
between the two viruses have been used as PCR primers and discriminatory probes 
selected from divergent intervening sequences (R. Jarrett, unpublished data). 
Alternatively a restriction enzyme site difference in the intervening sequence has been 
used to differentiate HTLV-I from HTLV-H (Lee etal. 1989). Kwok et al. (1988) have 
used a different approach, selecting virus specific primers and probes from sequences 
poorly conserved between the two viruses. The use of PCR to distinguish between 
HTLV-I and HTLV-H is highly specific. A number of studies using the technique have 
shown that IVDA in the USA and Italy are more likely to be infected with HTLV-H 
than HTLV-I (Ehrlich etaL  1989; Lee etal. 1989; Kwok etaL 1990a; Zella et al. 
1990), confirming the earlier observation of Tedder et al. (1984). However the 
sensitivity of PCR can result in considerable problems with false positives due to 
sample contamination and sophisticated laboratory equipment and technique are 
required.
Wiktor et al. (1990) have proposed a WB based algorithm for distinguishing between 
HTLV-I and HTLV-H antibody positive sera. Samples with pl9 reactivity of greater 
than or equal to the intensity of reactivity seen with p24 were scored as HTLV-I 
positive, while samples with p24 reactivity greater than the reactivity seen with pl9 
were scored as HTLV-H positive. This system gave 100% accuracy when tested with 57
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HTLV-I positive sera and 40 HTLV-II positive sera from persons in whom the identity 
of the infecting virus had been previously determined by PCR. A recombinant p21E 
was included with the viral lysate used in the WB strips, to increase the sensitivity with 
which antibodies to envelope proteins were detected. This technique would therefore 
appear to provide a useful approach for use at present, though its subjectivity and 
dependence on the consistency of viral preparations used in the WB may prove to limit 
its reliability. The commercially available WB kits are, in addition, relatively 
expensive.
There is therefore a need for a simple, inexpensive serological assay capable of 
distinguishing between infection with HTLV-I and HTLV-H. The problems associated 
with the detection of IR in HTLV-I negative sera, as described earlier, also emphasize 
the need for more specific assays for the diagnosis of HTLV-I infection. It is important 
for the development of more specific assays that the reasons for non-specific or 
indeterminate reactivity in HTLV-I negative sera are identified. If the indeterminate 
reactivities with HTLV-I core proteins represent cross reactivity with shared epitopes 
this will limit the specificity of assays using recombinant forms of these proteins as 
target antigens. Alternatively if the epitopes reactive with indeterminate sera are 
different to those reactive with HTLV-I positive sera, the use of incomplete 
recombinant proteins or appropriate peptides as targets could eliminate this problem.
5.1.4. Experimental aims.
Two of the major problems associated with the serological methods available for the 
diagnosis of HTLV-I infection are the interpretation of IR and the distinction between 
HTLV-I and HTLV-H infection.
IR involving pl9 reactivity on WB could be due to autoreactivity to cellular antigens as 
pl9 has been shown to share one or more antigenic epitopes with human tissues. There 
is evidence to support the hypothesis that a retrovirus related to HTLV-I may be 
responsible for some IR. This appears to be most convincing for populations identified 
in PNG though considerable differences in results have been obtained by different 
laboratories. Other possible explanations for IR include non-specific reactions with viral 
proteins, reactivity with co-migrating cellular proteins on HTLV-I WB, cross 
reactivity with antigens on other infectious agents or cross reactivity with endogenous 
retrovirus antigens.
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(I) Investigation of the origin of IR.
The main aim of this study was to investigate the origin of IR involving reactivity with 
pl9 on WB. In order to analyse the specificity of IR, HTLV-I pl9 was expressed as a 
fusion protein in bacteria and used as a target antigen in immunoblots with 
indeterminate sera.
Antibodies in indeterminate sera which are reacting with viral protein are likely to be 
directed against linear epitopes rather than discontinuous or conformational epitopes, as 
the target proteins in WB are denatured. Identification of the linear epitopes reactive 
with indeterminate sera therefore offers a method of investigating the specificity and 
origin of IR.
The epitope mapping technique developed by Gey sen et al. (1987) was used to 
determine the epitopes of HTLV-I pl9 reactive with HTLV-I positive sera and with 
indeterminate sera. Two groups of sera with IR were studied, sera from two Caucasian 
patients with dermatological disease and sera from nine individuals from PNG. Four 
monoclonal antibodies reactive with pl9 were also analysed.
(H) Identification of the linear epitopes of HTLV-I pl9 reactive with HTLV-H- 
positive sera.
The identification of epitopes on HTLV-I proteins which react with HTLV-I positive 
sera but do not cross react significantly with HTLV-II positive sera would be useful for 
the development of assays to distinguish between infection with the two viruses.
A group of five HTLV-II positive sera were analysed in order to determine the epitopes 
on HTLV-I pl9 cross reactive with HTLV-H positive sera.
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5.2. MATERIALS AND METHODS.
Some of the methods employed in the experiments described in this chapter have been 
described in Chapter 2. Methods that were not described earlier are detailed in the 
following sections. The sources of some of the materials that were used in the following 
experiments are given in Table n.I or Table V.I. The sources of materials that are not 
mentioned in the tables are described in the text
5.2.1. Origin and characterization of sera.
Monoclonal antibodies.
MoAb 12/1-2 ascites fluid was a gift from Dr. M. Robert-Guroff. MoAb 12/1-2 reacts 
with HTLV-I pl9 and precursor proteins and also cross reacts with HTLV-II p22 and a 
variety of normal and malignant human tissues, as described in section 5.1.2 (Robert- 
Guroff et al. 1981; Haynes et al. 1983; Suni et al. 1984). MoAbs 12G4,9G10, and 
13B12 were a gift from Dr. T. Palker and were all obtained as ascites fluid. MoAb 
12G4 appears to be specific for HTLV-I pl9 and has not been shown to cross react with 
human tissues (Palker et al. 1985). MoAb 12G4 was also obtained from Seralab as 
MAS 197c, the MoAb from either source is referred to as 12G4 in the following text. 
MoAb 13B12 reacts with HTLV-I pl9 and pl9 precursor proteins, but not with HTLV- 
II p22, and does not appear to cross react with human tissues (Palker et al. 1986). 
MoAb 9G10 reacts with HTLV-I pl9 but is not well characterized (Palker et al. 1986).
Polyclonal sera.
HTLV-I positive sera were obtained from a variety of sources and were characterized 
using a number of different assays. The origins of the HTLV-I positive sera used for 
epitope mapping experiments and the results obtained in HTLV-I assays are given in 
Table V.D. The origins and results of serological analysis of additional HTLV-I positive 
sera used in peptide ELISAs are given in Table V.DL For the purposes of this study all
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Table V.l. Sources of chemicals
Chemical Source
Acetic anhydride Sigma
Dichloromethane BDH
Diethanolamine buffer Biorad
Diisopropylethylamine Sigma
Dimethylformamide (DMF) Rathburn Chemicals Ltd. (RCL)
Methanol BDH
Novo Biolab wash buffer Dr. J. Fuller (Novo Biolabs Ltd.)
Piperidine RCL
P-nitro-phenol phosphate Biorad
Trifluoroaceticacid (TFA) RCL
Tween 20 BDH
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sera were confirmed as HTLV-I-positive using a competitive ELISA (J. Garson, 
personal communication). The HTLV-I-specific competitive ELISA was a modification 
of the ELISA described by Tedder et al. (1984).
Indeterminate sera from two Caucasian patients were identified during the screening of 
patients with dermatological disease for antibodies to HTLV-I.
Patient 215 was initially a member of a control group, but subsequent questions 
revealed that he had chronic acne. The serum from this patient was negative on HTLV-I 
ELISA (DuPont U.K. Ltd.) according to the manufacturers cutoff value, but the O.D. 
readings obtained in duplicate assays were high relative to those obtained with other 
HTLV-I negative sera. When tested in HTLV-I WB reactivity to p l9  was detected 
(Figure 5.2).
The second patient (487) had SS with typical skin lesions. Serum from this patient was 
negative on HTLV-I ELISA according to the manufacturers recommended cutoff but 
the O.D. reading was high relative to that obtained with other HTLV-I negative sera. 
This sample showed reactivity with pl9, p26 and p28 on HTLV-I WB (Figure 5.2).
Nine indeterminate sera from PNG were obtained from Professor J. Weber. The results 
obtained in WB analyses of these sera are shown in Table V.IV. The sera were negative 
for HTLV-I-specific antibodies in "in house" IgG antigen capture radioimmunoassays 
and competitive radioimmunoassays performed at the Central Public Health Laboratory 
(J. Tosswill, personal communication). The results obtained from the analysis of these 
sera in an HTLV-I-specific competitive ELISA are shown in Table V.IV (J. Garson, 
personal communication). Eight serum samples gave borderline results, one sample 
(number 42) was weakly positive.
HTLV-II positive sera were obtained from Dr. R. Tedder. Three sera were of American 
origin and were identified during the screening of blood donations. Serum sample 854 
was obtained from an Italian IVDA and serum sample 806 was obtained from a U.K. 
IVDA. All five sera were confirmed as HTLV-II positive and HTLV-I negative using 
the PCR (J. Garson, personal communication). Three sera, 806, 877 and 878, showed 
strong reactivity with HTLV-I pl9 on WB (DuPont); two sera, 854 and 876 reacted 
weakly to pl9 (J. Garson, personal communication, Figure 5.3).
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Figure 5.2. Reactivity of serum  sam p les  
215 and  487 in HTLV-I WB.
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(+ ), HTLV-I antibody-positive control serum . 
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Figure 5.3. Reactivity of HTLV-II antibody-positive 
serum samples in HTLV-I WB.
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The nomenclature of HTLV-I proteins has been 
described in the legend to Figure 5.1. (-), HTLV-I 
negative control serum; (+), HTLV-I positive control 
serum. WB analyses were performed by P. Tuke.
Control sera used in the epitope mapping experiments were obtained from a patient 
with mycosis fungoides (serum 400) and from healthy individuals (samples 1 and 2). 
All sera were screened by HTLV-I WB and showed no reactivity with viral proteins. 
Control sera used in other experiments were negative on HTLV-I ELISA (DuPont) and 
were obtained from healthy individuals (4 sera) and patients with autoimmune disorders 
(4 sera), haematological malignancies (31 sera) or idiopathic thrombocytopaenic 
purpura (3 sera).
5.2.2. PGEX-3X vector
The pGEX-3X vector for the expression of recombinant p l9  in bacterial cells was 
obtained from Amrad Corporation Limited and was first described by Smith and 
Johnson (1988). The vector is constructed to permit the expression of foreign 
polypeptides as fusion proteins with a 26-kDa glutathione-S-transferase (GST) 
originating from Schistosoma japonicum. The expressed fusion protein can be purified 
under non-denaturing conditions by affinity chromatography with glutathione linked to 
agarose beads. The structure of pGEX-3X is shown in Figure 5.4. The DNA sequence 
encoding the foreign polypeptide may be cloned into BamHI, Smal or EcoRI restriction 
enzyme sites. The 3’ vector sequences contain translation termination codons in all 
three reading frames. Fusion protein expression is under the control of the tac promoter, 
and is therefore inducible with IPTG (de Boer et al. 1983). PGEX-3X also contains 
coding sequences for a recognition site for the protease, factor Xa, in a 5’ position 
relative to the cloning site. Thus the foreign polypeptide may be cleaved from GST 
using factor Xa following expression of the fusion protein.
5.2.3. Cloning and sequencing of p!9.
The pl9 coding sequences of an HTLV-1 provirus integrated as a single copy in the 
leukaemic cells of a patient with ATL (patient 374) were cloned into the pGEM-7Zf(+) 
vector (Promega Corporation). The PCR was used to specifically amplify pl9 coding 
sequences, while incorporating restriction enzyme sites for cloning at 5’ and 3* ends.
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The PCR was performed as described in Chapter 2, section 2.3.4. The primers used for 
the amplification, P-19/5’ and P-19/3’ are shown in Figure 5.5. The amplified product 
was purified by PAGE as described in Chapter 2, sections 2.2.5-2.2.6, digested with 
BamHI and separated from the small terminal fragments by PAGE. The pl9 fragment 
was then ligated into the BamHI site of pGEM-7Zf(+) as illustrated in Figure 5.6. The 
products of ligation reactions were transformed into E. coli, strain DH5a, and 
recombinant plasmids were selected by a-complementation, as described in section 
2.5.3.
Plasmid pG7Zfl9.5, which contained the pl9  coding sequences in the orientation 
illustrated in Figure 5.6, was selected for nucleotide sequence analysis. The sequencing 
strategy is illustrated in Figure 5.7. The pl9 insert was sequenced on both strands using 
T7 and SP6  primers (Promega Corporation) to prime DNA synthesis from flanking 
plasmid sequences. Two primers, PI and P2, derived from sequences within the insert 
were obtained from an "in house" oligonucleotide synthesis facility and used to 
complete the nucleotide sequencing as shown in Figure 5.7.
Primer PI was a 17-mer oligonucleotide, ACTACTCCCTCCTAGCC, corresponding to 
the upper strand nucleotides 1014-1030 of lambda-ATK-1 (Seiki etal. 1983). Primer P2 
was a 17-mer oligonucleotide, ATTTCATTCACCCGGCC, corresponding to the lower 
strand nucleotides 1071-1055 of lambda-ATK-1 (Seiki et al. 1983). One hundred 
nanograms of each of the primers were included in the appropriate sequencing 
reactions. This quantity was calculated to give a molar ratio of primer to template of 
10:1.
Expression of rpl9.
HTLV-1 pl9 was expressed in E.Coli as a fusion protein with GST using the pGEX-3X 
expression vector (Smith and Johnson 1988). The pG7Zf 19.5 plasmid (Figure 5.6) was 
digested with BamHI and EcoRI and the p l9  insert subcloned into the BamHI and 
EcoRI sites of pGEX-3X to create the plasmid pGEX-3X19. E. Coli strains JM105, 
JM109 and HB101 were transformed with the recombinant plasmid and the relative 
efficiencies of expression of rpl9 in each strain assessed.
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Overnight cultures of E. coli transformed with pGEX-3X or the recombinant plasmid 
pGEX-3X19 were diluted 1:100 in lOOmls of LB-medium (E. coli strain HB101) or 
minimal medium (E. coli strains JM105 and JM109) containing lOOjig/ml of ampicillin 
and grown at 37°C to an OD^QQnm of 0.5. Expression of the recombinant or non- 
recombinant protein was induced by the addition of IPTG to a final concentration of 
0.5mM and the cultures were incubated at 37°C with shaking. The optimal induction 
time for fusion protein expression following the addition of IPTG was determined in 
time course experiments, using induction times of 0, 30, 60,90,120,150 and 180 
minutes. Optimal expression was obtained 120 minutes after the commencement of 
induction.
5.2.4. Preparation of cell extracts.
Small scale preparations of cell extracts were made using 2mls of the induced bacterial 
cultures. Cells were pelleted at 13000ipm for 1 minute, washed in filtered water and 
lysed in 200|il of SDS-PAGE sample buffer (Table V.V) by vigorous pipetting. Cell 
debris was removed by centrifugation at 13000rpm for 5 minutes and 20pl of the 
supernatant analysed for the presence of fusion protein by SDS-PAGE.
Large scale preparations of cell extracts were used for the purification of rpl9 and were 
performed by Shauna Crae as follows. Bacterial cells containing the recombinant 
plasmid were cultured in 500mls of LB-medium. Following centrifugation at 7000rpm 
for 10 minutes at 4°C, the bacteria were washed in 50mls of TNE then resuspended in 
lOmls of TNE. The bacteria were lysed using Triton X-100 and lysozyme and bacterial 
debris removed by centrifugation.
The supernatant was mixed with 2mls of 50% glutathione-agarose beads (sulphur 
linkage, Sigma) in mouse-tonicity phosphate buffered saline (MTPBS, Table V.VI). 
Glutathione-agarose beads were preswollen in MTPBS, washed twice and stored as a 
50% solution in MTPBS. The fusion protein was adsorbed onto the beads by mixing 
gently for 10 minutes. The beads were pelleted by centrifugation at 1000 ipm for 3 
minutes, and washed three times in MTPBS. The fusion protein was eluted from the 
beads by competition with reduced glutathione as follows. Two millilitres of freshly
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Table V.V. Buffers and solutions used for SDS-PAGE.
Coomassle blue staining solution.
Coomassieblue 
methanol 
glacial acetic acid
Destaining solution
methanol 
glacial acetic acid
SDS-PAGE running buffer
glycine 
Tris pH8.8 
SDS
SDS-PAGE running gel
acrylamide
methylene-bis-acrylamide
Tris pH8.8
SDS
ammonium persulphate 
TEMED
SDS-PAGE sample buffer
SDS
beta-mercaptoethanol 
Tris pH6.8 
glycerol
bromophenol blue 
SDS-PAGE stacking gel
acrylamide
methylene-bis-acrylamide
Tris HCL pH6.8
SDS
ammonium persulphate 
TEMED
0.05%
30%
10%
30%
10%
192mM
25mM
0.1%
10%
0.33%
0.56M
0.1%
0.025%
0.07%
2.5%
2.5%
100mM
10%
0.01%
5%
0.17%
0.12M
0.1%
0.075%
0.07%
Table V.VI. Buffers used in Immunoassays.
Blocking buffer
sodium phosphate, monobasic 9mM
sodium phosphate, dibasic 2.75mM
sodium chloride 145mM
adjusted to pH8.0 with phosphoric acid 
Tween 20 0.1%
ovalbumin 1%
bovine serum albumin 1 %
sodium azide 0.05%
Carbonate buffer
sodium hydrogen carbonate 10mM
EGTA 1 mM
adjusted to pH9.5 with sodium hydroxide
Disruption buffer
sodium phosphate, monobasic 0.1M
2-mercaptoethanol 0.1%
SDS 1%
adjusted to pH7.2 with sodium hydroxide
Mouse tonicity phosphate buffered saline (MTPBS)
sodium chloride 150mM
sodium phosphate, dibasic 16mM
sodium phosphate, monobasic 4mM
adjusted to pH7.3 with sodium hydroxide
Phosphate buffered saline (PBS)
sodium phosphate, dibasic 9mM
sodium phosphate, monobasic 2.75mM
sodium chloride 145mM
adjusted to pH7.2 with phosphoric acid
Substrate buffer
sodium phosphate, dibasic 0.1M
citric acid 0.08M
adjusted to pH4.0 with phosphoric acid
Table V.VI Buffers used in Immunoassays (continued).
Tris-buffered saline (TBS)
sodium chloride 144mM
TrispH7.4 25mM
Tris-Marvel-Tween 20 (TMT)
sodium chloride 144mM
TrispH7.4 5mM
dried milk (Marvel) 2%
Tween 20 0.5%
WB buffer
glycine 192mM
TrispH8.8 25mM
SDS 0.1%
methanol 20%
prepared reduced glutathione (Sigma) in 50mM Tris HC1 (pH 8.0) was added to the 
beads and mixed gently for 10 minutes. The beads were pelleted, the supernatant 
removed and a second elution performed. The eluates were combined and the 
concentration of protein determined by S. Crae using a kit manufactured by Biorad.
SDS-PAGE.
SDS-PAGE was used as described by Laemmli (1970) in order to fractionate bacterial 
cell extracts. Gels were run on a vertical gel set (Gibco-BRL) in SDS-PAGE running 
buffer using 10% acrylamide in the running gel and 5% in the stacking gel (Table V.V). 
The running gel was poured, leaving a 4cm space above, and allowed to polymerise for 
30 minutes under lOOpl of H2O saturated butan-2-ol. The butan-2-ol was rinsed away 
with dH2 0 , the stacking gel poured and allowed to polymerise for 30 minutes with the 
well-forming comb in place. Samples were boiled in SDS-PAGE sample buffer for 3 
minutes, loaded onto the gel and electrophoresed at a constant voltage of 200V for 3-4 
hours at room temperature. Protein bands were visualized by gentle agitation in 
Coomassie blue staining solution for 2 hours followed by destaining solution for 4 x 45 
minutes (Table V.V).
5.2.5. WB analysis of serum reactivity with rp!9.
(a) Preparation of WB strips.
Reactivity of rpl9 with HTLV-1 positive and indeterminate sera was evaluated by WB 
analysis. Purified GST or GST fusion proteins were loaded on SDS-PAGE gels at 
2.55|ig per well and electrophoresed as described above.
After electrophoresis gels were transferred to WB buffer (Table V.VI) for 10 minutes. 
Nitrocellulose membranes were cut to size and presoaked in WB buffer. Gels were 
placed onto the nitrocellulose membrane and inserted between sheets o f 3MM 
Whatman paper, which were presoaked for 10 minutes in WB buffer. The gel sandwich 
was placed between scotchbrite pads and clamped between the plates of a vertical 
electroblotting apparatus (Biorad). Protein transfer was effected by applying a constant 
voltage of 20V across the plates for 16 hours at 4°C.
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The nitrocellulose membrane was removed after protein transfer, agitated gently in 
200mls of tris-buffered saline (TBS, Table V.VI) containing 2% marvel for 3-4 hours, 
then washed for 2 hours in TBS containing 0.05% Tween 20. The membrane was dried 
at room temperature and stored until use at -20°C.
(b) Detection of antibody to rpl9.
WB analyses of sera for the detection of antibodies reactive with GST or the GST-ipl9 
fusion protein were performed by Shauna Crae, using WB strips prepared as described 
above. Sera were analysed at a 1:25 dilution.
5.2.6.Solid phase synthesis of octapeptides.
The materials and reagents used for the solid phase synthesis of multiple peptides were 
obtained from Cambridge Research Biochemicals. These included:
Chemically modified polyethylene pins embedded in polypropylene 
blocks in a 12 x 8 microtitre plate format.
Polypropylene trays with wells arranged in a 12 x 8 microtitre plate 
format
Side chain protected fluorenylmethoxycarbonyl- (Fmoc-) L-amino acid 
active esters.
1-hydroxybenzotriazole (HOBt).
Monoclonal antibody specific for an epitope on sperm-whale myoglobin 
(MoAbMyo).
Computer software (copyright, Commonwealth Serum Laboratories Commission, 
Parkville, Australia) obtained from Cambridge Research Biochemicals was used for the 
construction of peptide synthesis schedules and for the analysis of data.
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The published sequence of the lambda-ATK-1 clone of HTLV-I (Seiki etal. 1983) was 
used to derive the amino acid sequence of the p l9  core protein. One hundred and 
twenty two overlapping octapeptides based on this sequence were synthesized in 
duplicate. The 5* methionine of pl9 was numbered as amino acid 1, in order to conform 
to the numbering sequences used in previously published reports. However this residue 
is removed from the protein when myristylation occurs (Ootsuyama et al. 1985) and so 
was not included in an octapeptide. The first octapeptide to be synthesized was 
therefore numbered 2. The peptides were synthesized in situ on chemically modified 
polyethylene pins arranged in a microtitre plate format using a modification of the 
method described by Geysen et al. (1987), as recommended by the manufacturer. The 
synthesis uses mild base deprotection of Fmoc-L amino acids prior to amino acid 
coupling, in contrast to the strongly acidic conditions needed for deprotection of the t- 
butoxycarbonyl- (Boc-) amino acids used by Geysen etal. (1987).
F-moc depiotection of the Fmoc-P-alanine group pre-attached to the polyethylene pins 
was effected by immersing the pins up to half their height in a bath of 2 0 % 
(volume/volume) piperidine in dimethylformamide (DMF) for 30 minutes at room 
temperature. The pins were removed and washed in DMF (5 minutes) then methanol (4 
x 2 minutes), air dried for 10 minutes and washed in DMF (5 minutes). Fresh solvent 
was used for each wash.
Octapeptides were synthesized by the sequential coupling of preformed active ester 
derivatives of side chain protected amino acids onto the alanine residues. Synthesis 
commenced with the most C-terminal amino acid of each octapeptide.
Fmoc-amino acid active esters were dissolved to form 3M solutions in an equimolar 
solution of HOBt in DMF immediately prior to dispensing. One hundred microlitre 
aliquots of the amino acid solutions were dispensed into the wells of polypropylene 
trays, the deprotected pins inserted into the wells and the blocks of pins and trays sealed 
in plastic bags to reduce evaporative losses. The coupling reactions were allowed to 
proceed overnight and then the pins were washed in DMF (2 minutes), methanol (4 x 2 
minutes) and finally in DMF (2 minutes).
Cleavage of the Fmoc protecting group from the added amino acid was effected using 
the deprotection protocol described above. Coupling, washing and deprotection steps 
were repeated until synthesis of the octapeptides was completed. The final amino acid 
was acetylated after deprotection and washing as follows. The pins were inserted into
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wells containing DMF/acetic anhydride/triethylamine 5:2:1 (volume/volume/volume), 
the blocks and trays sealed in plastic bags and incubated at room temperature for 90 
minutes. Pins were then washed in DMF (2 minutes), methanol (4x2  minutes) and air 
dried for 10 minutes.
Side chain protecting groups were removed by incubating the pins with a mixture of 
TFA/phenol/ethanedithiol 95/2.5/2.5 (volume/weight/volume) at room temperature for 
4 hours. The pins were washed in dichlorom ethane ( 2 x 2  m inutes), 5% 
diisopropylethylamine in dichloromethane ( 2 x 5  minutes), dichloromethane (5 
minutes), air dried for 10 minutes, washed in H2O (2 minutes) and finally washed in 
methanol for 18 hours. The blocks of pins were dried under vacuum over silica gel 
overnight and then stored at room temperature in polythene boxes containing silica gel, 
in sealed plastic bags.
Control tetrapeptides were synthesized simultaneously to check the efficacy of 
synthesis. Two tetrapeptides were synthesized in duplicate on each polypropylene 
block. One of the peptides, with the amino acid sequence proline-leucine-alanine- 
glutamine is known to react with MoAbMyo. The other peptide, for which the amino 
acid sequence is glycine-leucine-alanine-glutamine, does not react with MoAbMyo. 
Reactivity of these peptides with MoAbMyo was assayed for each block of peptide- 
linked pins, when each set of peptides was first analysed and on a number of subsequent 
occasions.
5.2.7 Analysis of serum reactivity with octapeptides.
Sera were tested for reactivity with the peptides using an ELISA. Before use the pins 
were immersed in disruption buffer (Table V.VI) preheated to 60°C, and sonicated at 
35kHz (2 x 600 Watts per cycle) in a Transonic ultrasonic water bath (T780/H, Camlab) 
for 20  minutes. ~
Horse radish peroxidase (HRPO) ELISA.
Initially sera were analysed using the method recommended by Cambridge Research 
Biochemicals. All incubations and washes were performed with agitation. Non specific 
reactivity was blocked by incubating the peptide-coated pins and microtitre plates
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(Dynatech) in 200|il of blocking buffer (Table V.VI) containing 0.05% sodium azide 
for 2 hours at room temperature. The peptide-coated pins were then immersed in 175pl 
of sera diluted in blocking buffer containing 0.05% sodium azide and incubated 
overnight at 4°C. Unbound antibody was removed by washing (4 x 10 minutes) in 
phosphate buffered saline (PBS, Table V.VI) containing 0.05% Tween 20 (PBST) at 
room temperature. The peptide coated pins were then incubated with 175jil of a 1/1000 
dilution of HRPO-conjugated goat anti-murine IgG (Sigma) or HRPO-conjugated goat 
anti-human IgG (Sigma) in blocking buffer at room temperature for 1 hour. Unbound 
conjugated antibody was removed by washing (4 x 10 minutes) in PBST at room 
temperature. Bound conjugate was detected by immersing the pins in 150}il per well of 
substrate buffer (Table V.VI) containing 0 .5mg/ml 2,2’-azinobis(3-ethylbenzthiazoline- 
sulfonic acid) (ABTS, Sigma) and 0.3|il/ml of hydrogen peroxide. The substrate 
incubation was continued for 30 minutes at room temperature in the dark. Colour 
development was stopped by removing the pins and the absorbances read at 405nm in a 
Titertek plate reader (Flow Laboratories).
Before reusing the pins, the antibody-peptide interactions were disrupted using 
ultrasonication in disruption buffer as described above.
Amplified ELISA.
To increase the sensitivity of the assay an ELISA using alkaline phosphatase as the 
conjugated enzyme and a subsequent amplification step (AMPAK, IQ [Bio] Ltd.) was 
used (Figure 5.8). All polyclonal sera and MoAb 12/1-2 were assayed using the 
amplified ELISA.
The method was essentially similar to that described above for the HRPO ELISA, with 
the following alterations. One hundred and fifty microlitres of Tris-Marvel-Tween 20 
with 20% goat serum (TMT/GS, Table V.VI) were used for blocking nonspecific 
reactivity with the peptides. Serum samples and alkaline phosphatase-conjugated 
antibodies were diluted into a final volume of 125pi of TMT/GS. Novo Biolabs wash 
buffer was used in all washing steps. The secondary antibody conjugates used were 
alkaline phosphotase-conjugated goat anti-human IgG, gamma-heavy chain-specific 
(Seralab), used at a 1/1000 dilution and goat anti-murine IgG (Biorad), used at a 1/4000 
dilution. After removal of unbound enzyme-conjugated antibody by washing, the pins 
were incubated in lOOjil of AMPAK substrate solution for 10-30 minutes. The pins
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were removed and an equal volume of AMPAK amplifier solution was added and 
incubation continued for 10-30 minutes until colour development was optimal. The 
reactions were stopped by the addition of 0.3M sulphuric acid and the absorbances were 
measured at 495nm.
For polyclonal sera reactivity with an octapeptide was considered significant if the 
absorbance on each set of pins exceeded the mean plus three standard deviations of the 
lowest 90% of values. All sera were assayed on duplicate sets of pins. Some sera were 
analysed on multiple occasions at varying dilutions. Results for these sera are given for 
assays performed using the lowest dilution tested. If tested at this dilution on multiple 
occasions, only the octapeptides giving significant reactivities on each occasion were 
considered to be positive.
Comparison between HRPO and amplified ELISAs.
The sensitivity of the HRPO and amplified ELISAs was compared using the control 
tetrapeptides derived from sperm whale myoglobin that were synthesized as a control 
for the efficiency of synthesis (see section 5.2.6). Dilutions of MoAbMyo were assayed 
for reactivity with the tetrapeptides using the HRPO and the amplified ELISAs as 
described above. For the amplified ELISA, a substrate incubation time of 1 hour and an 
amplification time of 10 minutes were used.
MoAb 12/1-2 and four HTLV-I positive sera were assayed with both the HRPO ELISA 
and the amplified ELISA.
5.2.8. Confirmatory ELISAs.
Fifteen or twenty two amino acid long peptides were selected for additional 
experiments on the basis of results obtained in the PEPSCAN ELISAs. The amino acid 
sequences of these peptides are shown in Table V.VII. Peptides are numbered according 
to the positions of the amino-terminal and carboxy-terminal amino acids in the protein 
sequence of pl9. Approximately 0.1 mmole of a 22 amino acid long C-terminal peptide, 
P109-130, was obtained from Alta Bioscience (Birmingham University). P109-130 was 
synthesized using Fmoc chemistry and the amino acid composition analysed to confirm
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the accuracy of the synthesis. Fifteen peptides, fifteen amino acids in length, were also 
obtained from Alto Bioscience. These peptides were synthesized in approximately 5mg 
quantities using a BT7400 peptide synthesizer (Biotech Instruments).
Nine peptides derived from HTLV-I pl9 were chosen to overlap octapeptides reactive 
in the PEPS CAN ELISA. Four peptides were derived from homologous sequences in 
HTLV-II p22. Two peptides, overlapping in sequence by 10 amino acids, were derived 
from the translation of the nucleotide sequence of an HERV with homology to the C- 
terminus of HTLV-I pl9 (Perl et al. 1989).
Serum reactivity with 15 and 22 amino acid long peptides was detected using an 
ELISA. Optimal conditions for performing the assays were established following 
comparisons between Immulon I, Immulon H, Immulon IV and microtitre plates 
(Dynatech). Time course experiments using P109-130 were used to select the serum 
incubation time required to maximise binding to the peptide (90-120 minutes).
All incubations were performed with agitation. Microtitre plate (Dynatech) wells were 
coated with 100|il of peptide in carbonate buffer (Table V.VI) for 16 hours at room 
temperature. Peptide 109-130 was used at lng/jxl, all other peptides were used at 
lOng/pl. After washing the wells three times in Tris-buffered saline (TBS, Table V.VI) 
containing ImM magnesium chloride and 0.1% Tween 20 (TBST), nonspecific binding 
was blocked by incubation with 200|fi of TBST with 2% Marvel and 20% goat serum 
(TBMT/GS) for 2 hours at room temperature followed by washing as before. Sera were 
added at appropriate dilutions in 100 |il of TBMT/GS and incubated for 2 hours at room 
temperature, before washing the wells 6  times in TBST. Bound antibody was detected 
by incubation with lOOpl per well of alkaline phosphatase-conjugated goat antibody to 
human IgG, gamma-heavy chain-specific (Seralab) diluted 1/1000 in TBMT/GS for 1 
hour at room temperature. Wells were washed 6 times in TBST then lOOpl of p- 
nitrophenol-phosphate in diethanolamine buffer was added. Colour development was 
stopped after 30 minutes with 0.4M sodium hydroxide and absorbances read at 405nm.
Sera were assayed at multiple dilutions from 1/10-1/3000 except where stated 
otherwise. Results were defined as positive if the absorbance value exceeded the mean 
plus three standard deviations of the absorbance values obtained with negative control 
sera and was greater than 0.10.D. units. A minimum of four negative control sera were 
included in each experiment
150
5.2.9. Adsorption of p!9 specific antibody.
In order to confirm the specificity of antibody binding to pl9-derived peptides, four 
HTLV-I positive and four PNG sera were preadsorbed with rpl9 before assaying in the 
P109-130 ELISA. Serial ten-fold dilutions of rpl9, were made from stock solutions of 
3ng/jil to 0.3pg/|il and/or 10ng/|xl to O.lpg/jil in TBMT/GS. Serum samples were 
diluted in lOOjil of the ip l9  solutions and preincubated for 2 hours at room temperature. 
Sera were used at a dilution which gave 50% of the maximum absorbance in the pl09- 
130 ELISA, as determined from titration curves. The pl09-130 ELISA was performed 
as described above. Identical experiments using GST in place of rpl9 were performed 
as controls.
5.2.10. Secondary structure predictions.
The secondary structures and antigenic indices of HTLV-I pl9 and HTLV-II p22 were 
predicted and plotted using the programs "Peptidestructure" and "Plotstructure" from 
the Genetics Computer Group Sequence Analysis software package, version 4.7, on a 
Micro VAX 3600 computer. Secondary structure predictions are based on the algorithms 
of Chou and Fasman (1978). The antigenic index is based on weighted values for 
hydrophilicity (Hopp and Woods 1981), surface probability (Emini et al. 1985), 
flexibility (Karplus and Schultz 1985), and secondary structure (Chou and Fasman 
1978; Gamier et al. 1978), as described by Jameson and Wolf (1988).
5.2.11.Data base searches.
Computerized protein and nucleotide sequence databases were searched using the 
Genetics Computer Group Sequence Analysis software package, version 4.7.
A search of the NBRF protein sequence data bank for homology with the sequences of 
the 4 octapeptides reactive with MoAb 12/1-2 was performed using the program "Find". 
The search allowed 3 mismatches out of 8 amino acids.
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A search of the nucleotide sequence data banks for homology to the 10 amino acid 
sequence spanned by the three octapeptides reactive with 7/9 PNG sera was performed 
using the program "TFastA". This program translates all nucleotide sequences (upper 
and lower strands) containing open reading frames in all 3 reading frames and searches 
the translated peptide sequences for homology with a target sequence. The best 40 
matches from the Genbank (updated 1989), EMBL (updated September 1990) and 
NewEMBL (updated October 1990) data banks were examined.
An additional search of the NBRF protein sequence databank (updated July 1990) was 
performed using the program "Wordsearch" to look for protein sequences with 
homology to the C-terminal 30 amino acids of pl9.
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5.3. RESULTS.
5.3.1. Sequencing of the p!9 insert in pG7Zf!9.5.
The sequence of the pl9 coding sequences amplified from the HTLV-I provirus present 
in the PBMCs of patient 374 and cloned into pGEM-7ZF(+) is shown in Figure 5.9. An 
autoradiograph of representative results is illustrated in Figure 5.10. Seven nucleotide 
changes from the prototype lambda-ATK-1 sequence determined by Seiki etal. (1983) 
were identified. Translation of the nucleotide sequence identifies alterations to three 
amino acids, compared to the translated lambda-ATK-I sequence. A non-conservative 
change from arginine to glutamine was identified at position 17. A conservative change 
from alanine to valine was identified at position 58 and a non-conservative change from 
arginine to tryptophan was identified at position 59.
5.3.2.Expression of rp!9.
IPTG-induction of protein expression in bacteria containing the pGEX-3X19 plasmid 
resulted in increased expression of a protein which showed a relative molecular mass of 
41000 on analysis by SDS-PAGE. A higher level of expression was detected in 
extracts from the transformed E.coli strain HB101 compared to strains JM105 and 
JM109 (Figure 5.11). E.Coli strain HB101 was subsequently used for large scale 
expression of ipl9.
WB analysis using MoAb 12/1-2, confirmed that a protein of relative molecular weight 
41000, that was induced by IPTG in cultures of bacteria containing pGEX-3X19, 
reacted with MoAb 12/1-2 (Figure 5.11, panel B). MoAb 12/1-2 did not react with any 
proteins present in extracts of IPTG-induced cultures of bacteria containing pGEX-3X.
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Figure 5.10. Representative results obtained 
from the analysis of the nucleotide sequence 
of pG7Zf19.5 using the SP6 primer. 
Nucleotides 31 -118 of the upper strand of the 
p19-coding region are illustrated (nucleotides 
are numbered from the A of the initiation 
codon). Differences from the published 
nucleotide sequence of the lambda-ATK-1 
clone of HTLV-I (Seiki et al. 1983) are 
underlined.
Figure 5.10. Nucleotide sequence 
analysis of pG7Zf19.5.
Figure 5.11. Proteins were purified from bacterial cell extracts 
using glutathione-agarose beads, as described in section 
5.2.4 and separated on SDS-PAGE. Cell extracts were made 
from IPTG-induced cultures of E. Coli strains HB101 (r1), 
JM105 (r2) and JM109 (r3) containing the recombinant 
plasmid, PGEX-3X19; and JM109 containing the 
non-recombinant plasmid pGEX-3X (G). The thick arrows 
show the migration distances of protein molecular weight 
markers (Amersham International pic), the relative molecular 
weights (x1000) of the markers are indicated alongside.
Panel A, Coomassie blue-stained gel. The protein with the 
highest relative molecular weight (41000) seen in lane r1 was 
taken to be the recombinant fusion protein, rp19, as indicated 
by the thin arrow. The proteins of lower relative molecular 
weight are probably breakdown products of rp19 (see 
below). The non-recombinant GST protein is seen in lane G, 
migrating with a relative molecular weight of 27000.
Panel B, the reactivity of MoAb 12/1-2 with the purified 
proteins was analysed by WB after transferring a replica of 
the gel shown in panel A onto nitrocellulose membrane. 
MoAb 12/1-2 bound to proteins of relative molecular weight 
41000 in extracts of all E. Coli strains containing the 
recombinant plasmid, supporting the identification of this 
protein as  the rp19 fusion protein. The reactivity of MoAb 
12/1-2 with multiple lower molecular weight proteins in lanes 
r1, r2 and r3, indicates that these proteins are breakdown 
products of rp19.
Figure 5.11. E xpression of the  rp19 fusion protein in bacteria 
and  reactivity of rp19 with MoAb 12/1-2.
M r1 r2 r3 G M r1 r2 r3 G
92.5 -► 92.5
69-*- m 4 1 69
46 —► * * 46
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30 —► 30
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5.3.3. Reactivity of HTLV-I-positive and indeterminate sera with
rp !9 .
HTLV-I positive serum 374 showed reactivity with the ipl9 fusion protein and did not 
react with any proteins on WB strips made using non-recombinant GST (Figure 5.12). 
Two indeterminate sera from PNG were analysed for reactivity with rpl9 by WB. Both 
samples showed reactivity with the ipl9 fusion protein (Figure 5.12). The PNG sera 
reacted in addition with two proteins of higher relative molecular weight in WB strips. 
Reactivity with these two proteins was detected in WB strips made from purified 
extracts of cultured bacteria containing the non-recombinant plasmid in addition to 
extracts from bacteria containing the recombinant plasmid. It is therefore likely that 
these reactivities represent antibody binding to bacterial proteins that are copurified 
with GST and the GST-fusion protein.
5.3.4.Epitope mapping.
The results obtained from the comparison between the HRPO and amplified ELISAs 
are shown in Figure 5.13. Use of the amplified ELISA produced at least a ten-fold 
increase in sensitivity, though the ratio of the positive to the negative signals was 
similar.
Analysis of monoclonal and polyclonal sera with the pl9 octapeptides using the HRPO 
and amplified ELISAs gave qualitatively similar, though not completely identical, 
results. Experiments to determine the relative sensitivity of the two techniques for the 
analysis of sera with the pl9  octapeptides were not performed.
Monoclonal antibodies.
MoAb 12/1-2 (1:1000 dilution of ascites) reacted with four adjacent octapeptides, 
numbers 116-119, near the C-terminus of p 19 in duplicate assays (Figures 5.14 and 
5.15). These octapeptides share the common sequence PPYVE, which is completely 
conserved in the p22 core protein of HTLV-H. Analysis of MoAb 12/1-2 with the 
HRPO and amplified ELISAs gave qualitatively similar results (Figures 5.14 and 5.15).
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Figure 5.12. Reactivity of HTLV-I antibody-positive 
and  PNG se ra  with th e  rp19 fusion protein.
374 
a b
92.5 
69
46
rp19
30
21.5
886 891
a b a b
HTLV-I antibody-positive serum sample 374 and PNG serum 
samples 886 and 891 were analysed for reactivity with the 
glutathione S-transferase (GST)-pl 9 fusion protein (rp19), (a), and 
for reactivity with GST, (b), as described in section 5.2.5. The 
thick arrows show the migration distances of protein molecular 
weight markers (Amersham International pic), the relative 
molecular weights (x1000) of the markers are indicated alongside. 
Rp19 migrates with a relative molecular weight of 41000 (thin 
arrow).
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Figure 5.14. The graphs show the results obtained from the analysis 
of MoAb 12/1-2 for reactivity with the p19 octapeptides using the 
horse-radish peroxidase (HRPO) ELISA. The heights of individual 
bars indicate the absorbance readings obtained for individual 
octapeptides in the ELISA. Panels A and B show the results of 
ELISAs performed on duplicate sets of octapeptides. MoAb 12/1 -2 
was analysed at a dilution of 1 /1000.
Figure 5.15. The graphs show the results obtained from a similar 
analysis of MoAb 12/1-2 using the amplified alkaline phosphatase 
(AMPAK) ELISA. The scale on the y-axis extends to 3.0 O.D. units, 
compared with 0.6 O.D. units in Figure 5.14, thus the signal-to-noise 
ratio obtained with the amplified ELISA is higher than that obtained 
with the HRPO ELISA.
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Figure 5.14. Reactivity of MoAb 12/1 -2 with p19 OOtaPePtictes: 
HRPO ELISA.
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Figure 5.15. Reactivity of MoAb 12/1 -2 with p19 octapeptides: 
amplified ELISA
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In the amplified ELISA the absorbance readings obtained with non-reactive 
octapeptides were lower relative to those obtained with reactive peptides when 
compared with the readings obtained in the HRPO ELISA.
MoAb 12G4 (1/200 dilution of MAS 197c) was assayed three times using the AMPAK 
detection system on duplicate sets of pins. No consistent reactivity with any octapeptide 
or group of octapeptides was identified. Negative results were also obtained with 
MoAbs 13B12 and 9G10. MoAb 13B12 was assayed at a dilution of 1/80 
(recommended working dilution 1/50-1/100) using the HRPO detection system only, 
due to the limited amounts of antibody available. MoAb 9G10 was assayed using the 
AMPAK detection system at a dilution of 1/160. This is below the recommended 
working dilution of 1/50-1/100 but was limited by sample availability.
HTLV-I positive sera.
Ten HTLV-I positive sera were analysed in the PEPSCAN ELISA at dilutions that 
varied from 1/200 to 1/800. The dilution used was selected on the basis of serum 
availability and the titre of HTLV-I antibody detected by ELISA (DuPont) or by GPA 
(ATLA, Serodia).
The patterns of reactivity of the ten HTLV-I positive sera with duplicate sets of 
octapeptides are shown in Figures 5.16-5.25. A summary of the data is shown in Figure 
5.26. Nine of the ten sera showed reactivity with one or more groups of 2-8 adjacent 
peptides derived from the C-terminal 21 amino acids of pl9 (octapeptides 110-123). 
Three of these sera, numbers 628,796 and 797, also reacted with groups of 2-5 adjacent 
peptides between octapeptide 102 and octapeptide 108. None of the HTLV-I positive 
sera reacted with octapeptide 109. Serum 716 showed reactivity with isolated 
octapeptides only.
Reactivity with various single peptides in duplicate sets of pins was seen with a number 
of other sera. No groups of 2 or more octapeptides other than those derived from the C- 
terminal 29 amino acids of pl9 showed reactivity with the HTLV-I positive sera.
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Figures 5.16-5.25. The graphs show the results obtained from 
the analysis of HTLV-I antibody-positive serum samples in the 
PEPSCAN ELISA. The heights of the bars indicate the 
absorbance readings obtained for individual octapeptides in 
the ELISA. Panels A and B show the results of ELISAs 
performed on duplicate sets of octapeptides. Sera were 
analysed at dilutions of 1/200 (sample 731), 1/400 (samples 
628, 733, 737, 739, 741, and 796), 1/500 (samples 374 and 
716) or 1/800 (sample 797).
A
bs
or
ba
nc
e 
oo 
A
b
so
rb
a
n
ce
Figure 5.16. Reactivity of HTLV-I antibody-positive serum 374
with p19 octapeptides.
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Figure 5.17. Reactivity of HTLV-I antibody-positive serum 628
with p19 octapeptides.
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Figure 5.18. Reactivity of HTLV-I antibody-positive serum 716
with p19 octapeptides.
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Figure 5.19. Reactivity of HTLV-I antibody-positive serum 731 
with p19 octapeptides.
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Figure 5.20. Reactivity of HTLV-I antibody-positive serum 733
with p19 octapeptides.
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Figure 5.21. Reactivity of HTLV-I antibody-positive serum  737
with p19 octapeptides.
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Figure 5.22. Reactivity of HTLV-I antibody-positive serum 739
with p19 octapeptides.
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Figure 5.23. Reactivity of HTLV-I antibody-positive serum 741 
with p19 octapeptides.
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Figure 5.24. Reactivity of HTLV-I antibody-positive serum 796 with
p19 octapeptides.
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Figure 5.25. Reactivity of HTLV-I antibody-positive serum  797 with
p19 octapeptides.
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Reactivity of these sera with the C-terminal region of p l9  was confirmed with an 
ELISA using P109-130. All ten HTLV-I positive sera reacted with this peptide. The 
highest serum dilutions which gave a positive result varied from 1/300-1/3000 (Table
v.vm ).
In order to investigate the significance of the reactivities detected with isolated 
octapeptides, selected sera were analysed in ELISAs using 15 amino acid long peptides 
overlapping the reactive octapeptides. The results of these experiments are given in 
Table V.IX. None of the sera which had reacted with isolated octapeptides showed 
reactivity with 15 amino acid long peptides that included the same sequence.
The lack of reactivity detected in these experiments was not solely due to the use of 
peptides of a different length and from a different source, as three fifteen amino acid 
long peptides derived from the C-terminal 29 amino acids of pl9 did show reactivity 
with one or more of serum samples 374,737 and 739 (Table V.IX). The 15 amino acid 
long peptides that were reactive with these sera were derived from regions of pl9 that 
corresponded to groups of reactive octapeptides.
For serum sample 716 antibody binding to a longer peptide corresponding to an isolated 
reactive octapeptide was detected. This serum sample reacted with the 22 amino acid 
long peptide, P109-130, at dilutions up to 1/3000 (Table V.VIII). Serum sample 716 
was not tested for reactivity with a fifteen amino acid long peptide derived from this 
region.
Indeterminate sera.
(a) Sera from Caucasian patients.
T he sp ecific ity  o f  the indeterm inate reactions ob served  w ith  sera from  tw o Caucasian 
patients, numbers 215 and 487, w as assessed  using tw o approaches.
To determine whether factors in serum other than Ig were contributing to binding to 
pl9, IgG was purified from serum and used in HTLV-I WB (DuPont) at a concentration 
equivalent to a 1/100 serum dilution. No change in the pattern of reactivity was 
observed with either sample (S. Crae, unpublished results).
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Table V.VIII. Reactivity of HTLV-I antibody-positive. HTLV-II 
antibody-positive and indeterminate sera with P109-130.
HTLV-I + HTLV-II + Indeterminate sera
sera sera PNG Caucasian
No. Titre No. Titre No. Titre No. Titre
374 3000 806 884 +50* 215 -
628 3000 854 - 885 1000 487 -
716 3000 876 - 886 +50*
731 300 ! 877 10 887 100
733 1000 S 878 30 888 100
737 3000 ! 889 3000
739 3000 i 890 3000
741 1000 i 891 3000
796 3000 : 892 1000
797 3000 l
Sera were tested at dilutions of 1/10,1 /3 0 ,1 /100 etc. up 
to 1/3000. ELISAs were performed as described in 
section 5.2.8. The titre indicates the highest dilution 
giving a positive result. No., number; PNG, Papua New 
Guinea; HTLV-I+, HTLV-I antibody-positive; HTLV-II+, 
HTLV-II antibody-positive; -, negative; *, there was 
insufficient sample material to assay these sera £t 
multiple dilutions, both sera were positive when tested 
at a dilution of 1/50.
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To determine whether serum binding to p l9  was due to interaction with a specific 
epitope on the protein, purified IgG from samples 215 and 487 were analysed in the 
PEPSCAN ELISA. The IgG samples were analysed at concentrations equivalent to 
serum dilutions of 1/100. Sample 215 showed strongest reactivity with a group of 6 
adjacent octapeptides numbers 102-107 and weaker reactivity with two pairs of 
octapeptides, numbers 99-100 and 117-118 (Figure 5.27). Sample 487 reacted with one 
pair of octapeptides, numbers 112-113 and with two additional isolated octapeptides, 
39 and 115 (Figure 5.28).
When tested in ELISAs using longer peptides overlapping the regions reactive in the 
PEPSCAN ELISA, both sera gave negative results (Tables V.VIII and V.IX). Serum 
215 did not react with P97-111, P102-116, P107-121, PI 11-125 or with P109-130. 
Serum 487 did not react with P109-130.
Serum samples 215 and 487 were also analysed in ELISAs using the 15 amino acid 
long peptides derived from the endogenous retrovirus, HRES-1/1 (Table V.VII). 
Neither of the samples showed evidence of reactivity with these peptides.
(b) Sera from residents of Papua New Guinea.
Nine sera from Papua New Guinea which reacted with p l9  and related proteins on 
HTLV-I WB were tested in the PEPSCAN ELISA. Sera were analysed at dilutions 
which varied from 1/400 to 1/800, as limited by serum availability. The results obtained 
are illustrated in Figures 5.29-5.37 and summarized in Figure 5.38. Seven of the sera 
showed reactivity with a group of 3 adjacent octapeptides, numbers 109-111, one of 
these sera (sample 891) reacted in addition with octapeptide 112. Serum 887 reacted 
with two of these octapeptides, 110 and 111. Serum 886  did not show significant 
reactivity with any group of octapeptides when tested at a dilution of 1/800. All nine 
sera showed reactivity with isolated octapeptides elsewhere in pl9.
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Figures 5.27-5.28. The graphs show the results obtained from 
the analysis of IgG purified from serum samples obtained 
from two Caucasian patients in the PEPSCAN ELISA. The 
heights of the bars indicate the absorbance readings 
obtained for individual octapeptides in the ELISA. Panels A 
and B show the results obtained in ELISAs performed on 
duplicate sets of octapeptides. Purified IgG was diluted to a 
final concentration of 0.035mg/ml for analysis; this was 
equivalent to serum dilutions of approximately 1 /100.
Figure 5.27. Reactivity of indeterminate serum 215 with p19
octapeptides.
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Figure 5.28. Reactivity of indeterminate serum 487 with p19 
octapeptides.
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Figures 5.29-5.37. The graphs show the results obtained from 
the analysis of serum samples from residents of Papua New 
Guinea (PNG) in the PEPSCAN ELISA. The heights of the 
bars indicate the absorbance readings obtained for individual 
octapeptides in the ELISA. Panels A and B show the results 
of ELISAs performed on duplicate sets of octapeptides.Sera 
were analysed at dilutions of 1/400 (samples 887 and 884) or 
1/800.
Figure 5.29. Reactivity of PNG serum 884 with p19 octapeptides.
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Figure 5.30. Reactivity of PNG serum 885 with p19 octapeptides.
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Figure 5.31. Reactivity of PNG serum 886 with p19 octapeptides.
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Figure 5.32. Reactivity of PNG serum 887 with p19 octapeptides.
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Figure 5.33. Reactivity of PNG serum 888 with p19 octapeptides.
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Figure 5.34. Reactivity of PNG serum 889 with p19 octapeptides.
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Figure 5.35. Reactivity of PNG serum 890 with p19 octapeptides.
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Figure 5.36. Reactivity of PNG serum 891 with p19 octapeptides.
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Figure 5.37. Reactivity of PNG serum 892 with p19 octapeptides.
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Seven of the sera were tested at multiple dilutions in the P 109-130 ELISA, there was 
insufficient serum to perform titrations of samples 884 and 886 . The seven sera tested 
were positive at dilutions from 1/100-1/3000 (Table V.Vm). Titration curves for the 
sera are shown in Figure 5.39. The results obtained for five of the seven sera are not 
distinguishable from titration curves obtained with the HTLV-I positive sera (Figure 
5.40). The results obtained with the remaining two PNG sera (samples 887 and 888) are 
more similar to the titration curve obtained for the HTLV-II positive sample 878 
(Figure 5.39, panel B).
HTLV-II positive sera.
Five HTLV-II positive sera were analysed at dilutions that varied from 1/200 to 1/400 
with the PEPSCAN ELISA. The dilution used depended on serum availability. HTLV- 
II positive sera showed a less consistent pattern of reactivity than HTLV-I positive sera 
(Figures 5.41-5.45). A summary of the data is shown in Figure 5.46.
HTLV-H-positive sera showed significant binding to single octapeptides or pairs of 
octapeptides only. Two sera, 877 and 878, reacted with isolated octapeptides within the 
epitope reactive with MoAb 12/1-2.
ELISAs using 15 and 22 amino acid long peptides derived from HTLV-I p 19 sequences 
were used to further investigate the reactivities observed with HTLV-II positive sera in 
the PEPSCAN ELISA. Fifteen amino acid long peptides derived from regions of 
HTLV-II p22 that were homologous to the reactive pl9 octapeptides were also used in 
ELISAs. The results of these experiments are summarized in Table V.IX. Samples 806 
and 854 were negative when assayed with P2-16 and P7-21. These samples were also 
tested for reactivity with peptides from homologous regions of HTLV-II p22 and again 
gave negative results. Serum 876 was negative when tested in ELISAs using P67-81 
and the homologous HTLV-II peptide, P(II)67-81. All five HTLV-II positive sera were 
tested for reactivity with P109-130, serum samples 877 and 878 were weakly reactive, 
the other sera were negative (Table V.VIII). There was insufficient serum available 
from samples 877 and 878 for testing with PI 16-130 or the homologous HTLV-II 
peptide, P(II)118-133.
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Figure 5.39. Serum samples were tested at dilutions of 1/10, 
1/30,1/100 etc. to 1/3000. Serum reactivity in the P109-130 
ELISA was determined as described in section 5.2.8. The 
results are shown on two seperate graphs for clarity. Panel A 
shows the results obtained from the analysis of four serum 
samples obtained from residents of Papua New Guinea 
(PNG); Panel B shows the results obtained from the analysis 
of three PNG serum samples (solid lines) and two HTLV-II 
antibody-positive serum samples (dashed lines). Individual 
curves indicate the results obtained from the analysis of the 
samples shown on the right of each panel.
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Figure 5.39. Reactivity of PNG sera  and of HTLV-H 
antibody-positive se ra  in the P109-130 ELISA: serum  titrations.
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Figure 5.40. Serum samples were tested at dilutions of 1/10, 
1/30,1/100 etc. to 1/3000. Serum reactivity in the P109-130 
ELISA was determined as described in section 5.2.8. The 
results are shown on two seperate graphs for clarity. Panels 
A and B show the results obtained from the analysis of nine 
HTLV-I antibody-positive serum samples. Individual curves 
indicate the results obtained from the analysis of the samples 
shown on the right of each panel.
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Figure 5.40. Reactivity of HTLV-1 antibody-positive sera  in the 
P109-130 ELISA: serum  titrations.
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Figures 5.41-5.45. The graphs show the results obtained from 
the analysis of HTLV-II antibody-positive serum samples in the 
PEPSCAN ELISA. The heights of the bars indicate the 
absorbance readings obtained for individual octapeptides in 
the ELISA. Panels A and B show the results of ELISAs 
performed on duplicate sets of octapeptides. Sera were 
analysed at dilutions of 1/200 (samples 876, 877 and 878) or 
1/400.
Figure 5.41. Reactivity of HTLV-II antibody-positive serum 806
with p19 octapeptides.
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Figure 5.42. Reactivity of HTLV-II antibody-positive serum  854
with p19 octapeptides.
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Figure 5.43. Reactivity of HTLV-II antibody-positive serum 876
with p19 octapeptides.
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Figure 5.44. Reactivity of HTLV-II antibody-positive serum  877 
with p19 octapeptides.
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Figure 5.45. Reactivity of HTLV-II antibody-positive serum 878
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HTLV-negative sera.
Three sera which gave negative results in HTLV-I ELISA (DuPont) and HTLV-IWB 
(DuPont) were analysed in the PEPS CAN ELISA. All sera were analysed at a dilution 
of 1/200. The results of these analyses are shown in Figures 5.47-5.49. All three serum 
samples showed reactivity with isolated octapeptides in duplicate assays. Sample 2 
showed reactivity with a group of 3 adjacent octapeptides, numbers 101-103. The 
absorbance values obtained in the ELISAs with these three octapeptides were low 
relative to the background readings, when compared to the peak reactivities seen in 
HTLV-I-positive sera (Figure 5.48).
5.3.5. Reactivity of HTLV-I-positive and PNG sera in P109-130 
ELISA following preadsorption with rp!9.
To investigate further the pl9 specificity and the relative affinity of the reactions seen 
with P109-130,4 PNG sera and 4 HTLV-I positive sera were preadsorbed with rpl9 
before testing in the ELISA. Preadsorption with rp l9  resulted in a concentration 
dependent reduction in antibody binding to P109-130 in the 4 PNG sera (Figure 5.50). 
Similar results were obtained with HTLV-I positive sera 733,737 and 739 (Figure 
5.50). The reactivity of sample 716 in the P109-130 ELISA was less efficiently reduced 
by preadsorption with rpl9 (Figure 5.50, panel a).
5.3.6. PI09-130 ELISA.
In order to assess whether the C-terminal region of pl9 showed consistent reactivity 
with HTLV-I positive sera, an additional 32 sera that were positive in the HTLV-I 
competitive ELISA, were analysed in the P I09-130 ELISA. Nine of the HTLV-I- 
positive sera tested in the PEPS CAN ELISA were also analysed. Sera were tested in 
four replicate assays a dilution of 1/50, with the exception of two samples which were 
tested once in duplicate. The results were compared to those obtained with 45 sera that 
gave negative results in HTLV-I ELISA (DuPont). The results obtained are shown in 
Figure 5.51. The two groups of sera could be readily distinguished using a cut-off 
value equal to an O.D. of 0.29, as shown in the figure.
159
Figures 5.47-5.49. The graphs show the results obtained from 
the analysis of HTLV-I antibody-negative serum samples for 
reactivity with HTLV-I p19 octapeptides in the PEPSCAN 
ELISA. The heights of the bars indicate the absorbance 
readings obtained for individual octapeptides in the ELISA. 
Panels A and B show the results of ELISAs performed on 
duplicate sets of octapeptides. Sera were analysed at 
dilutions of 1 /200.
Figure 5.47. Reactivity of HTLV-I antibody-negative serum 1
with p19 octapeptides.
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Figure 5.48. Reactivity of HTLV-I antibody-negative serum 2
with p19 octapeptides.
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Figure 5.49. Reactivity of HTLV-I antibody-negative serum 400
with p i 9 octapeptides.
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Figure 5.50. The reactivity with P109-130 observed following 
preabsorption of serum samples with the recombinant p19 
fusion protein (rp19) is expressed as a percentage of the 
result (absorbance of light at 495nm) obtained in an 
identical ELISA using unabsorbed sera. The results are 
shown on two graphs for clarity. Solid lines show the results 
obtained when serum samples were preabsorbed with rp19. 
Dashed and dotted lines show the the results obtained in 
control experiments following preabsorption with 
glutathione-S-transferase. The results are the mean values 
obtained in duplicate experiments. A, HTLV-I 
antibody-positive serum samples 716 (—&—) and 733 
(-H&-+-), PNG serum samples 885 (-X-&-X-) and 889 (-B-&-Q-); 
B, HTLV-I antibody-positive serum samples 737 (—&—) and 
739 (-+-&-*-), PNG serum samples 890 (-X-&-X-) and 891
% 
of 
ma
xim
um
 
ab
so
rb
an
ce
 
%
 o
f 
ma
xim
um
 
ab
so
rb
an
ce
Figure 5.50. Reactivity of HTLV-I antibody-positive and PNG
sera in the P109-130 ELISA following preadsorption with rp19.
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Figure 5.51. Panel A, HTLV-I antibody-positive sera; 
panel B, HTLV-I antibody-negative sera; panel C, 
HTLV-II antibody-positive sera; panel D, sera from 
Caucasian patients showing reactivity with HTLV-I p19 
on WB; panel E, sera from residents of Papua New 
Guinea (PNG) showing reactivity with HTLV-I p19 on 
WB. The results shown are the means of four 
determinations with the following exceptions; the PNG 
sera and two of the HTLV-I antibody-negative sera 
were assayed in duplicate owing to limited sample 
availability. The shaded area at the base of the graph, 
delineated by dashed lines, indicates a region that is 
not drawn to scale, but represents absorbance 
readings of less than 0.02 O.D. units. The dotted line 
at 0.29 O.D. units indicates the cut-off value that 
discriminates between the HTLV-I antibody-positive 
and HTLV-I antibody-negative samples in this assay.
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Figure 5.51. Reactivity of serum samples in the
P109-130 ELISA.
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Three samples were analysed that gave discordant results in other assays. The results 
obtained with these sera are shown in Table V.X. All three samples were negative in 
competitive ELISA. One of the samples was positive (i.e. above the cut-off value) in 
the P109-130 ELISA, while the other two were negative.
The HTLV-II positive and indeterminate sera were also tested in the P109-130 ELISA 
under the conditions described above. The results, as the mean of duplicate 
determinations, are shown in Figure 5.51. HTLV-II positive sera gave O.D. readings 
within the range of results obtained with negative control sera. The two indeterminate 
sera from Caucasian patients also gave results within the range obtained with negative 
control sera. Indeterminate sera from PNG gave O.D. readings within the range of 
results obtained with HTLV-I positive sera, with the exception of samples 888 and 887, 
which gave results below the cutoff value.
5.3.7. Secondary structure predictions.
The predictions for hydrophilicity, surface probability, flexibility, antigenic index and 
secondary structure for HTLV-I pl9  are shown as one-dimensional curves in Figure 
5.52. Figure 5.53 shows a two-dimensional plot of the predicted secondary structure of 
pl9, according to the modified Chou-Fasman method described in the reference manual 
for Wisconsin GCG. The region of p l9  most strongly predicted to be antigenic 
according to the algorithm of Jameson and Wolf (Jameson and Wolf 1988) includes 
amino acids 111-117. This overlaps the region predicted to be an antigenic determinant 
according to the algorithm of Hopp and Woods (1981), which lies between amino acids 
109-116. Additional regions with a high antigenic index are located between amino 
acids 15-18 and 35-42.
Figures 5.54 and 5.55 show the results obtained from similar analyses of HTLV-II p22. 
The regions of HTLV-II p22 most strongly predicted to be antigenic according to the 
algorithm of Jameson and Wolf are located between amino acids 15-18,35-42 and 129- 
132. Use of Hopp and Woods’ algorithm indicates that the region of p22 between 
amino acids 36-42 is likely to be an antigenic determinant
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5.3.8. Data bank searches.
(a) The NBRF protein sequence data bank was searched for protein sequences with 
homology to the amino acid sequences of octapeptides 116-119 which showed 
reactivity to MoAb 12/1-2. The amino acid sequence of octapeptide 120 was also 
included in the search as this octapeptide showed a low level of reactivity with MoAb 
12/1-2 in the HRPO ELISA.
A total o f493 sequences were identified which shared 5/8 amino acids in common with 
one or more of the five octapeptides. A complete match with the sequence PPYVE, the 
sequence shared between the four most strongly reactive octapeptides, was identified 
for a number of proteins. Homology was identified with amino acids 129-133 of the 
alpha chains of the DNA-directed RNA polymerases of spinach chloroplast (Sijben 
Muller etal. 1986) and tobacco chloroplast (Shinozaki etal. 1986). Amino acids 563- 
567 of the precursor protein of the major surface antigen of Leishmania tropica also 
showed complete homology with this sequence (Button and McMaster 1988). The 
hypothetical protein, F-215, of Vaccinia virus contains the sequence PPYVE at 
positions 12-16 (Niles et al. 1986).
(b) The Genbank, EMBL and NewEMBL data banks were searched for nucleotide 
sequences which would code for amino acids contained in the 10 amino acid long 
sequence of P19 that showed reactivity with PNG sera. No sequences were identified 
that would code for a region with more than four consecutive amino acids identical with 
the target sequence of DPPDSDPQIP. The maximum match with the target sequence 
obtained was 6/8 amino acids and this was obtained with numerous protein sequences. 
The majority of matches obtained were with proline rich sequences.
(c) A search for homology with the C-terminal 30 amino acids of HTLV-I pl9 revealed 
limited homology with a range of proteins. In most cases the homology was due to the 
presence of multiple proline residues in protein sequences.
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5.4.DISCUSSION.
5.4.1 HTLV-I positive sera.
This study has identified the C-terminal 30 amino acids of the p l9  gag protein of 
HTLV-I as the location of the linear B-cell epitopes reactive with HTLV-I positive sera. 
Within this region a number of patterns of reactivity were observed, with no one 
octapeptide or group of octapeptides showing reactivity with all sera. Octapeptide 118 
was most frequently reactive, forming part of a reactive group of peptides in 8/10 sera.
These results are in agreement with previous data suggesting that amino acids 100-130 
of p l9  are highly immunogenic in man and may form at least two antigenic regions 
(Palker et al. 1986; Kuroda et al. 1990). Data from both these studies suggested that 
peptides including the 11 or 12 most C-terminal amino acids of pl9 were reactive with 
the majority of HTLV-I positive sera. Palker et al. (1986) found that 16/18 HTLV-I 
positive sera reacted with peptide SP71, corresponding to amino acids 120-130, while 
2/9 sera reacted in addition to peptide SP61 (amino acids 102-115). Kuroda et al. 
(1990) detected reactivity to P19-100II (amino acids 100-130) in 94/94 HTLV-I 
positive sera, while fewer of the sera, 80/94, reacted with P19-100I (amino acids 100- 
119).
Our data indicate that the C-terminal 30 amino acids of p l9  do include more than one 
antigenic region. The data shown in Figure 5.26 identifies these regions as sequences 
included within octapeptides 102-108 and octapeptides 110-121. In addition, serum 
716 appears to react with a distinct linear antigenic determinant within the C-terminal 8 
amino acids of pl9. Reactivity with the antigenic region spanned by octapeptides 110- 
121 was more consistently found in HTLV-I positive sera (9/10 of sera tested) than 
reactivity with the region spanned by octapeptides 102-108 (3/10 sera tested).
The variation in the patterns of reactivity seen within these regions, indicates that each 
region includes a number of overlapping epitopes. These regions may therefore be 
considered to represent "antigenic sites", as suggested by Schoofs et al. (1988). The 
variation observed in different sera may be a result of genetic variation in antibody 
repertoires. Other studies performed with polyclonal sera directed against heterologous 
antigens have also shown that a number of overlapping epitopes may be identified 
within an antigenic site (Schoofs et al. 1988).
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Kuroda et al. (1990) suggest that a peptide containing amino acids 100-130 of pl9 
could be used reliably as a target antigen in assays for the detection of HTLV-I 
antibodies. Our epitope mapping data suggest that it may be possible to use a smaller 
peptide containing amino acids 110-130 without loss of sensitivity. We used a 22 amino 
acid long peptide, P109-130 as a target antigen in an ELISA to test this hypothesis and 
were able to clearly distinguish 46 HTLV-I positive from 42 HTLV-I negative sera.
It is of interest that Horal et al. (1990) found that 1/21 HTLV-I positive sera did not 
react in an ELISA using a slightly smaller peptide containing the C-terminal 19 amino 
acids of pl9. In this report it is not clear how the HTLV-I positive sera were defined. 
This may be important, as HTLV-I and HTLV-II positive sera are difficult to 
distinguish using routine assays, as discussed earlier. However the result we obtained 
from epitope mapping serum 733 suggest that the difference in length between our 22 
amino acid long peptide and the 19 amino acid long peptide used by Horal etal. (1990) 
may have been significant. Serum 733 reacted most strongly with octapeptides 110 and 
111 in the PEPSCAN ELISA while no significant reactivity was observed with 
octapeptide 112 which corresponds to the amino terminal portion of the peptide used by 
Horal et al. (1990). Figure 5.26 shows that serum 733 did show significant reactivity 
with octapeptides 116-118. However antibody binding to these octapeptides was weak 
relative to the reactivity with octapeptides 110 and 111 (Figure 5.20). The results of 
epitope mapping would therefore predict that this serum might not react with a peptide 
corresponding to the C-terminal 19 amino acids of pl9.
5.4.2. Monoclonal antibody 12/1-2.
The four adjacent octapeptides reactive with MoAb 12/1-2 in the PEPSCAN ELISA 
share the sequence PPYVE. This sequence, therefore, includes the essential residues for 
interaction between the antibody and pl9.  This amino acid sequence is completely 
conserved in HTLV-II p22 (residues 125-129). The identification of this sequence as 
the epitope reactive with MoAb 12/1-2 is consistent with the known reactivity of this 
MoAb with the p22 protein of HTLV-II (Palker et al. 1985).
An epitope reactive with MoAb 12/1-2 is known to be present on one or more cellular 
antigens (see previous discussion, section 5.1.2). A search of the NBRF-protein 
sequence data bank did not reveal homology with any proteins likely to produce the 
patterns of cross reactivity that have been observed with this MoAb.
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However, it may not be possible to detect a cross reactive epitope on a different protein 
on the basis of sequence homology with the actual epitope on pl9. The residues that are 
essential for interaction with antibodies have been identified in various epitopes using 
peptides in which each amino acid is replaced in turn (Schoofs et al. 1988; Scopes et 
al. 1990). These studies have shown that in some epitopes all residues are essential for 
the interaction with antibody, while in others as few as 2/6 or 3/7 residues may be 
essential. If only 2 amino acids in the epitope sequence are essential for interaction 
with the MoAb it would not be possible to identify candidate cross-reacting proteins on 
the basis of sequence homology.
5.4.3. Indeterminate sera.
We used two approaches to study IR detected in 2 HTLV-I negative sera obtained from 
Caucasian patients. The possibility that unknown factors in serum were contributing to 
non-specific binding to viral proteins was addressed by testing purified IgG on HTLV-I 
WB. Identical patterns of reactivity with pl9 and related proteins were detected. While 
this does not exclude the possibilities that high levels of IgG or immune complexes may 
be the cause of non-specific binding, the results do show that the reactions observed 
with pl9 are IgG mediated.
Analysis of purified IgG from serum samples 215 and 487 in the PEPSCAN ELISA 
detected reactivity with different groups of pl9 octapeptides near the C-terminus of the 
protein. A significant level of binding to octapeptides reactive with MoAb 12/1-2 was 
detected in sample 215, though the level of reactivity was low relative to that detected 
to octapeptides 103-108 (Figure 5.27). Sample 487 did not react with octapeptides 
recognized by MoAb 12/1-2. Thus the indeterminate reactivities detected in these two 
samples do not appear to be due to autoantibodies directed against the cellular 
antigen(s) recognized by MoAb 12/1-2.
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Neither of these sera reacted in ELISAs using longer peptides from the regions reactive 
on the PEPSCAN ELISAs. This may be due to low antibody titres or low antibody 
affinity as the epitope density and quantity in the peptide ELISAs is low compared to 
the density and quantity of peptide that should be present on the pins (Geysen et al. 
1987). The negative results obtained in ELISAs using peptides from the HERV 
sequence HRES-1/1 are difficult to interpret for similar reasons. Autoantibodies to 
endogenous antigens are likely to be of low affinity and low titre, and therefore might 
not be detectable under the assay conditions used.
It is unlikely that the results obtained in the PEPSCAN ELISAs represent spurious 
reactivities, as for both samples reactivity with groups of adjacent peptides was 
detected, and similar patterns of reactivity were not detected in negative control sera. 
Experiments using appropriate peptides for preadsorption prior to either WB or 
PEPSCAN ELISA would be useful to confirm the results obtained in this study.
Other MoAbs to p l9  show cross reactivity with human tissues (Palker et al. 1985) and 
the data suggest that p l9  shares more than one epitope with cellular antigens, as 
discussed earlier. Analysis of these MoAbs with the PEPSCAN ELISA was 
unsuccessful. This have have been due to the use of suboptimal serum concentrations in 
the assays. Alternatively these MoAbs may be directed against conformational epitopes 
and thus might not react with the octapeptides. It is possible that the reactivities 
detected with pl9 octapeptides in samples 215 and 487 might be due to autoantibodies 
directed to epitopes shared with cellular antigens, other than that identified with MoAb 
12/ 1-2 .
The analysis of indeterminate sera from PNG produced very different results to those 
obtained with indeterminate serum samples 215 and 487. Eight of the nine PNG sera 
showed reactivity with a consistent group of peptides near the C-terminus of pl9 and 
these sera gave high O.D. readings in an ELISA using a longer peptide spanning this 
region. The data therefore show that the indeterminate results obtained with the PNG 
sera are due to reactions with a specific antigenic site on p i9. In some of the PNG sera, 
the affinity and titre of antibodies reacting with the pl9 peptide, as estimated by serum 
titrations and preadsorptions with rp 19, could not be distinguished from results obtained 
with HTLV-I positive sera. These results suggest that the antibodies in the PNG sera are 
directed against an epitope with an high degree of homology with the reactive region of 
pl9.
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These data offer support for the hypothesis that the IR detected in PNG sera are due to 
infection with a retrovirus related to HTLV-I. As recent reports have indicated that 
HTLV-I infection is present in PNG, it is necessary to consider the possibility that these 
sera may be derived from HTLV-I infected persons. However the results of other 
serological assays suggest that these sera are distinct from HTLV-I positive sera. These 
sera do not react with env encoded proteins in HTLV-I WB, and with one exception do 
not react with p24 in HTLV-I WB. They also give negative results in IgG antigen- 
capture radioimmunoassays and competitive radioimmunoassays, "in house" assays 
developed at the Virus Reference Laboratory (J. Tosswill personal communication).
The results of our experiments suggest that the antigens eliciting the p l9  reactive 
antibodies in the two groups of sera are not identical though are likely to be highly 
related. As a group the PNG sera showed a more consistent pattern of reactivity to pl9 
octapeptides than the HTLV-I positive sera. In addition there were differences in the 
octapeptides most frequently reactive with the two groups of sera. Although the 
peptides reactive with the PNG sera overlapped the more C-terminal antigenic site 
identified with HTLV-I positive sera, seven of the samples reacted with octapeptide 
109, which did not react with any HTLV-I positive sera. It should be noted, however, 
that the results obtained with HTLV-I positive sample 733 and PNG sample 887 in the 
PEPSCAN ELISA are very similar. The results obtained in the PEPSCAN ELISA could 
not, therefore, be used to distinguish between the two groups of sera.
An alternative explanation for the data is that the antibody response to HTLV-I proteins 
detected in the sera from residents of PNG varies from that seen in the HTLV-I-infected 
persons because of genetic variation in antibody repertoire. This could give rise to 
differences in the pattern of antibody response to an identical antigen. If this 
interpretation of the data is correct it is necessary to argue that these individuals are 
unable, in most cases, to mount an immune response to the p24 core protein of HTLV-I.
The possibility remains that the reactivity of the PNG sera with the p 19 antigenic site is 
due to cross reactivity with an antigen present on some other infectious agent, e.g. £. 
falciparum. It is difficult to exclude this possibility, but searches of the NBRF-protein 
databank and the GenBank and EMBL databanks have failed to identify candidate 
nucleotide or protein sequences with homology to the region of pl9 identified in our 
experiments. No P. falciparum proteins were identified in any of the data bank 
searches.
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The results of the epitope mapping experiments provide a potential approach to testing 
the hypothesis that a retrovirus related to HTLV-I is present in these individuals. The 
peptide sequence common to the reactive octapeptides could be used to derive potential 
coding sequences, and these used to synthesize redundant primers for PCR, as discussed 
in Chapter 1 (section 1.5.3). It would then be possible to attempt to amplify viral DNA 
using, for example, a predicted primer binding site sequence for the 5’ PCR primer and 
the above 3’ primer.
5.4.4.HTLV-II positive sera.
The identification of antigenic epitopes on HTLV-I proteins that are reactive with 
HTLV-II positive sera offers the potential for the development of serological assays 
capable of distinguishing between infection with these two viruses. The epitope reactive 
with MoAb 12/1-2, PPYVE, is completely conserved between the two viral proteins. 
However only two of the HTLV-II positive sera showed reactivity to octapeptides 
within this region when analysed in the PEPSCAN ELISA. In these two samples 
reactivity was detected to 1 or 2 isolated octapeptides (115 and/or 117) only. Both sera 
reacted weakly in ELISAs using a longer peptide overlapping this region, P 109-130, 
suggesting that the reactivities detected with these isolated octapeptides may represent 
low titre or low affinity antibodies.
The significance of the reactivities with isolated or paired octapeptides elsewhere in pl9 
detected in the other 3 HTLV-II positive sera is more difficult to assess, as the sera did 
not react in ELISAs using longer peptides overlapping some of the reactive 
octapeptides. Possible explanations for the detection of reactivity with isolated 
octapeptides in the PEPSCAN ELISAs are discussed below.
5.4.5. P109-130 ELISA.
The results obtained from the analysis of HTLV-I-positive, HTLV-II-positive and 
HTLV-I-negative control sera suggest that an ELISA using P I09-130 may have 
diagnostic potential. Figure 5.51 shows that sera that are positive in the HTLV-I 
competitive ELISA may be clearly distinguished from negative control sera.
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The results obtained from the analysis of three sera that give discordant results on other 
assays are intriguing. As false positive results may frequently be obtained with the 
GPA (Matsumoto et al. 1990), it is likely that the results for sample 746 reflect lack of 
HTLV-I-specific antibody. For samples 835 and 840, the negative results obtained in 
the competitive ELISA and the P109-130 ELISA may reflect the relative lack of 
sensitivity of these assays compared to the GPA, ELISA and IF assays. Both these 
patients were relatives of TSP patients, and thus were at increased risk of HTLV-I 
infection (Mowbray etal. 1989). However the possibility that the low titre reactivities 
detected in these two samples using the GPA, ELISA and IF may represent false 
positive results cannot be eliminated in the absence of additional confirmatory testing.
It was possible to distinguish the 5 HTLV-II positive sera from HTLV-I positive sera 
using the P109-130 ELISA. Although only a very limited number of HTLV-II positive 
sera have been analysed, the data indicate that testing of additional sera would be 
worthwhile, in order to establish the potential of the assay for distinguishing HTLV-I 
and HTLV-II positive sera.
Two indeterminate sera from Caucasian patients gave similar results to HTLV-I 
negative sera in the p 109-130 ELISA. However 7 of the 9 indeterminate sera from 
PNG gave results within the range of those obtained with HTLV-I positive sera. Thus 
if, as suggested above, the PNG sera are from persons infected with a retrovirus related 
to HTLV-I, infection with this putative retrovirus could not be distinguished from 
infection with HTLV-I using this assay.
Lipka et al. (1990) have recently described the identification of an HTLV-I specific 
epitope present on the gp46 envelope glycoprotein. Chen et al. (1990b) have also 
described recombinant proteins containing HTLV-I and HTLV-II envelope protein 
sequences that were used in WB to distinguish between HTLV-I-positive and HTLV-II- 
positive sera. However a significant proportion of HTLV-I positive sera showed cross­
reactivity with the HTLV-II derived recombinant protein in the latter study. It is likely 
that assays capable of distinguishing reliably between HTLV-I-positive and HTLV-II- 
positive sera will need to include a number of different, virus-specific epitopes. The C- 
terminal p l9  peptide identified in the experiments described in this chapter may 
therefore be useful in combination with other antigenic epitopes for the distinction 
between HTLV-I-positive and HTLV-II-positive sera.
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5.4.6. Comparison with secondary structure predictions.
The results of PEPSCAN analysis of p 19 are in good agreement with the prediction of 
antigenic index, based on secondary structure, hydrophilicity, surface probability and 
flexibility shown in Figures 5.52-53. The region most strongly predicted to be antigenic 
is included within the site which was most frequently reactive with HTLV-I positive 
sera.
The region of HTLV-II p22 most strongly predicted to be antigenic lies between amino 
acids 36-42. Homology between HTLV-I p l9  and HTLV-II p22 in this region is 
relatively low, only 4/7 amino acids are identical. Reactivity to octapeptides from this 
region of pl9 was detected in two HTLV-II positive sera, samples 854 and 876, though 
in sample 876 reactivity was with an isolated octapeptide only. Additional experiments 
using peptides from this region of HTLV-I pl9  or HTLV-II p22 were not performed, 
thus assessment of the significance of the result obtained with samples 854 and 876 is 
difficult
5.4.7. Reactivity with isolated octapeptides.
The reactivity of serum 716 with the C-terminal octapeptide was confirmed in 
experiments using a longer, 22 amino acid C-terminal peptide. The reactivity of sample 
716 with an isolated octapeptide is likely to be due to the C-terminal location of the 
reactive epitope, as discussed below. HTLV-II positive samples 877 and 878, which 
reacted with octapeptides 115 and/or 117 also reacted weakly with a longer, 
overlapping C-terminal peptide. However the reactivity observed in these and other 
HTLV-I and HTLV-II positive serum samples with isolated peptides elsewhere in pl9 
could not be confirmed in ELISAs using overlapping, longer peptides. In addition 
reactivity to isolated octapeptides was observed in HTLV-I negative control sera.
These data suggest that reactivities to isolated octapeptides usually represent spurious 
nonspecific binding. This may occur due to coincidence between the sequence and/or 
confirmation of the octapeptide and some other antigenic epitope that is not preserved 
in adjacent peptides. Alternatively antibody may be binding to synthetic by-products, 
such as partially deleted or prematurely terminated peptides, present on the same pins. 
However this latter explanation seems unlikely where reactivity with an isolated 
octapeptide is detected on duplicate pins.
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Shi et al. (1984) found that non-specific binding to solid-phase-bound peptides was 
associated with the presence of lysine near the amino terminus. This effect was 
enhanced by the presence of adjacent hydrophobic residues and reduced by the presence 
of adjacent acidic residues. These authors suggest that small peptides with an overall 
cationic and hydrophobic character are likely to bind many antibody types. The isolated 
reactivities seen in the PEPSCAN ELISA involved 33 of the 122 octapeptides. Two of 
the three octapeptides that were most frequently reactive, numbers 11 and 70, contain 
cationic and hydrophobic residues. However the third most frequently reactive peptide, 
number 105, has a number of polar and acidic residues.
An alternative explanation for binding of sera to isolated octapeptides is that amino 
acids essential for interaction with antibody occur at either end of the octapeptide. It has 
been suggested that sequential epitopes are from 5-8 residues in length (Kabat 1970; 
Schechter 1971). As discussed above, only a few of the residues making up a defined 
epitope may be essential for interaction with the relevant antibody. Essential residues in 
defined epitopes have been shown to be separated by from 2-4 amino acids (Geysen et 
al. 1984; Schoofs et al. 1988; Scopes et al. 1990). Thus reactivity with an isolated 
octapeptide could arise if an epitope contained two residues essential for interaction 
with antibody that were separated by 6 amino acids. However the results of experiments 
using longer peptides overlapping isolated reactive octapeptides do not support this 
interpretation.
The reactivity of serum 716 with octapeptide 123 and not with adjacent octapeptides 
suggests that the C-terminal leucine residue is an essential component of the epitope 
reacting with this serum. In this case reactivity with an isolated octapeptide could be 
due to lack of any adjacent octapeptides C-terminal to this one. If the C-terminal 
leucine is an essential residue for interaction with serum 716, this would be consistent 
with the result obtained in the P109-130 ELISA following preadsorption with ipl9. The 
recombinant protein did not appear to adsorb out P109-130 specific antibodies from this 
serum as effectively as from the other HTLV-I positive sera. Foreign proteins expressed 
in bacteria are frequently degraded at their C-termini (Carroll and Laughon 1987) and 
loss of the C-terminal leucine residue could result in a significant loss of antibody 
affinity for rpl9 if this residue is essential for interaction with antibodies in this serum.
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5.4.8. Conclusions.
This study has identified a region at the C-tenninus of the pl9 gag protein of HTLV-I 
that contains the linear B-cell epitopes reactive with HTLV-I positive sera. These 
epitopes appear to form at least two antigenic sites located within the C-terminal 30 
amino acids of HTLV-I pl9.
The epitope reactive with a MoAb, 12/1-2 which reacts with HTLV-I pl9 and cross- 
reacts with HTLV-II p22 and a number of normal and malignant human tissues was 
identified as amino acids 119-123 of pl9.
The reactivity with pl9 in HTLV-I WB detected in sera from two Caucasians appeared 
to involve antibody binding to different C-terminal regions of pl9. These reactive 
regions did not coincide with the epitope reactive with MoAb 12/1-2. The IR detected 
in these serum samples could not, therefore, be explained by the presence of antibodies 
directed against the endogenous, cellular antigen(s) recognized by MoAb 12/1-2.
The reactivity with pl9 in HTLV-I WB detected in sera from PNG was shown to be due 
to specific reactivity with a defined epitope in the C-terminal region of HTLV-I pl9. 
The antibodies to the C-terminus of pl9 that were present in four of the PNG sera were 
of similar titre and affinity to those present in HTLV-I positive sera. The data provide 
some support for the hypothesis that IR in these sera may be due to infection with a 
retrovirus related to HTLV-I.
Preliminary experiments suggest that a peptide derived from the C-terminal 22 amino 
acids of pl9 has potential as a diagnostic reagent. This peptide should be useful for the 
serological diagnosis of HTLV-I infection and may also be useful for distinguishing 
between HTLV-I and HTLV-II positive sera.
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CHAPTER SIX.
GENERAL DISCUSSION:
CONCLUSIONS AND PROSPECTS FOR FURTHER STUDY.
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6.1. THE CLASSIFICATION OF HD.
6.1.1. The detection of Ig gene rearrangements in tumour biopsies.
The clinical and epidemiological features of HD, described in Chapter 1 (section 1.3.2) 
indicate that this disease is heterogeneous. There is therefore a need for further 
characterization of HD cases and possibly for novel classification systems, as has been 
discussed in Chapters 1 and 3. The data described in Chapter 3 suggest that HD cases 
may also vary in terms of the presence or absence of clonal Ig gene rearrangements in 
the HRS cells. It is of considerable interest to determine whether there are any clinical 
or biological differences in HD cases which differ in this respect
The analysis of tumour tissues by Southern hybridization, the technique employed in 
this study, is however likely to be of limited use for the further investigation of this 
question. The small numbers of malignant cells in HD tumour tissues and the 
difficulty of identifying conclusively the cell types containing the rearrangements limit 
the number of cases likely to provide useful information. A number of other 
experimental approaches may be of value. Southern blot analysis of purified HRS cell 
populations, derived using cell-separation techniques such as those described by 
Sundeen etal. (1987) and Sitar et al. (1989) may permit the conclusive identification of 
the cells containing the rearrangements. However it may be difficult to purify HRS cells 
from other cell types (Sundeen et al. 1987) and it may be difficult to obtain sufficient 
numbers of HRS cells for analysis.
Recendy described techniques for the detection of Ig and TCR gene rearrangements 
using the PCR (d’Auriol et al. 1989; McCarthy et al. 1990) offer the potential to 
surmount the problem of small cell numbers. In addition Haase et al. have recently 
described the analysis of tissue sections for Maedi Visna virus using the PCR in situ 
(personal communication). The use of this method for the detection of clonal Ig gene 
rearrangements in HD tissues could show conclusively whether or not the HRS cells 
contain the rearrangements.
173
6.1 .2 . The relationsh ip  between the detection of Ig gene
rearrangements and of EB V genomes.
The HD biopsies that were charaterized in the experiments described in Chapter 3 were 
also analysed for the presence of EBV genomes. The results obtained showed that the 
detection of EBV genomes did not correlate with the detection of Ig gene 
rearrangements, though only a small number of cases contained sufficient HRS cells for 
assessment (Gledhill et al. in press). Similar results have been obtained by others 
(Weiss etal. 1987a; Herbst etal. 1989). Possible explanations for these findings have 
been discussed in Chapter 3.
Although it was not possible to relate the presence or absence of clonal Ig gene 
rearrangements in HD cases to biological difference between cases, the detection of 
EBV genomes did show a relationship with patient age. Analysis of over 90 cases of 
HD has shown that HD patients aged 50 years or over and paediatric patients are more 
likely to be EBV positive than patients 15-34 years old (Jarrett et al. manuscript 
submitted).
The distribution of EBV-positive HD cases is related more closely to the 
epidemiological subgroups of HD identified by MacMahon (1966) than to the 
histological subtypes more commonly used to classify HD (see section 1.3.2). These 
data support the suggestion made in section 1.3.2, that there is a requirement for more 
detailed characterization of HD and possibly for alternative classification systems for 
this disease.
6.2. THE INVOLVEMENT OFHHV-6 IN LYMPHOPROLIFERATTVE
DISORDERS.
The results of a study to investigate the role of HHV-6 in lymphoproliferative disorders 
have been described in Chapter 4. HHV-6 genomes were detected in tumour and non- 
tumour tissues from two patients with lymphomas. The assessment of the significance 
of a molecular association between a virus and a malignancy was discussed in Chapter 
1 (section 1.4.3). The two methods of assessment described were (a) the determination 
of the clonality of the tumour cells and virus-infected cells and (b) the determination of 
the consistency of the association.
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Both of the lymphomas that were positive for HHV-6 DNA were shown to be clonal in 
origin. However it could not be conclusively shown that the viral DNA sequences were 
present in the tumour cells. Nor was it possible to determine whether the virus-infected 
cells had undergone clonal expansion. The lack of suitable material for in situ 
hybridization precludes further investigation of the former issue. Further 
characterization of the HHV-6 genome may permit the latter question to be addressed, 
possibly by a method similar to that used to assess the clonality of EBV-infected cells 
(Raab-Traub and Flynn 1986).
HHV-6 DNA sequences were identified in an AIL-like T-cell lymphoma and in a B-cell 
lymphoma occurring in a patient with a history of Sjdgren’s syndrome. HHV-6 
genomes were not consistently identified in tissues from patients with either AIL-like 
lymphoma or lymphomas occurring in the context of Sjdgren’s syndrome.
The significance of the molecular association between HHV-6 and the these 
lymphomas therefore appears questionable. However although the majority of 
lymphomas occurring in patients with Sjftgren’s syndrome are negative for HHV-6 
sequences (Josephs et al. 1988b; R.F. Jarrett unpublished data), there are a statistically 
significant excess of HHV-6-positive cases in comparison to other types of lymphoma.
The possibility that lack of a consistent association between a virus and a tumour could 
result from inappropriate disease classification was discussed in Chapter 1 (section 
1.4.3). Thus one possible explanation for these data is that lymphomas occurring in 
Sj5gren*s syndrome patients may include more that one distinct disease entity. The 
alternative possibility discussed in Chapter 1, that a phenotypically identical tumour 
could arise as a result of a distinct pathogenic mechanism offers a more plausible 
explanation. The possible involvement of herpesviruses in addition to HHV-6 in the 
pathogenesis of lymphomas occurring in the context of Sjdgren’s syndrome was 
discussed in Chapter 4. If this speculation is correct, only a subset of such lymphomas 
would show a molecular association with HHV-6.
The molecular similarity between HHV-6 and CMV (Lawrence eta l. 1990) suggests 
that it is unlikely that HHV-6 is directly involved in lymphomagenesis. Evidence that 
regions of HHV-6 DNA may contribute to cell transformation in vitro (Razzaque 1990) 
is of uncertain significance, as similar data have been reported for CMV (Galloway et 
al. 1986; Sugden 1986) which does not appear to be oncogenic in vivo.
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The data reported in Chapter 4 are more consistent with the hypothesis that HHV-6 is 
playing an indirect role in lymphomagenesis in Sjdgren’s syndrome and/or AIL. 
Indirect involvement of viruses in lymphoid malignancy may be difficult to establish 
using a molecular approach, as discussed previously (section 1.4.21. Serological studies 
have supported an association between HHV-6 and Sj5gren’s syndrome (Ablashi et a l  
1988). However there is a need for case-control studies to confirm this association.
The possibility that HHV-6 and other herpesviruses could be involved in the 
pathogenesis of Sjdgren’s syndrome itself is intriguing and warrants further 
investigation. Chronic immune stimulation due to viral antigen expression or 
altered expression of cellular antigens by virus-infected cells could result both in 
autoimmune phenomena and in lymphomagenesis.
6.3. THE USE OF EPITOPE MAPPING IN THE SEARCH FOR 
RETROVIRUSES RELATED TO HTLV-I.
Chapter 5 describes the results of experiments that form part of a novel approach to the 
identification of viruses related to known leukaemogenic viruses. The data provide 
evidence to support the notion that residents of PNG whose sera react with HTLV-I 
proteins on WB are infected with a retrovirus related to HTLV-I. Specific epitopes on 
HTLV-I pl9 that are reactive with these sera have been identified. These data may now 
be used to predict a coding sequence for this region, assuming that the amino acid 
sequence is conserved in the putative related vims. Various techniques for using amino 
acid sequences to generate oligonucleotide primers for use in the PCR have been 
described. These include the synthesis and use of mixtures of oligonucleotides which 
have all four alternative nucleotides present at every third base (Compton 1990). 
Alternatively, the inclusion of inosine residues at every third base has been shown to 
permit base-pairing with any nucleotide at this position (Knoth etal. 1988).
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The choice of an additional 5’ or 3* primer remains a problem. For most of the sera 
analysed in this study, the reactivity with HTLV-I proteins can largely be explained by 
reactivity with an epitope on pl9 alone (see Table V.IV and Figure 5.1), thus analysis 
of additional HTLV-I proteins may not reveal additional conserved epitopes. The tRNA 
used to prime synthesis of negative strand DNA during retroviral replication is 
conserved between the related retroviruses HTLV-I, HTLV-II and BLV; all use 
tRNApj.0 as a primer (Seiki etal. 1982; Sagata etal. 1985; Shimotohno etal. 1985). 
The sequence of the tRNApj.0 binding site could therefore be used to derive a 5* primer 
for use in the PCR.
Although evidence for the presence of HTLV-I itself in PNG has recently been reported 
(Yanagihara et al. 1990a; Yanagihara etal. 1990b), HTLV-I related diseases have not 
been described. This could be due to significant under-reporting of disease as many 
areas of PNG are remote and some populations have had little contact with outsiders. In 
addition the low incidence of HTLV-I related disease could reflect the short life- 
expectancy of persons from this region, as the majority of cases of ATL and TSP occur 
in persons over 50 years old (Yamaguchi et al. 1990).
This region has not been reported to show a high incidence of other haematological 
malignancies, that could be associated with other leukaemogenic retroviruses. This 
could be a result of disease under-reporting and short life-expectancy, as discussed 
above. However retroviruses closely related to HTLV-I may not necessarily be 
oncogenic in vivo, as illustrated by the lack of association between HTLV-II infection 
and malignant disease. The isolation of such retroviruses is still of considerable value. 
The comparative study of closely related viruses is likely to provide insights into the 
features of HILV-I that are important in leukaemogenesis.
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